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Burns represent one of the most devastating forms of injury with infection 
complications representing the highest risk of mortality. The primary objective of the 
Bacteriosafe project was the development of a smart wound dressing that would 
respond to the presence of bacteria in burn wounds. The basis of this sensing system 
employed the use of phospholipid vesicles, containing a self-quenchable fluorescent 
dye. These vesicles mimic the eukaryotic cell membrane and as such are susceptible 
to bacterial cytolytic factors which lyse the vesicles, generating an observable and 
measurable fluorescent response. My primary role in this project was to identify the 
vesicle lysing agents secreted from the two most frequent burn wound colonisers, 
Staphylococcus aureus and Pseudomonas aeruginosa. We identified the small 
amphipathic alpha helical peptide toxins from S. aureus and glycolipid molecules 
derived from P. aeruginosa as the agents responsible for vesicle lysis. The 
identification of these molecules led to the development of two novel phenotypic 
assays designed to measure these important virulence factors, as discussed in chapter 
3 and 4. In chapter 5 we examined the role of toxic shock syndrome toxin-1 (TSST-
1) in repressing global exoprotein expression. Our results demonstrate that TSST-1 
does not repress toxin secretion and strains expressing TSST-1 retain their ability to 
lyse vesicles. In chapter 6 we explored the use of subinhibitory oxacillin in inducing 
the alternative penicillin binding protein 2a (PBP2a) in community-acquired 
methicillin resistant S. aureus (CA-MRSA) strains to down-regulate toxicity. 
Previous work in the Massey lab demonstrated that the expression of the mecA gene, 
which encodes PBP2a, resulted in reduced toxicity in hospital-acquired (HA) -
MRSA. CA-MRSA strains are considered highly toxic and have a considerably 
lower level of PBP2a expression. Treatment of CA-MRSA strains with subinhibitory 
oxacillin did result in a down-regulation of some toxins but also the up-regulation of 
others, highlighting the pleiotropic effect oxacillin had on virulence regulation. In 
chapter 7 we developed an approach that uses the genome sequences of a set of 
related clinical S. aureus strains to identify novel virulence loci by associating 
genetic polymorphisms with specific virulence phenotypes using a genome wide 
association study (GWAS). This analysis resulted in the identification of four novel 
loci which when mutated lead to a reduction in toxicity. We demonstrate that the 
 
 
GWAS approach is an effective method in identifying candidate SNPs which may be 
important in altering virulence but do highlight limitations of this approach, 
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1.1 Development of active wound dressing for detection of 
pathogenic bacteria in burns patients 
___________________________________________________________________________________________ 
 
urns represent a complex and traumatic event and are classified as one of 
the most debilitating forms of injury due to the adverse local and systemic 
effects on normal homeostasis. In the United States alone, 1.2 million 
people suffer burn injuries each year with a mortality rate of 5-10% in those patients 
suffering from moderate to severe burns (1, 2). Although there has been a huge 
improvement in the treatment of burn victims in areas such as fluid resuscitation and 
nutritional support, 75% of all deaths are related to infection complications (3, 4). 
The patients’ age group can have a major influence on the cause of trauma. The 
annual admission of children under the age of five suffering from burn injury in 
England and Wales is 4,300 and 53% of all scald related injuries are suffered by this 
age group (5). Furthermore, this age group is particularly susceptible to burn-related 
infection, due partly to a thinner dermal layer increasing the propensity for deeper 
burns and invasive infection and an immature immune system (6). These statistics 
represent a growing need to tackle burn-related injury especially in young children, 
as it is the third leading cause of accidental death (5).  
 
1.1.1 Biology of a burn wound 
 
The skin plays a major role as a protective barrier to infection but is also extremely 
important in fluid homeostasis, thermoregulation and various immunological and 
metabolic functions. Thermal injury dismantles this protective function and causes a 
rapid degree of cellular damage. The process which leads to burn eschar begins with 




and disruption of intramolecular bonds causing protein denaturation, liberation of 
oxygen radicals, disruption of cell membrane integrity and eventual cell death (7, 8). 
The depth of the burn is based on the intensity and duration of heat exposure and can 
be classified into three main degrees as shown in figure 1.1, each with an increasing 
predisposition to infection (9). Superficial or first degree burn only affects the 
outermost epidermal layer and is characterised by a painful erythematous appearance 
without blistering. Partial thickness or second degree burns can be divided into two 
subgroups; superficial and deep partial thickness. Superficial partial thickness affects 
the papillary dermis illustrated by a weeping moist texture and blistering with 
minimal scarring, whereas the deep partial thickness burns affect the reticular dermis 
usually causing a loss of 50% of the dermis (10). Common features of these burns 
are white dry texture with minimal pain as nerve fibres have been destroyed, with 
healing taking up to 6 weeks if no complications occur. It is these types of burns that 
are most associated with scald related injury (9). Full thickness or third degree burns 
penetrate the skin into the subcutaneous fat and sometimes deeper. They have a waxy 
leathery appearance, with no bleeding due to the thrombosed vessels and are at the 
highest risk of infection. As the body tries to maintain homeostasis after burn injury, 
the clinical picture of necrotic coagulation unveils.  
 
Three distinct zones are associated with burn wounds as described by Jackson 
et al (11). The zone of coagulation is at the centre focus of the injury nearest the heat 
source, consisting of devitalised tissue which forms the burn eschar. The zone of 
stasis represents the tissue adjacent to the necrotic area and is still viable but at risk 
of irreversible death because of ongoing ischemia due to decreased perfusion, while 
the zone of hyperaemia is the most peripheral zone which consists of normal skin 




Figure 1.1: Classification of burn wounds: First degree burns are localised to the epidermis layer of 
the skin, causing a painful pink to red appearance with no blister formation. Second degree burns 
affect either the superficial dermis layer causing severe pain and blistering or the deeper reticular layer 
which generally results in scarring. Third degree burns result in charring and total destruction of the 




1.1.2 Systemic response to burn injury 
 
Thermal injury causes systemic pathophysiological changes, resulting in clinical 
manifestations such as shock, respiratory and renal failure, hypermetabolism and 
catabolism, intestinal alterations and immunosupression, in which the latter two 
directly predispose the patient to infection (12-15). Like the skin, the gastrointestinal 
epithelium provides a mucosal barrier against infection. Following thermal injury, 
gastrointestinal motility and absorption is impaired (16, 17). Gastroduodenoscopy on 
patients suffering from burns revealed a high degree of stomach and duodenum 
lining erosion (18). Bacterial translocation and macromolecular leakage is also 
evident after burn injury, resulting in the dissemination of endogenous 
gastrointestinal flora (19-22). Intestinal ischemia triggers oxidative stress, generated 
from monocyte derived molecular mediators, culminating in the production of 
hydrogen peroxide (H2O2) and nitric oxide (NO) which are toxic to enterocytes, 
resulting in the observed increase in gut permeability (23, 24).   
  
The immune system responds to trauma by rapidly expressing 
proinflammatory cytokines and other factors important in acute inflammation. 
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However, this proinflammatory cascade requires an equally important anti-
inflammatory response to compensate and prevent further injury. Many of the 
chemical mediators involved in this compensatory response are highly 
immunosuppressive (25, 26), which can lead to the patient being colonised by 
opportunistic organisms (27, 28).  
 
 Directly after a burn injury a proinflammatory response is generated, 
characterised by increased serum levels of proinflammatory cytokines such as 
interleukin-1β (IL-1β) and tumour necrosis factor α (TNFα) (29). Both of this 
cytokines stimulate the expression of prostaglandin E2 (PGE2) and IL-6 from 
endothelial cells and macrophages (30), and as with IL-1β and TNFα, IL-6 
contributes to the activation of T cells (31). Interferon gamma (IFN-γ), another 
proinflammatory cytokine, is produced by natural killer (NK) cells and Th-1 cells in 
response to burn trauma and is important in macrophage activation and CD4
+
 T cell 
differentiation into Th-1 cells (32).  
  
Early immune suppression is evident 3 days after burn injury in patients with 
burns greater than 30% total body surface area (TBSA) (9, 33). This is mediated by 
an opposing set of cytokines which impact the adaptive immune system, particularly 
the T cell population. Biochemical alterations influencing the expression of steroid 
hormones and catecholamines inhibit the production of proinflammatory but not anti-
inflammatory mediators (34, 35). Macrophages increase production of PGE2 and 
decrease expression of IL-12, causing an inhibition of Th-1 but not Th-2 cell 
proliferation and function (14, 36). The differentiation of T helper cell population 
from Th-1 to Th-2 cells reduces cell-mediated immunity and leads to an increase in 
anti-inflammatory cytokines such as IL-4 and IL-10 (37). Increased IL-4 and IL-10 
inhibit Th-1 cell activation, decrease production of proinflammatory cytokines and 
interfere with bactericidal and fungicidal activity (38-40). Increased PGE2 can also 
lead to the reduction of IL-1β and inhibit the activity of NK cells (41). Neutrophil 
dysfunction, in terms of chemotaxis and intracellular killing impairment, is also 
evident following major burn injury (42, 43). Macrophages also display reduced 
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phagocytosis and major histocompatibility complex class II (MHC II) expression and 
antigen presentation following severe thermal injury (44-46). 
 
1.1.3 Epidemiology of burn wound infections  
 
Although the burn wound surface is initially sterile immediately after thermal injury, 
there is a temporal colonisation of the wound with microorganisms originating from 
either nosocomial transmission from contaminated healthcare workers, fomites or 
from the patient’s own endogenous flora (47, 48). In the last three decades there has 
been a change in burn management from controlling bacterial growth on the wound 
surface, allowing for breakdown of burn eschar coupled with debridement and daily 
immersion hydrotherapy (conservative exposure) to early excision and closure of the 
wound and shower therapy (49). However, only two randomized, controlled trials of 
early excision vs controlled exposure have been published with neither illustrating a 
significant reduction in burn wound infection in burn wounds >15% TBSA (50, 51). 
Importantly, this change in burn wound care has altered the epidemiology of burn 
wound infections (49), therefore epidemiological studies from the era of conservative 
exposure therapy has largely been omitted from this thesis.  
 
Exposed burned tissue is susceptible to colonisation from microorganisms 
typical of gastrointestinal and upper respiratory tract flora (52), but following initial 
thermal injury, Gram-positive bacteria are first to colonise the wound (53, 54). 
Coagulase-negative staphylococci (CoNS) and Staphylococcus aureus are the most 
common microorganism found in burn wounds, particularly small TBSA burns (33, 
41, 47-49, 55-57). A recent study investigating the change in microbial flora in burn 
wounds during treatment found that CoNS (63%) and S. aureus (19.7%) were most 
prevalent upon admission, but a gradual decrease in CoNS isolates (34.7%) and an 
increase in S. aureus (37.6%) and P. aeruginosa (16.2%) isolates was observed at 
day 21 (48). Interestingly, antibiotic resistance in S. aureus increased with increasing 
hospital stay in the burns patient, while MRSA nasal carriage increased from 3.9% 




Gram-positive cocci are gradually replaced with gram-negative bacilli, which 
are hypothesised to have a greater propensity to invade and are associated with larger 
burn areas (33, 56, 61). Of the Gram-negative organism, the Pseudomonas species, 
particularly P. aeruginosa, are the most frequent colonisers [48, 55, 56, 59, 65-67], 
with P. aeruginosa associated with high mortality in burn patients (62). In a similar 
fashion to S. aureus, P. aeruginosa also exhibited decreasing susceptibilities to 
various antibiotics with increasing hospital stay in the burns patient (57). P. 
aeruginosa is inherently resistance to antibiotics due to constitutive expression of β-
lactamases and efflux pumps, coupled with the possession of a low permeable outer 
membrane (63-65). P. aeruginosa also has a remarkable capacity to acquire 
resistance to various classes of antibiotics, and has been shown to contain practically 
all known mechanisms of antibiotic resistance (66).    
 
Different geographical locations have a different prevalence and spectrum of 
organisms that are capable of causing burn wound infections. For example, 
Enterococcus species play an important role in burn wound infections in the US, 
accounting for up to 12% (67), but were significantly less prevalent (3%) in a 
Brazilian study (68).  A recent review of 104 US burn units found that P. aeruginosa 
is the most frequent pathogen among Gram-negatives at 44%, followed by 
Acinetobacter baumannii and Enterococcus spp (69). In China, A. baumannii and 
Proteus mirabilis are responsible for the most burn infections (70). Different 
prevalence rates have also been shown for Acinetobacter spp (71), Candida albicans 
(72) and various gram-negatives including Klebsiella pneumonia and Escherichia 
coli (73), however, in the vast majority of burn hospitalisations, S. aureus and P. 
aeruginosa are the earliest and most frequent colonisers of burn wounds.  
 
1.1.4 Pathogenesis of burn wound  
 
The susceptibility of burns wounds to infection is the result of a combination of 
factors including the disruption of the skin barrier, depression of innate and adaptive 
immunity and an environment rich in nutrients in the form of coagulated proteins, 
exudate and necrotic tissue (30, 56). Incidence of ventilator associated pneumonia, 
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primary blood stream and wound infection are all higher in the burn patient than 
other intensive care unit (ICU) patients (73).   
 
Frequently, after colonisation of the burn wound, microorganisms can 
penetrate the eschar and invade the underlining unburned subcutaneous tissues. S. 
aureus is well equipped to achieve this and after invasion can form abscesses with 
thick walls that further obstruct antibiotic therapy and an already weakened host 
defence, which can lead to the  haematogenous dissemination of the infection (56). 
P. aeruginosa has a preference for warm, moist environments, and is well adapted to 
colonise the burn patients. Both of these major burn pathogens expresses and secrete 
a plethora of virulence factors which are fundamental in burn wound colonisation 
and infection. 
 
 A great deal of information on the specific virulence factors which P. 
aeruginosa utilises in burn infection has been documented (74-78). Virulence factor 
expression in P. aeruginosa is coordinated through an elegant hierarchy cell density 
quorum sensing system, involving the lasRI, rhlRI, quinolone signalling system and 
multiple accessory factors that alter these regulatory circuits at the transcriptional, 
post-transcriptional and translational level (79-85). It has been shown previously that 
the lasRI and rhlRI systems are extremely important in initial spread from the 
inoculation site in a burn wound and for dissemination throughout the body (75), 
highlighting the role of virulence factors in burn wound pathogenesis.  
 
P. aeruginosa expresses two surface appendages, a single flagellum and type 
VI pili, that are involved in multiple roles including adhesion, locomotion, biofilm 
formation, natural transformation, DNA binding and invasion (86-89). Mutants 
deficient in either of these structures have reduced virulence in a mouse burn model, 
displaying reduced persistence at the wound site and lower dissemination to target 
organs (74). Rhamnolipids are glycolipids that have bio-surfactant properties and are 
important in motility and colonisation of surfaces, and are likely play a role in burn 
wound colonisation (90, 91) (see section 4.2 for additional information). Efficient 
dissemination in the burn wound also requires the production of elastases and other 
8 
 
proteases, which are present in both P. aeruginosa and S. aureus (76). The 
importance of elastase in burn wounds is governed by its ability to degrade collagen 
and non-collagen host proteins and disrupt the integrity of the basement membrane, 
providing an avenue for dissemination (77).  
 
Direct evidence for the production of the P. aeruginosa ADP-ribosylating 
toxin, exotoxin A, in a burn wound mouse model has been shown (78). Exotoxin A 
catalyses the transfer of the ADP-ribose molecule from nicotinamide adenine 
dinucleotide (NAD
+
) to a residue on elongation factor 2 (EF-2), inactivating this 
protein and subsequently inhibiting protein synthesis in the target cell (92). Exotoxin 
A causes cell death and necrosis at the site of colonisation (93), and is continuously 
expressed for up to 35 h after infection (78), underling the possibility that other 
toxins are also continuously produced at this rate. Additional P. aeruginosa virulence 
factors that have been reported to be involved in burn wound infection include the 
phospholipase C enzyme, which targets phospholipid membranes (94), and the 
effector molecules of the type III secretion system, namely exoenzyme S (95), 
another ADP-ribosylating toxin.  
 
Detailed experiments identifying specific virulence factor involvement in S. 
aureus burn wound infection are lacking. However, S. aureus expresses a multitude 
of virulence determinants which are likely to be important in burn wound 
pathogenesis. These factors can be divided into three main virulence categories: 
adhesins, immune evasins and toxins (96, 97). S. aureus is well equipped to adhere to 
the host, utilising a diverse array of surface adhesins to interact with a myriad of 
extracellular matrix proteins and cell types (98). S. aureus also employs multiple 
factors which can interact and impede the various arms of the immune system (99) 
and evolved to expresses a plethora of membrane damaging toxins and enzymes, 
designed to destroy immune cells and host tissue (100). [The S. aureus virulence 






1.1.5 Biofilm and burns 
 
Biofilms exist as a community of organisms attached to a surface, surrounded by a 
polymeric matrix and are associated with persistence and antibiotic resistance (101-
103). Both S. aureus and P. aeruginosa are capable of forming single and 
multispecies biofilms, in a wide range of artificial and natural environments (101). 
Generally, biofilms are associated with foreign device-related and chronic infections 
but recent evidence suggests that biofilm formation plays an active role in burn 
wound pathogenesis (102-104). Biofilm development occurs through three key 
stages: attachment, maturation and detachment (Fig 1.2). This classification is further 
subdivided into (I) initial attachment, (II) irreversible attachment, following the 
production of extracellular polymeric substances (EPS) or exopolysaccharide matrix, 
(III) early construction of biofilm architecture, (IV) biofilm maturation and (V) cell 
dispersion or detachment (Fig 1.2) (101, 105). The environmental cues which trigger 
initial biofilm formation include an abundance of nutrients, oxygen availability and 




Figure 1.2: Biofilm development: Following specific environmental signals, planktonic bacteria 
begin to adhere to abiotic or biotic surfaces in the (I) initial attachment stage of biofilm formation. 
Biofilm development moves into the (II) irreversible adherence stage after the production of an 
exopolysaccharide matrix. Biofilms mature in stages III and IV and finally disperse or detach (V) 
following specific signals, leading to the dissemination of single cells with the potential to initiate new 
biofilm colonies.  
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In P. aeruginosa biofilms, initial attachment is largely governed by the adhesins and 
surface appendages such as flagella and type IV pili, which allow independent 
movements of twitching and gliding (108). Alteration in the O-polysaccharide of 
lipopolysaccharides (LPS) can alter the adherence properties, where a loss in the A-
band results in reduced attachment to hydrophilic surfaces and increased adherence 
to hydrophobic surfaces, which may be important depending on the surface for initial 
biofilm attachment (109). Following the initial reversible interaction, P. aeruginosa 
commences the production of alginate and other polysaccharides (EPS)  initiating the 
transfer into early maturation stage (110). Upon contact, flagellar synthesis is down 
regulated and alginate synthesis increased, suggesting a surface-mediated alteration 
in gene expression (111). EPS maintains biofilm architecture and protects against 
shear forces in fluid environments acting as a ‘glue’ keeping cells together (112). 
Alginate appears to protect the biofilm from the reactive oxygen species released 
from inflammatory cells and prevents phagocytosis from immune cells (113, 114). 
The Psl exoploysaccharide (Polysaccharide synthesis locus) is required for binding to 
a substratum, cell-cell interactions and maturation and maintenance of the biofilm 
architecture (112, 115). Another polysaccharide, Pel, was shown to be important in 
biofilm initiation only in non-piliated mutants, highlighting a role for both Pel and 
type IV pili in initial attachment (116). In addition to exopolysaccharides, 
extracellular DNA (eDNA) is an important factor of the matrix in early biofilms 
(117). The liberation of eDNA and the regulation of pel biosynthetic genes involved 
both the las and rhl quorum sensing systems, highlighting their respective roles in 
biofilm formation and maturation (118).  
 
Rhamnolipids play major roles in P. aeruginosa biofilm maturation, 
maintenance and detachment (119-121). These amphipathic glycolipids have been 
shown to be involved in construction of channels and interstitial voids allowing a 
type of circulatory system to exist within the biofilm, supplying a critical avenue for 
efficient nutrient supply and waste removal (120). Rhamnolipids are hypothesized to 
be central in the development of mushroom cap formation (119) and directly 




S. aureus is also an excellent biofilm former and utilises similar gene 
products as P. aeruginosa in the construction, maintenance and dispersion of 
biofilms. S. aureus expresses a plethora of surface proteins which have the capacity 
to bind and interact with multiple matrix proteins (122) and are intimately involved 
in the initial attachment phase of staphylococcal biofilm formation (123). Although 
the composition of EPS or matrix of S. aureus differs from that of P. aeruginosa, its 
function is largely the same; important in intracellular aggregation, protection and 
construction of fluid-filled and mushroom shaped cell towers.  
 
The primary molecule responsible for intracellular adhesion is the 
polysaccharide intercellular adhesin (PIA) (124), which functions by providing 
charge differences permitting electrostatic interactions between the teichoic acid-
mediated negatively charged bacterial cells (125). However, PIA-independent 
biofilms do exist (126), and in these cases the adhesive function of PIA appears to be 
substituted by adhesive proteins, primarily the accumulation-associated protein (Aap) 
and fibronectin binding proteins (FnBPs) (127). Keeping with the importance of 
preserving the biofilms ability to distribute nutrients and remove waste products, S. 
aureus employs quorum sensing dependent, surfactant peptides, known as Phenol-
soluble modulins (PSMs) (reviewed in section 1.3.5.2.3), to structure biofilms (128). 
Similar to the importance of rhamnolipids in P. aeruginosa biofilms, these PSM 
peptides are also multi-functional and are employed in an effective method for 
biofilm detachment and dissemination (128).  
 
The presence of biofilms in burns has only been recently established (102-
104). Biofilms have been demonstrated to form in burn wounds of thermally injured 
mice (102, 129). In these studies, biofilms began to form around blood vessels and 
adipose cells within 8 h of infection. Under these conditions, P. aeruginosa strain 





in under 24 h (75). A recent study investigating the presence of bacterial biofilm 
from human burn wound biopsies observed increased bacterial colonies surrounding 
ulcerated and surgical site lesions, which were largely accompanied by necrotic 
material and wound exudates within 7 days post-injury (103). These biofilms were of 
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mixed species and evidence of glycocalyx and EPS were observed (103). These 
results demonstrate that biofilm formation does occur in burn wounds which may 
have implications for the future development of wound dressings.   
 
1.1.6 Current and ‘smart’ burn wound dressings  
 
Wound healing progresses through overlapping stages involving a variety of cellular 
and biochemical processes which act together to re-establish tissue integrity (130). 
New advances in burn wound technology have centred on achieving an ideal wound 
condition:  moist, warm environment conducive to growth and tissue regeneration 
while preventing microbial infection.  
 
 The prevention of microbial colonisation and subsequent infection is a key 
criterion of burn wound dressings. Silver (Ag) has very broad microbicidal activity, 
being highly reactive in its charged state, Ag
+
, binding with high efficiency to 
negatively charged particles. This leads to direct killing on contact due to 
interference with electron transport and cellular respiration, denaturation of  proteins 
and DNA and destabilising membrane permeability (131-133). Nanocrystalline silver 
(Ag
0), which is actively released from Aticoat™ wound dressings, display 
impressive antibacterial activity and protective covering of skin grafts, greater than 
that observed using silver nitrate or silver sulfadiazine (132). This greater activity has 
been attributed to the use of non-charged Ag, causing a less reactivity and sustained 
release of Ag into the wound rather than a mass active event which is short lived 
(131). Unfortunately, silver, even in the form demonstrated in Aticoat™ dressings, 
have been shown to be toxic to skin cells, fibroblasts and keratinocytes (134). Poon 
et al further warned against the use of Ag containing dressing in burn wounds where 
rapidly proliferating kerationcytes are exposed (134). Dressings which continuously 
expose antimicrobials to the burn wound may also increase the rate at which 
microorganism acquire resistance, leading to further complications, increasing 




Occlusive dressings are an important element in modern burn management 
and highlight the importance of autolysis in burn care. These types of dressing 
provide a barrier to the external environment, allowing the body’s phagocytic 
processes to natural debride and shape the wound (136). Hydrocolloid dressings are 
among the most important and widely used occlusive dressings (137). These 
dressings are composed of a gel forming colloidal agent combined with either 
adhesives or with other materials such as alginates. They are used frequently in burn 
care due their impermeability properties, flexibility and ease of removal, an 
important feature particularly in paediatric burn care (5, 137). Unfortunately, most 
burn wounds produces heavy exudate causing hydrocolloid dressing to swell, 
dislodge and fall apart. These dressings also require frequent changing, every 2-5 
days, which can strip immature epithelial layers (136, 137).   
 
In recent years, biological dressings or bioengineered skin substitutes have 
been introduced with great success in the management of superficial and deep partial 
thickness burns (138). These dressing have the advantage of containing 
biodegradable components, such as collagen or elastin, which play an active part of 
the natural tissue extracellular matrix and regeneration. One example of a biological 
dressing widely used in the United Kingdom is registered as Biobrane™. This 
dressing is composed of a nylon mesh attached to a silicone membrane bonded with 
purified porcine derived dermal collagen (139). Although Biobrane™ and other 
similar biological dressing have shown improved wound adherence, flexibility, and 
healing in burn wounds (140, 141) their failure rate can be attributed to wound 
infection, as they have no means to sense or tackle infection (142).  
 
Currently the only methods used to investigate burn wound infection are by 
analysing surface swabs and tissue biopsy specimens (143, 144). This requires direct 
wound assessment and removal of adherent dressing. These methods are slow, cause 
discomfort to the patient, are costly and can increase the risk of life-long scarring and 
further infection (5). Assessment of the clinical condition of the patient is not 
sufficient as a sole method to evaluate infection, as the clinical signs of infection, 
particularly in paediatric patients, are non-specific (5, 145). At present time there is a 
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need for technology which can be used in combination with biological dressings 
which can sense the presence of pathogenic bacteria in the wound environment. The 
core principle behind the development of a ‘smart’ dressing, which will be discussed 
in this thesis, is the use of a colorimetric sensor device which responds to the 
presence of bacteria in the burn wound. The sensor acts as a molecular mimic of the 
plasma membrane of eukaryotic cells and responds to the action of bacterial secreted 






















1.2 Using phospholipid vesicles as biosensors  
___________________________________________________________________________________________ 
 
hospholipid molecules, in partnership with proteins and nucleic acids, 
represent the essential factors for all living matter. Phospholipid molecules 
are amphiphilic, containing a polar, water-soluble, hydrophilic head group 
attached to a non-polar, water-insoluble, hydrophobic hydrocarbon or fatty acid 
chain(s). Glycerolphospholipids are phospholipids that contain two acyl chains, 
which can be saturated or unsaturated, linked to a headgroup by means of a glycerol 
backbone (Fig 1.3). These molecules are a major component in all cytoplasmic 
membranes as well as phospholipid vesicles (vesicles).  
 
 The vesicles used in this study are artificially formulated, spherical, self-
enclosed structures, composed of lipid bilayers. An important feature of this structure 
is the ability to encapsulate the surrounding solvent within the aqueous cavity (Fig 
1.3). Vesicles vary in size from 20 nm to several micrometers, and can be generated 
containing one (unilamellar vesicle) or more (multilamellar vesicle) lipid bilayers, 
each spanning a thickness of approximately 4 nm, surrounding an equal number of 
aqueous spaces. The bilayers are usually composed of natural or synthetic 
phospholipids and cholesterol, but incorporation of other sterols, fatty acids, 
glycolipids proteins and other membrane factors is also possible (146). 
 
 Unilamellar vesicles make fantastic model systems for investigating the 
dynamics and structural features of many cellular processes including viral 
interactions with membranes (147) and endocytic features (148) and are used 
extensively in investigating toxin-membrane interactions (149-153). In addition to 
being important models in understanding fundamental molecular research, vesicles 
have been developed as vehicles for drug delivery (154) and gene transfer (155). 
Vesicles are very attractive structures to use in medical therapy because they are 
biocompatible, biodegradable, and those composed of natural phospholipids, are 








Figure 1.3: Representation of phospholipid structure and liposome. Phospholipid molecules 
consist of a hydrophilic phosphate head group and a hydrophobic fatty acid tail. Liposomes care 
spherical, self-closed structures consisting of phospholipid bilayers, which can encapsulate the 





As previously stated phospholipids are amphiphiles and therefore spontaneously 
aggregate into a variety of different structures based on their dual solvent preference.  
The hydrophobic effect dictates this self-assembly, by driving the organisation of 
amphiphiles (156). Both ends of the phospholipid molecule imposed a 
thermodynamic preference which is satisfied by self-association, with the fatty acid 
chains in the middle, avoiding the aqueous solvent and the polar head groups at the 
surface as depicted in figure 1.3. This self-organisation is usually accompanied by an 
increase in the entropy of the system. This arises as the polar/non-polar interactions 
force the water molecules into an ordered state around the fatty acid chains (156). 
Movement of the hydrophobic parts out of the aqueous solution releases the ordered 
water molecules and sequesters the hydrophobic elements within the interior of the 
structure. This is hypothesised to lead to an overall gain in free energy, permitting 
spontaneous aggregation.  
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1.2.2 Lipid polymorphism and aggregate structure 
 
The spontaneous aggregation of amphiphilic lipids in aqueous solution can result in 
the formation of many structures. Although the hydrophobic effect is important in 
aggregation, other parameters of the amphiphile, most notably the shape of the 
individual molecules and the concentration, play an important role in the formation 
of these structures (157). The shape of the lipid aggregates is determined by the 
surfactant packing parameter,     (157):  
 
       
 
where   is the volume of the hydrophobic portion of the amphiphile,   is the length 
of the hydrocarbon chains and   is the area of the polar head group. The relative 
sizes of the head group and hydrocarbon chains will dictate the way in which 
packaging into different geometrical aggregates occurs. By convention, if the 
curvature of an aggregate is around the hydrophobic portion it is considered positive, 
whereas if it is around the polar portion it is considered negative (158). The positive 
curvature forms normal aggregates and phases, whereas the latter forms reversed 
ones. If the surfactant packaging parameter ( ) is <1/3, only spherical micelles are 
formed in solution. If   =1 a balance between the sizes of the polar head groups and 
hydrophobic tails exist, forming planar aggregates with a bilayer structure. When   
>1 the surfactant form reversed micelle structures (Fig 1.4).  
 
 One of the major components of the vesicles used throughout this thesis is    
1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC). This lipid, like most bilayer-
forming lipids, has a shape parameter of approximately 1, which means it has a 
cylindrical shape and tends to form bilayers. As lipid concentration increases, these 
molecules generally form lamellar phases where planar lipid bilayers alternate with 
water layer (Fig 1.4). Aggregate formation in different phases depends on the free 
energy per lipid molecule. This differs in lamellar and hexagonal phases, in which 
the molecule occupies different volumes. This shape dependent free energy involves 
the fatty acid energies, bending of the lipid monolayers, hydration and electrostatic 
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potentials (158). In the hexagonal II phase (HII) water molecules are sequestered 
within the cylindrical tubes. If the concentration of water-to-lipid increases, this 
results in an increase fatty acid packaging free energy. This can lead to an ordering 
of aggregates relative to each other or a change in the aggregate shape, which 
happens when monolayers curl and undergo a Lα to HII phase to lower the total free 




Figure 1.4: The geometrical packaging concept. The general relationship between the lipid 
molecule and preferred aggregate structure is illustrated, according to the surfactant packaging 
parameter. When the surfactant packaging parameter, S, is 1, the lipid is roughly cylindrical and can 
form stable bilayers (lamellar phase) when in aqueous solutions. When S <1/3 lipids tend to organise 
into micelles in a hexagonal phase I, whereas S>1 tends to cause lipid to form inverted micelles 






1.2.3 Lamellar Phases 
 
Lipid bilayers are dynamic structures which can exist in many different physical 
states (159). Phase behaviour is defined as the relative fluidity of the lipid bilayer 
with respect to changes in lipid composition and temperature (160). Typically, there 
are two major phases: the lamellar liquid-crystalline or liquid phase (Lα) and the 
lamellar gel or solid phase (Lβ). In the liquid phase, molecules freely diffuse within 
the two dimensional plane, rapidly exchanging position with neighbouring molecules 
in a process known as lipid ‘flip-flop’ or transbilayer lipid motion (161). Lipids in 
the gel phase are fixed in place and exhibit limited mobility. The attractive 
interactions between individual adjacent molecules are important in determining the 
phase behaviour. The length of the fatty acid chains permits more interactions 
between adjacent molecules leading to tighter packaging of lipid molecules and 
therefore less mobility (162). The degree of saturation of hydrocarbon tails also 
affects the phase behaviour, with the addition of double bonds disrupting lipid 
packaging and increasing mobility and flexibility (162). The melting or transition 
temperature (Tm) is defined as the temperature where the gel-to-liquid phase 
transition occurs and is a function of the chemical composition of the bilayer, 
particularly the acyl chains.  
 
1.2.4 Vesicle formation  
 
Vesicles are self-closed bilayer structures which can encapsulated the solution from 
which they are formed in. Bilayer edges tend to seal when they are mechanically 
dispersed in aqueous suspension, due to their amphipathicity, the hydrophobic effect 
and the assembly of hydrocarbon chains away from water molecules. When planar 
bilayers are dispersed in a hydrophilic environment, bending curvature minimises the 
high surface tension at the rim of the bilayer sheet. A thermodynamically favourable 
structure results when an entropically driven encapsulation of hydrocarbon chains 
into spherical vesicles occurs (156, 158, 163). Lipids which are used to formulate 
vesicles are generally cylindrical in shape containing more than 11 carbons in their 
acyl chain (158). Vesicles can be classified on the basis of lamella, either uni- or 
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multilamellar and size (163). Multilamellar vesicles (MLVs) contain concentric 
bilayers and are easily prepared by simple shaking of a dried lipid film in aqueous 
solution (163). Unilamellar vesicles (ULVs) can be sub-divided into two categories, 
small unilamellar vesicles (SUVs) or large unilamellar vesicles (LUVs) (158, 163). 
SUVs have diameters of 20-50 nm and are prepared through extensive sonication of 
MLVs, or through extrusion through polycarbonate filters of defined size. LUVs are 
vesicles with diameters between 100 nm and 5 µm and are formed in a similar 
fashion to SUVs, but with an added freeze-thaw step which induces fusion of SUV 
(164). 
 
 Using liposomes as biosensors for bacterial detection requires a vesicle type 
which exhibits stability in diverse environments, but also sensitive to secreted 
virulence factors. The vesicles used throughout this thesis contain 16 carbon DPPC 
and 16 carbon 1, 2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE) 
phospholipids. Both of these lipids are saturated, resulting in a higher transition 
temperature and a more stable vesicle. The incorporation of a polydiacetylene, 10, 
12-tricosadiynoic acid (TCDA) is also performed. This lipid is amphiphilic and can 
self assemble and incorporate into the lipid bilayer following ultra-violet (UV) 
induced polymerisation, providing stability (165). The addition of cholesterol has 
major effects of membrane fluidity causing the vesicle membrane to transition from a 
liquid-disordered to liquid-ordered state (166). Cholesterol influences the rigidity of 
the membrane controlling permeability and will affect the incorporation of bacterial 
toxins and the sensitivity of these vesicles.  Overall the liposome recipe, as depicted 
in section 2.2 and highlighted above, was chosen to satisfy the two biophysical 
parameters of stability and sensitivity.   
 
Carboxylfluorescein (CF) is a fluorescent molecule that is self-quenchable at 
high concentrations due to the formation of non-fluorescent dimer molecules at 
concentrations above 0.2 M (167). This trait allows this molecule to be used as a 
sensor dye, only fluorescing when diluted, in cases such as liposome burst. 
Additionally this molecule is an attractive candidate to use in such biosensors as it is 
cheap and relatively non-toxic at concentrations used in this thesis (168).  
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1.3 Staphylococcus aureus  
___________________________________________________________________________________________ 
 
taphylococcus aureus was identified as a causative agent of disease in 1882, 
when Sir Alexander Ogston highlighted its role in abscess formation and 
sepsis (169). In the past century our knowledge of S. aureus in areas of 
epidemiology, physiology and pathogenicity, has increase exponentially, however 
this fantastically equipped organism remains a global threat to human health.           
 
S. aureus is a Gram-positive, facultative anaerobic, coccal bacterium, and is a 
common commensal of mammals. This bacterium is non-flagellated, but does have 
the ability to spread on soft agar at temperatures between 30-43°C, a method of 
mobility dependent on the expression of teichoic acids and surfactant molecules such 
as the PSM peptides (170, 171). Exactly what advantage this colony spreading 
mechanism of mobility confers to bacteria is unknown, but it may aid effective 
colonisation over surfaces such as host tissue or inanimate objects such as catheters. 
Macroscopically, this bacterium generally grows with a golden colour due to the 
expression of the carotenoid pigment staphyloxanthin, which plays a role in 
resistance against hydrogen peroxide and hydroxyl radicals, compounds important in 
neutrophil killing (172). This carotenoid molecule acts as an antioxidant, 
sequestering oxygen free radicals through its conjugated double bonds (172, 173). 
Microscopically, S. aureus presents as clusters, as cell division occurs in three 
alternating perpendicular planes resulting in sister cells remaining attached after 
division, causing the irregular clumping phenotype (174). In the environment, S. 
aureus can withstand harsh conditions and is extremely versatile, capable of growing 
in a wide range of temperatures, from 7 to 48.5°C (175), pH between 4.0 and 10.0 
and sodium chloride up to 3 M (176).  
 
1.3.1 Genome and evolution of S. aureus 
 
The genomes of S. aureus consist of a single circular chromosome which range in 




a plethora of S. aureus strains have now been sequenced, allowing comparative 
genetics to identify conserved and variable features of the genome.  
 
1.3.1.1 Core genome 
 
The S. aureus genome can be divided into two parts; the core and accessory 
genomes. Approximately 75% of the genome is core, defined as genes conserved in 
all strains (179). Unsurprisingly, the majority of these genes are required for essential 
functions, central in metabolism and survival (179). However, genes involved in 
virulence are also contain within these genetic blocks, coding for surface and capsule 
proteins and as well as adhesins, toxins and enzymes (179).  
 
At first instance it would seem that genes within these region do not play 
major roles in the diversity observed between S. aureus lineages, however, subtle 
minute changes in genes can have drastic effects on gene function and overall 
phenotypes of strains (177). Isolates from the same clonal complex or lineage have 
very conserved core genomes while isolates from different lineages can have major 
differences with variability in hundreds of genes (179). Genetic diversity can arise 
due to single base-pair changes (single nucleotide polymorphisms SNPs), insertion or 
deletion (InDels) of a single or run of bases pairs within genes or intergenic regions, 
or by large scale rearrangements observed through blocks of divergent sequence due 
to recombination (177, 180). Most of the observed diversity within the core genome 
is a result of SNPs, which can result in either a synonymous or non-synonymous 
mutation. A non-synonymous mutation results in a change in amino acid and may 
result in altered gene and/or protein expression. Synonymous mutations can be 
regarded as ‘silent’ mutations as codon change does not result in amino acid change, 
however a codon bias may result. This codon usage alteration can become substantial 
if it affects the efficiency of translation of essential proteins (181).  
 
Recombination in the core genome can drastically influence bacterial 
physiology. Genetic information up to several kilobase pairs can be exchanged 
through homologous recombination, evident within the variable region between agrB 
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and agrC in the accessory gene regulator operon (182). This recombination event is 
responsible for the four different auto-inducing peptide (AIP) groups which define 
Agr activity (183), enabling cross activation or inhibition of other groups (184).  
 
1.3.1.2 Accessory Genome  
 
The variable or accessory component of the S. aureus genome consists of non-
essential genes involved in virulence, substrate utilisation, antibiotic and heavy metal 
resistance and other metabolic functions (177, 185). Horizontal gene transfer (HGT) 
plays an important role in shaping the accessory genome, as many of the mobile 
genetic elements (MGE) which comprise the accessory genome (bacteriophages, 
staphylococcal pathogenicity islands, plasmids, transposons, and staphylococcal 
cassette chromosomes) can all be transferred horizontally between bacteria. 
Therefore, the MGEs are much more varied than the core genome, and can be key 
factors in driving the evolution of S. aureus clones.  
 
Three mechanisms dictate HGT: transformation, conjugation and 
transduction (186). Until recently, S. aureus was regarded as unable to acquire ‘free’ 
DNA from the environment by natural transformation. However, the recent 
identification of a novel sigma (σ) factor, σH, has been demonstrated to assist RNA 
polymerase (RNAP) in the expression of competence genes, the comG and comE 
orthologues in S. aureus (187). Interestingly, sigH
 
expression is cryptic and is not 
detected under normal laboratory conditions, whereas artificial overexpression can 
induce competence genes (187). Morikawa et al highlighted that σH is expressed in a 
fraction of the population involving chromosomal gene duplication rearrangements 
which occur spontaneously and at low frequency permitting the expression of a new 
chimeric sigH gene (188). This expression is also under post-transcriptional control, 
possibly by a small regulatory non-coding RNA, and requires growth in a specific 
medium (187). Under these conditions the successful transformation of recipient 
cells was observed through the acquisition by transformation of a Staphylococcal 
cassette chromosome mec (SCCmec II) element (188). 
24 
 
Conjugation involves the transfer of genetic material from a recipient to a 
donor cell, by pili or pores. S. aureus does not contain pili, therefore it is 
hypothesized that conjugation is pore-mediated between cells in close contact, but is 
not a common mechanism of HGT found in S. aureus (177, 189). tra (transfer) genes 
are important in the transfer encoding the necessary machinery for conjugation to 
occur, and this method of HGT is restricted to conjugate plasmids containing these 
genes (190) which were found in only 13 of the 243 sequenced S. aureus plasmids 
(191).  
 
The main method of HGT in S. aureus is believed to be via transduction, 
which is the transfer of DNA mediated by bacteriophage. Bacteriophages are viruses 
which infect bacteria and either incorporate their genetic material into the bacterial 
chromosome (prophage) or package and deliver ‘foreign DNA’, derived from the 
bacterial chromosome or plasmids, in a process known as generalised transduction 
(177). After infection, phage can be induced to excise, replicate, synthesis new phage 
particles and lyse the bacterial cell releasing new phage leading to infection of 
susceptible cells. Lysogenic phage (phage which remain integrated within the host 
genome), are common in S. aureus, with most strains carrying between one and four 
types (177). Phage genomes are approximately 45 kb in length, which limits the 
amount of genetic material that can be packaged inside phage heads, prior to 
infection. Many bacteriophage carry with them virulence genes which code for 
virulence factors such PVL (192)), enterotoxin A (193), and exfoliative toxin A 
(194).  
 
S. aureus pathogenicity islands (SaPIs) are related to bacteriophages; they are 
14-27 kb in length, contain phage-like repressors, integrases and terminases as well 
as virulence genes (195). Some of the SaPIs encode superantigens, (SaPI 1 encodes 
tst, sek and seq (196)) and immune inhibitory proteins, (SaPI5 codes for chemotaxis 
inhibitory protein (chp) (197) and staphylococcal complement inhibitory protein 
(scn) (198)). However, the genes required for transfer (synthesis of capsid heads and 
tails) are absent. SaPIs are normally repressed and integrated within the bacterial 
chromosome, but during HGT, helper phages (such as bacteriophage 80α (199)) 
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encode proteins which inactivate SaPI repressor proteins permitting efficient 
mobilization (195). These helper phage package SaPIs and deliver them to new S. 
aureus strains whereby SaPIs may integrate at specific site, in an analogous fashion 
to phage (196).  
 
Plasmids are autonomously replicating, circular segments of DNA which 
encode a variety of genes beneficial to the host, including resistance to antibiotics 
(pT181 (200), tetracycline resistance in S. aureus strain COL), heavy metal 
resistance (pI258 cadmium resistance in S. aureus (201)) and exfoliative toxin B 
(pETB (202)). Historically, plasmids have been classified based on size and 
incompatibility (203). A more recent classification system has been developed based 
on the sequence of replication (rep) genes (204). Recent work has reported on the 
distribution of plasmids, conferring antibiotic resistance and virulence, in S. aureus 
populations, highlighting specific plasmid groups with specific lineages (191). This 
observation suggests that there are genetic pressures and restrictive barriers to 
evolution of hyper-resistant, hyper-virulent S. aureus strains (191). 
 
Transposons are MGEs which encode a transposase gene, conferring the 
ability to excise, replicate and integrate into the chromosome or plasmid. 
Transposons are generally small and encode resistance to antibiotics, for example 
Tn554 encodes resistance to erythromycin (205). Transposons can integrate multiple 
times in the chromosome and also integrate within other MGE such as SCCmec or 
plasmids (206). It is this ‘hitch-hiking’ on other MGE which is the hypothesised 
method of how the undergo HGT.  
 
 Staphylococcal cassette chromosomes (SCCs) are relatively large DNA 
fragments of 21-53kb in length that can encode either antibiotic resistance and/or 
virulence factors. SCCs can be divided into those which contain the mecA gene, 
which confers resistance to the beta-lactam antibiotics (SCCmec) and those that do 
not (non-SCCmec). mecA encodes that alternative penicillin binding protein 2a 
(PBP2a) which has a much lower binding affinity to semi-synthetic penicillins (207). 
Beta-lactam antibiotics work by preventing the crosslinking of peptidoglycan 
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polymers by inhibiting the transpeptidase action of native PBPs, therefore the 
introduction of PBP2a circumvents this inhibition. The SCCmec elements, in 
addition to the mecA gene, comprise mecI and mecR, which encode the repressor and 
signal membrane transducer respectively. Another important feature are site-specific 
recombinases, known as cassette chromosome recombinases (ccr) which catalyse the 
integration and excision of SCCmec elements within a specific attachment site 
(attBscc) at the 3’ end of the S. aureus chromosome (208). All SCCmec elements  
share certain characteristic: presence of the mec and ccr gene complexes, integration 
at a specific site, known as the integration site sequence (ISS) and direct repeats 
flanking the ISS (209). Currently, there are eight described SCCmec types in S. 
aureus, as shown in figure 1.5. Classification of these elements is based on a 
combination of ccr and mec gene complexes (209). Presently there are 3 ccr genes, 
ccrA, ccrB and ccrC. The ccrA and ccrB genes have been grouped into 4 allotypes 
based on the designation of genes within the same allotype with nucleotide identities 
of  ≥ 85%. There is only one ccrC allotype, as all identified variants show nucleotide 
similarities of  ≥ 87%.  The mec gene complex is composed of mecA, the regulatory 
genes and the commonly associated insertion sequence (IS431) downstream of 
mecA. Four mec gene complexes exist in S. aureus, based on the genetic diversity 
within the mecI-mecR1 region. Class A is the prototypical class, with an intact and 
functioning mec gene complex. Classes B, C1 and C2 have truncated mecR1 genes 
due to either insertion of IS1272 within mecR1 (class B) or IS431 in mecR1 (class C1 
and C2 differ in the orientation of the insertion sequence). Variants of the mecA class 
also exist, as shown in the type IV variant in figure 1.5., which has a Tn4001 
insertion within the mecR1 gene. The SCCmec also contains a region known as the J 
or joining region, which consist of non-essential components of the element, but 
often carry additional antimicrobial resistance factors in the form of integrated 
plasmids or transposons. For example the pUB110 plasmid integrated within 
SCCmec II elements harbours the ant4’ gene, encoding resistance to several 











                                        
Figure 1.5: Classification of SCCmec. The primary structures of the eight SCCmec elements are 
shown. The different mec gene complexes and ccr groups are highlighted in brackets. Insertion 
sequences and common accessory genes in the J-regions are also illustrated. The red arrows indicate 
the integration site sequence. Adapted from (209).  
 
 
Another genetic component within certain SCCmec elements (SCCmec II, III and 
VIII) is the phenol soluble modulin psm-mec, the only identified toxin within a 
mobile antibiotic resistance determinant (211, 212). psm-mec appears to have 
opposing functions; as a transcript it acts as a regulatory RNA inhibiting the 
translation of the agrA gene (213). Introduction of psm-mec into CA-MRSA or a 
MSSA strain decreases production of core genome PSMs (214), as PSMs are 
positively regulated by direct AgrA binding to psm promoter regions (215). 
Consistent with these observations, deletion of psm-mec from certain HA-MRSA 
strains increases expression of AgrA and core genome PSMs (213), illustrating the 
inhibitory effect of psm-mec in the expression of important virulence factors. The 
translational product of psm-mec, the cytolytic PSM-mec peptide, is active against 
human neutrophils and it has been shown that psm-mec has a positive effect on 
virulence in a mouse skin and systemic infection models (216). However, this effect 
appears to be strain dependent, as this positive correlation between virulence and 
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psm-mec is not observed in all HA-MRSA strains (213, 216). Therefore, this element 
appears to have both virulence inhibiting and activating properties, based on its 
transcriptional or translational status. The inhibitory effect of psm-mec is partly 
responsible for the increased virulence observed in CA-MRSA, due to the absence of 
psm-mec on SCCmec elements generally associated with CA-MRSA strains (213).  
 
Certain SCC elements encode other factors which benefit the bacterial host in 
a non-antibiotic resistance fashion. For example, SCCcap1 contains genes involved 
in the synthesis of capsular proteins, important in immune evasion (217). SCCmec 
elements spread relatively slowly and the exact mechanism which promotes 
replication and transfer is not known. It has been suggested that the SCCmec IV 
which spread more easily and frequently, maybe able to package into phage head and 
undergo transduction due to its smaller size (177). With respect to the larger SCCmec 
elements, the newly described proteins involved in transformation (188) may be an 
important method of transfer but this is not known as of yet.  
 
1.3.1.3 Identifying related strains – Genotyping  
 
Monitoring S. aureus strains is important from an epidemiological, evolutionary and 
preventative perspective; in light of these requirements, various methods have been 
designed to investigate the relatedness of S. aureus isolates.  
 
 Multilocus sequence typing (MLST) is a sequencing-based genotypic method 
of discriminating between strains based on single nucleotide variants (alleles) of 
multiple housekeeping genes (218). For S. aureus, 450 bp internal fragments of 
seven housekeeping genes (arcC, aroE, glpF, gmk, pta, tpi, yqiL) are sequenced, and 
differences in each fragment are assigned different alleles, with the cumulative 
alleles of the seven genes generating a sequence type (ST) (219). If five or more of 
the loci are identical, the strains are grouped within the same clonal complex (CC). 
Mutations within these housekeeping genes accumulate slowly, therefore MLST can 




 Pulse-field gel electrophoresis (PFGE) is a highly discriminative typing 
method for S. aureus and was considered gold standard for investigating MRSA 
outbreaks in hospitals and evaluation of recent evolution among lineages. The 
method relies on the digestion of chromosomal DNA with the restriction enzyme, 
SmaI, and the separation of DNA fragments by agarose gel electrophoresis with an 
alternating voltage gradient. The resulting pattern of DNA bands are analysed using 
specialised software and related strains are grouped according to an 80% similarity 
coefficient (220).  
 
spa typing is a sequence based analysis, which determines the variation 
within the polymorphic region X of the spa gene (encodes protein A) (221). 
Differences in the sequences of the variable-number tandem repeats allow 
discrimination between strains. This method is inexpensive, less laborious and time 
consuming than MLST as only one locus is sequenced. However, spa typing can lose 
its discriminative power which occurs when the same or related spa gene occurs in 
different clonal lineages, possibly through recombination (222).   
 
 The methods stated above do not fully discriminate between isolates of the 
same lineage and therefore do not provide the high resolution required to define 
specific relationships between strains. Next generation sequencing (NGS) technology 
has been employed to gain a more precise understanding of the relationship between 
strains, down to the finest of details. NGS has been used to generate ultra-fine data 
based on the mapping of SNPs and InDels from whole populations to that of a 
reference sequence (223). Each whole genome can be tagged individually allowing 
multiple strains to be sequenced rapidly and efficiently, with SNP and InDel outputs 
presented highlighting where changes to the reference genome occurred. This 
method was used in monitor the hospital and intercontinental transmission of a 
highly transmissible, multi-drug resistant clone of MRSA, ST239 (223). Results from 
this project illustrate the high discriminative power and superiority NGS has over 
other typing methods, resolving 5 strains which differed by only 14 SNPs. On the 
basis of SNP variation and sensitivity of the whole genome analysis, isolates can 
now be traced during outbreaks, and used to investigate their relatedness (224, 225).   
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1.3.1.4 Evolution and clonal diversification of MRSA  
 
Molecular epidemiology reveals that the population structure of S. aureus and 
evolution of MRSA is predominantly clonal (226, 227). By analysing the sequence 
changes at MLST loci, it was estimated that point mutations occurred 15-fold more 
frequently than recombination and that this is the driving force behind the initial 
stages of clonal diversification (226). However, recombination plays an important 
role in shaping the genome of S. aureus and is generally restricted to the MGEs of 
the non-core or accessory genome, but within core genomes the highest rates of 
recombination are localised to cell envelope proteins (180). Long-term evolution of 
S. aureus can be influenced by large chromosomal replacements (226, 228), as seen 
in the mosaic chromosome of ST239, a descendent of ST8 lineage, which underwent 
a significant recombination event acquiring 635 kb fragment from ST30 background 
(178). Recently, it has been observed that the recombination rate varied significantly 
within a single clone of S. aureus (ST239), and that this variation was associated 
with phylogeography (180). What is ultimately causing this variation is currently 
unknown but could be due to a variety of factors including genetic changes in the 
bacterial genome affecting restriction and modification system thereby imposing 
barriers to recombination within specific sub-clones (180, 189). 
 
The history of methicillin resistance S. aureus began with the successful 
introduction of the SCCmec element into a methicillin susceptible S. aureus (MSSA) 
host. The origins and mechanism of transfer of SCCmec are still unknown but an 
ordered progression of SCCmec transmission among the staphylococci has been 
proposed (228, 229). Considering that a PBP belonging to S. sciuri has the highest 
amino acid similarity (88%) to PBP2a, it is feasible to suggest that this organism was 
the evolutionary precursor of the mecA found in MRSA strains (229, 230). It has 
been hypothesised that the SCCmec element was first formed in coagulase negative 
staphylococci (CoNS), after the recombinases (ccr) and mec regulatory genes were 
assembled on a MGE in CoNS, which then acted as donors for transmission to S. 
aureus (228, 230). There are several lines of evidence that suggest this transmission, 
notably the intact nature of IS1272 found in CoNS and on SCCmec elements  
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consistent with transmission from a CoNS, the in vivo development of MRSA as a 
result of transmission of mecA from S. epidermidis to S. aureus (231), the high rate 
of methicillin resistance found in S. epidermidis and the observation that SCCmec IV 
was present in S. epidermidis before S. aureus (228).    
 
 There have been multiple introductions of SCCmec into S. aureus, and 
although the origins of MRSA are not completely understood, it is now agreed that 
MRSA did not arise from a single ancestral clone, highlighted by the evidence that 
strains with the same ST have different SCCmec types (227). It has now been 
determined that acquisition of SCCmec has occurred at least 20 times, with models 
predicting that acquisition was 4 times more likely than replacement (232). The S. 
aureus population consists of approximately 11 different lineages or clonal 
complexes (CC1, CC5, CC8, CC12, CC15, CC22, CC25, CC30, CC45 and CC51) 
with the most dominant HA-MRSA isolates belonging to CC5, CC8, CC22, CC30 
and CC45 (227). Enright et al investigated the evolutionary origins of a vast 
international collection of MSSA and MRSA isolates and identified 11 major STs 
within the five major lineages above (227).  
 
The ancestral MRSA genotype has shown to be ST250 which arose after the 
acquisition of SCCmec I by ST-250 MSSA, which itself descended from ST8 MSSA 
(227). CC8 is a successful clonal complex, containing three other major epidemic 
MRSA (EMRSA) STs (ST8, ST247 and ST239). Although ST8 is a successful 
MSSA clone, it has also acquired SCCmec types II and IV and is a widely 
disseminated EMRSA clone (227). ST247 is a single locus variant (SLV) of ST250 
and has spread internationally, known commonly as the Iberian clone (233) whereas 
the Brazilian clone (ST239), which also has genetic roots from CC8, is highly 
transmissible and multidrug resistant (234). The other major internationally 
disseminated EMRSA STs (ST5, ST22, ST30 and ST45) are very different 
genetically to the CC8s and originated from epidemic MSSA lineages that acquired 




 The first antibiotic resistant S. aureus was the penicillin-resistant phage type 
80/81 pandemic strain which caused infections in both the hospital and community 
(235). EMRSA-16 is one of the most successful MRSA clones to have emerged over 
the past 20 years, and belongs to the same clonal complex of phage type 80/81, CC30 
(236). Interestingly, after genetic characterisation and comparison of genome 
sequences of isolates representing phage type 80/81, and CC30 hospital clones, it 
was shown that these strain diverged from a recent common ancestor (237). The shift 
from highly virulent phage type 80/81 to less virulent hospital restricted EMRSA-16 
clone maybe due to the acquisition of the SCCmec type II element which has been 
shown to interfere with agr signalling and reduction in cytolytic toxin expression 
while conferring resistance to beta-lactam antibiotics (238).  
 
EMRSA-15 represents a particularly successful clone associated with rapid 
and efficient transmission within the hospital environment, with evidence of spread 
to other countries (239, 240). EMRSA-15 belongs to the ST-22 family and is one of 
the most frequent found MRSA clones in Europe (240). In order to understand the 
genetic changes that contributed to the success of this clone, Holden et al sequenced 
the genomes of 193 ST-22 isolates from 15 countries (241). Of the many mutation 
and genetic rearrangements that were identified in order to explain ST-22 success, 
two nonsynonymous SNPs associated with fluroquinolone resistance were 
highlighted as key factors, with the authors suggesting that resistance to this 
particular antibiotic may have given ST-22 a competitive advantage and promoted 
colonisation in an environment where this antibiotic was frequently used. Other 
studies have shown that the acquisition of specific genetic elements can contribute to 
enhanced spreading, colonisation, virulence and success of MRSA clones. The 
acquisition of the ΦSPβ-like prophage containing the sasX gene has been implicated 
in the successful spreading and dominance of ST239 in China in the past 10 years 
(242). This 15kDa surface protein promotes nasal colonisation through increased 
attachment to nasal epithelial cells, bacterial aggregation and biofilm formation and 
impedes phagocytosis, increasing survival within the blood (242). The expression of 
this multifactorial protein promotes abscess formation in mice (242) and is a key 
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factor in increased pathogenic activity and epidemiological success of this specific 
epidemic clone. 
 
 Community acquired- (CA-) and hospital acquired- (HA-) MRSA are very 
different both in terms of genetic background and phenotype (discussed in detail in 
section 1.3.3), and are not from related lineages, with more clonal diversity observed 
within CA-MRSA than HA-MRSA (243, 244). Presently there are 5 major CA-
MRSA clones in circulation globally: ST1 clone in disseminating in Asia, Europe 
and the US, ST8 predominantly caused by USA300 clone in the US, but becoming 
more frequent in Europe, ST30 clone of Australia, Europe and South America and 
the ST80 clone harbouring in Asian Europe and the Middle East (222). The 
acquisition of SCCmec by CA-MRSA strains most likely occurred by MSSA 
acquiring SCCmec IV, as PVL positive MSSA strains were present in Japan and 
acquired SCCmec IV (245).  
  
The evolutionary success and dominance of certain S. aureus clones can be 
attributed to the successful acquisition of genetic elements horizontally, highlighted 
recently by the acquisition of sasX by ST239 strains in Asia. Recent evidence 
suggests that within certain lineages, MGEs are transferred with higher frequency 
than in others, potentially enhancing the successful spread of new MRSA clones 
(177). One method that S. aureus has evolved to prevent transfer of genes between 
different lineages is highlighted by the restriction and modification systems which 
targets and destroys ‘foreign’ DNA based on sequence and modification patterns 
(189). Therefore, these RM systems can dictate bacterial evolution by preventing 
transfer of virulence or resistance genes between different CCs. However, in certain 
cases, lack of a particular target sites enables genetic transfer between lineages which 
may be an important feature in driving the evolution of MRSA clones (246).   
 
1.3.2 S. aureus and the human host  
 
The main ecological niche for the colonisation of the human host by S. aureus is 
localised to the non-ciliated, keratinized epithelium of the anterior nares (vestibulum 
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nasi) (247-249). Other anatomical sites may also be colonised including the axillia 
and perineum (247), and in some cases the  pharynx; however it is unclear whether 
this is a permanent or transient site, as S. aureus adherence to nasopharyngeal 
ciliated epithelium is poor (250). Nasal carriage is a recognised risk factor for 
staphylococcal disease (249, 251). Patients undergoing medical treatment are more 
likely to become infected if they are carriers than those who are not (252, 253). It has 
been widely accepted that the majority of infecting strains are identical to that of the 
carriage strain (254, 255) with one particular study highlighting nasal isolates as a 
source of bacteraemia in greater than 80% of cases (251). Elimination of nasal 
carriage using topical antimicrobials generally eliminates colonisation from other 
anatomical site, highlighting the nares as the dominant reservoir for infection (256). 
 
Historically, S. aureus nasal colonisation of humans has been divided into 
three groups: persistent carrier, which accounts for approximately 20% of 
individuals, intermittent carrier (~30%) and non-carriers (~50%) (247, 248, 257). 
However, the rate of re-colonisation after elimination varies widely, as does the 
prevalence of S. aureus with respect to ethnicity, age, sex and patients with chronic 
underlying illness (255, 258-260). The identification of specific features of the 
different carriage types has redefined nasal carriage classification (261). Using a 
human colonisation model, S. aureus strains were observed to have a significantly 
higher survival rate in persistent carriers as opposed to intermittent and non-carriers, 
which show similar rates (261). Coupled with differences in bacterial load in colony 
forming units (CFU) per sample and anti-staphylococcal antibody profiles between 
the persistent and intermittent/non-carriers groups, nasal carriage is now grouped as 
either persistent or others (261). The ability of S. aureus to persist in the nasal 
cavities in certain individuals is not fully understood, but is likely to be a result of a 
combination of host and bacterial factors and the presence of commensal organisms, 
as illustrated in figure 1.6.  
 
The pattern of carriage of S. aureus suggests a host genetic predisposition to 
colonisation, supported by the observation that nasal carriage varies with ethnicity 
(262). Recent studies have shed light onto specific genetic polymorphisms and 
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environmental nasal conditions which modulate colonisation. Nasal secretions 
contain anti-staphylococcal potential in the form of antimicrobial peptides (AMPs) 
such as lysozyme, lactoferrin, phospholipase A2 and defensins (263). Unsurprisingly, 
reduced expression of these AMPs  have been implicated with increased nasal 
carriage (264). Curiously, certain individuals produced secretions which promoted 
nasal colonisation (265). Protease treatment and immunoprecipitation studies 
revealed haemoglobin as the substance conferring increased colonisation (265). It 
was observed that haemoglobin not only increased bacteria attachment to collagen 
and fibronectin, but decreased the inoculum size required for establishing successful 
colonisation in a rat model (265). Interestingly, this effect was independent of iron as 
apohaemoglobin also promoted this phenomenon. It has been observed previously 
that the alpha and beta chains of haemoglobin inhibit exotoxin production in S. 
aureus (266). Interestingly, it was shown that haemoglobin specifically inhibited the 
accessory gene regulatory (Agr) quorum sensing system (Agr reviewed in section 
1.3.4.1) and that constitutive expression of RNAIII, the effector molecule of the 
system, inhibits nasal colonisation (265). The authors suggest that since Agr 
regulates proteases, the downregulation of agr by haemoglobin may infer an 
advantage by inhibiting the activation of proteases which may cleave surface proteins 
important in attachment and colonisation to squamous epithelial cells (265). Other 
host factors contributing to a persistent nasal carriage state involved polymorphisms 
in genes which can modulate immune activity, such as glucocorticoids, C-reactive 
proteins, interleukin 4 and complement inhibitor proteins (267, 268). 
 
It is widely known that commensal bacteria can compete and inhibit 
pathogenic bacteria and influence colonisation (257). Recently, the impact of normal 
flora on S. aureus nasal colonisation has been reported. Here a subset of 
Staphylococcus epidermidis strains secreting a serine protease, Esp, lead to inhibition 
of biofilm formation and nasal colonisation by S. aureus (269). This inhibitory effect 
is augmented when Esp is combined with human beta-defensin 2 (hBD2) an AMP 
secreted by keratinocyes, resulting in higher biofilm destruction (269). Introduction 
of wild type but not esp mutants in human S. aureus positive volunteers lead to the 
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elimination of S. aureus colonisation, clearly showing the importance of S. 




Figure 1.6: Factors affecting persistent nasal colonisation of S. aureus. This schematic represents 
some of the major factors affecting persistent nasal carriage of S. aureus. The expression of proteins 
(ClfB, IsdA and SdrC and D) and polymers (wall teichoic acids (WTA)) on the surface of S. aureus 
interact with the squamous epithelium facilitating adherence and colonisation. ClfB specifically 
interacts with two ligands on the surface of squamous epithelial cells, loricrin and cytokeratin. Nasal 
secretions contain different antimicrobial peptides (AMPs) which can inhibit the growth of S. aureus 
in the nasal cavity. Nasal secretions can also contain factors which increase colonisation, exhibited 
here by high haemoglobin concentrations. Haemoglobin interferers with Agr signalling, which may 
interrupt protease activation resulting in higher surface protein expression and increase nasal 
colonisation.  A subset of S. epidermidis strains secrete the Esp protease which reduces biofilm 
formation and nasal carriage, which occurs through a mechanism involving human beta-defensin 2 
(hBD2) AMP.  
 
 
Bacterial factors are also extremely important in nasal colonisation. The most 
influential factor for nasal carriage is the ability of S. aureus to adhere to epithelial 
surfaces. For this interaction to take place, bacteria need to expresses the correct 
surface proteins to interact with the corresponding ligands present on cells. One of 
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the major ligands on the cell surface of S. aureus is clumping factor B (ClfB) (98). 
This protein has been shown to interact with two specific structural proteins of 
squamous epithelial cells, cytokeratin 10 and loricrin (270) and the absence of either 
ClfB or loricin in mouse models diminishes nasal colonisation (270, 271). Through 
the use of surrogate expression, isogenic mutants and ex vivo squamous adherence 
assays, other surface proteins have also been implicated in nasal colonisation, most 
notably the iron surface determinant protein IsdA, and the serine-aspartic acid repeat 
proteins, SdrC and SdrD (272). The S. aureus cell envelope also contains complex 
surface-exposed polymers, known as wall teichoic acids (WTA) (273). These 
molecules are composed of ribitol phosphate repeating units modified with N-
acetylglucosamine and D-alanine (273). The role of these complex polymers in nasal 
colonisation was explored, with mutants deficient in key teichoic acid biosynthetic 
steps impaired in their adherence to primary nasal epithelial cells and human airway 
epithelial cells (274), however the precise receptors to which WTA in anchors with 
remains to be determined.  
 
1.3.3 Epidemiology and disease of S. aureus  
 
Humans are a natural reservoir of S. aureus and can exist in a non-pathogenic 
relationship with the host. Generally, initiation of infection begins with a breach in 
the natural barriers of the skin and/or mucosa, from which bacteria can invade the 
adjoining tissues or bloodstream (275, 276). S. aureus can cause a wide range of 
pathophysiological complications and is a leading cause of hospital-acquired 
infections (277). S. aureus is the primary cause of lower respiratory tract and surgical 
site infections (278) and among the most prevalent causes of bacteraemia (279) and 
pneumonia (67, 277, 278). 
 
 In the US alone, hospitalization and rates of infection increased substantially 
between 1999 and 2005 (277), and in 2009 an estimated 463,017 MRSA-related 
hospitalizations was recorded, at a rate of 11.74 hospitalisations per 1,000, 
illustrating the increasing burden this pathogen imposes on health care resources 
(280). Fatalities due to MRSA infection in hospitalised Americans approximate at 
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19,000 annually, a number that is equal to the combined deaths due to AIDS, 
tuberculosis and viral hepatitis combined (281, 282). The severity of the disease 
depends on the complex interplay between the multitude of S. aureus virulence 
determinants (reviewed in section 1.3.5) and the capabilities of host immune defence. 
Although the vast majority of S. aureus infections require a combination of these 
virulence determinants, in some cases, individual factors can be singled out as the 
predominant cause, such as in toxic shock syndrome (283), staphylococcal scalded 
skin syndrome (284) and necrotic lesions of the skin or mucosa (285).  
 
S. aureus is notoriously difficult to treat due to antibiotic resistance. Since the 
first appearance of methicillin resistance in 1960, MRSA strains have spread globally 
and are now endemic, and in some cases, epidemic in hospitals, care facilities and 
communities (67, 281, 286). The high incidence of MRSA is not only localised to the 
US, with South East Asia, southern Europe, parts of South America and Australia all 
having rates of prevalence between 25-50% (228). This is in stark contrast to the 
Scandinavian countries and the Netherlands, which have the lowest MRSA 
prevalence rates, due to their effective search and destroy policies of screening, 
isolation of MRSA-positive carriers and eradication (287). In Europe, MRSA clones 
display higher levels of clustering and regional distribution than their MSSA 
counterparts (240). However, as MRSA strains tend to emerge from MSSA strains 
and considering that the acquisition of SCCmec is a rare event, there are fewer 
MRSA clones which have had less time to diversify and have had more of a selective 
pressure in harsher environments which may constrain their diversity. In contrast, 
MSSA strains have a much weaker selection which may bias the geographical 
clustering of MRSA (240). Of growing concern is the emergence of MRSA infection 
in people who had no prior contact with hospitals or health care or other risk factors, 
the so called community-associated MRSA (CA-MRSA).  
 
Historically, S. aureus, particularly MRSA, was associated with hospital 
infection, so called hospital acquired/associated (HA)- MRSA (288). Risk factors for 
colonisation included surgery, intensive care unit admission, exposure to antibiotics 
or MRSA-colonised patient and prolonged hospital stay (288). Higher carriage rates 
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are associated with intravenous drug users, healthcare workers, patients with 
underlying illness such as dermatological conditions, indwelling devices and diabetes 
(275, 288). In recent years, MRSA epidemiology has changed from predominantly 
hospital acquired, to infections that are acquired in the community (289). With this 
switch came an increase in hospitalisations, primarily due to an increase in skin and 
soft tissue infections (SSTIs) caused by these CA-MRSA strains (290). The 
epidemiology of CA-MRSA is markedly age dependent, with CA-MRSA strains 
causing disease in younger patients with no previously defined health risk factors. 
How these CA-MRSA strains differ from HA-MRSA strains, in terms of clonal 
background, antibiotic resistance, virulence and transmissibility is described in the 
following section. MRSA is also found colonising livestock including pigs, cattle and 
poultry, a third epidemiological group known as livestock-associated- (LA-) MRSA, 




In the past HA-MRSA strains were restricted to the healthcare setting and out-
competed CA-MRSA in this environment probably due to their higher antibiotic 
resistance potential. CA-MRSA dominated in the community setting being fitter and 
more virulent than their HA-MRSA counterparts. Presently, there exists a more 
complex epidemiology, whereby both HA- and CA-MRSA circulate in the 
community and highly successful CA-MRSA clones are invading hospitals and 
healthcare facilities (292, 293). In spite of this, certain molecular traits can be used to 
discriminate between the two groups, a summary of which is shown in figure 1.7.  
 
In the early 1990s, the first documented CA-MRSA cases began to emerge in 
the US, with MRSA infections causing high mortality in healthy individuals in the 
community (294). In the following years, CA-MRSA became a global problem.  
Virulent CA-MRSA strains have been shown to belong to different lineages, with a 
geographical predominance (295). In the US, the most dominant CA-MRSA strain is 
USA300 (ST-8), replacing the first CA-MRSA strain observed in the US, USA400 
(ST-1), in all of North America and is considered to have caused the most severe 
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outbreak globally (296). CA-MRSA strains are highly associated with skin and soft-
tissue infections (296, 297) and under rare circumstances can cause more severe, 
often fatal diseases such as necrotizing pneumonia, Waterhouse-Friderichsen 
syndrome and necrotizing fasciitis (298).  
 
Comparative genomics of HA- and CA- MRSA strains was essential in 
assessing the molecular basis for CA-MRSA pathogenic success. Two mobile 
genetic elements were highlighted as possible markers for the enhanced virulence 
associated with CA-MRSA: SCCmec type IV and prophage ΦSA2pvl (299). In 
general terms, HA- and CA-MRSA differ substantially in terms of antibiotic 
resistance. The elucidation of a new, shorter SCCmec belonging to CA-MRSA (types 
IV,V or VII), highlighted a possible reason for the observed increased dominance 
and transmissibility, as these SCCmec elements (particularly SCCmec IV) were 
shown to cause less of a fitness burden than those SCCmec elements associated with 
HA-MRSA (namely SCCmec I, II and III) (300). CA-MRSA isolates are usually 
sensitive to most non-beta-lactam antibiotics, while HA-MRSA, due to the selection 
imposed on them by their environment, are generally multidrug resistance (301). 
Importantly, differences in the antibiotic minimum inhibitory concentration (MIC) 
are significantly different, with HA-MRSA requiring much higher antibiotic 
concentrations for efficient killing (296).  
 
The association between the Panton-Valentine Leukocidin (PVL) and CA-
MRSA has been carved into the history books of S. aureus as one of its most 
controversial chapters. PVL is a bi-component beta-barrel forming leukocidin 
(reviewed in section 1.3.5.2.2). Enormous interest surrounding the role of PVL in 
CA-MRSA infections began after epidemiological studies showed a positive 
association between the presence of pvl genes and CA-MRSA (302). In an attempt to 
unravel the role of PVL in CA-MRSA disease, isogenic mutants of lukS-PV (or lukF-
PV) were created and the effect this mutation had on either human neutrophils, or 
specific animal models, examined. The controversy stemmed from experimental 
practice: culture supernatants proved strongly dependent on growth media used 
(303), while different groups, using different animal models, observed contradictory 
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results (304-307). Recently, a receptor for PVL has been identified (C5a receptor 
(308)), explaining the low sensitivity of mouse neutrophils to PVL and the earlier 
results stating a non-involvement of PVL in CA-MRSA disease. PVL is important; 
however its importance is disease specific. Rabbit neutrophils are sensitive to PVL, 
in a range similar to humans (309), and it has been observed that PVL plays a 
significant role in the development of pneumonia (310). PVL involvement is less 
clear in skin infections, where it has been shown that α-haemolysin and phenol 
soluble modulins (PSMs)  involvement is critical (311). Finally, the observation that 
increasing numbers of CA-MRSA strains do not contain pvl genes (301), suggests 
that although PVL may be important in some diseases, it is not the only factor 
contributing to CA-MRSA enhanced virulence.  
 
Increased expression of core genes rather than the acquisition of novel 
elements is suspected to be behind the high virulence of CA-MRSA strains. 
Enhanced expression of two classes of toxin; α-haemolysin and phenol-soluble 
modulins (reviewed in section 1.3.5.2), have been implicated in the success of CA-
MRSA (312, 313). α-haemolysin is one of the most widely studied and well 
characterised of the staphylococcal toxins, forming pores in susceptible cells such as 
erythrocytes and macrophages (314). Studies investigating the effects of hla deletion 
in CA-MRSA resulted in a negative impact on virulence, particularly in pneumonia 
(315) and skin and soft tissue models of infection (311), highlighting its central role 
in CA-MRSA pathogenesis. PSMs are small amphipathic peptides, which do not 
require a proteinaceous receptor and can lyse a variety of cells including 
erythrocytes, macrophages and neutrophils (312, 316). PSMs are produced in huge 
quantities in CA-MRSA, and although the psm genes are present in HA-MRSA, they 
are expressed at significantly lower levels (312). This higher expression of PSMs is a 
major factor involved in the observed increase in virulence in CA-MRSA strains, 
complemented by the fact that deletion of the psmα operon significantly reduces the 
mortality rates in skin infections (311) and bacteremic mouse models (312). PSMs 
exhibit high antimicrobial activity, which may also be important for colonisation and 
spread in the population in which out-competing competitors is suspected to be 
important (317). Both toxins are regulated by the central virulence regulator, Agr, 
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which is highly active in CA-MRSA (318). The specific events and minute genetic 
changes in central regulators, such as Agr, may be behind the increase expression of 
core genes, the specifics of which have yet to be determined.   
 
CA-MRSA strains have undergone a rapid global expansion, and 
understanding the basis behind this is required if novel intervention strategies are to 
be developed. Factors that can enhance fitness and the ability to successfully colonise 
the host, are of major importance in the spread and epidemiological success of CA-
MRSA in the population. The arginine catabolic mobile element (ACME) is specific 
to the USA300 strain, physically linked to SCCmec IV (IVa), and considering its 
dominance in North America and growing success in Europe (319, 320) and South 
America (321), it was hypothesized that ACME may be important in overall fitness, 
enhancing colonisation and transmissibility (322). The ACME element, originally 
acquired from S. epidermidis, encodes two main clusters; an arginine deiminase (arc) 
hypothesized to reduce the acidic environment of the skin through production of 
ammonia, and the oligopeptide permease (opp) which may be important in nutrient 
uptake (322). No significant impact on virulence was established for the ACME 
element, and its role is enhanced colonisation and skin survival remains to be 
established.  
 
Polyamines are aliphatic compounds which have pleiotropic effects in many 
aspects of cellular biology particularly important in wound healing and inflammation 
(323). Interestingly, S. aureus is hyper-sensitive to polyamines, inhibiting rather than 
enhancing survival, a feature almost unique to S. aureus (324). However, USA300 
clones are the notable exception, illustrating resistance to such compounds (325). 
The polyamine-resistant dependent phenotype depended upon the expression of a 
spermine/spermidine acetyl transferase (speG) located within the ACME element 
(325), and this polyamine resistance phenotype was shown to contribute a major 
fitness advantage in SSTI models (326). Considering that CA-MRSA are a major 
cause of SSTI, and that these infections are likely to have increased polyamine 
production,  this particular resistance feature may contribute to the dominance of 




Other factors including the presence of additional superantigen genes 
(se1Q(327)) and virulence regulators (AryK, in the Australian clone, ST93 (328)) 
may also impact on the hyper-virulence of CA-MRSA. The higher incidence of CA-
MRSA in the US compared to Europe cannot be solely attributed to different clonal 
lineages as USA300 is present in Europe, but factors such as low socioeconomic 
standards, high rate of incarceration and lack of access to adequate  healthcare (292) 




Figure 1.7: Molecular traits associated with CA-MRSA. Outlined are the general traits associated 
with CA-MRSA concerning antibiotic resistance and elements which may contribute to increased 








1.3.4 Virulence gene regulators   
 
Virulence gene expression in S. aureus is regulated in a temporal, growth-phase 
dependent manner, through a complex regulatory network employing two-
component systems (TCS), multiple DNA binding proteins and a subset of regulatory 
RNAs. These systems are sensitive to environmental signals and allow the bacterium 
to adapt to niche habitats and are central in pathogenesis.  
 
1.3.4.1 Quorum sensing and the accessory gene regulator (Agr) 
 
Quorum sensing is a cell-to-cell communication system mediated by diffusible 
signalling molecules, or auto-inducing peptides (AIP), which allow bacteria to 
synchronise the expression of specific genes. This sophisticated chemical 
communication is used by S. aureus to modulate the activation of selected virulence 
genes (329). One of the most well-characterised genetic elements in S. aureus is the 
quorum sensing accessory gene regulator (agr) system, which decreases the 
expression of surface proteins and increases the expression of secreted 
toxins/enzymes as a function of bacteria density, specifically during the transition 
from late exponential to early stationary phase of in vitro growth (329, 330).  
 
 The agr system is encoded on a 3kb locus consisting of five genes (agrACDB 
and hld) composed of two divergent transcripts, RNAII and RNAIII,  driven by two 
distinct promoters, P2 and P3 respectively (Fig 1.8) (331). The agr-activating ligand 
is a post-translationally modified peptide, encoded by the agrD gene, which is 
processed and digested by the polytopic transmembrane protein agrB, which secretes 
a mature AIP composed of seven to nine aminoacyl residues, containing a 
functionally critical thiolactone (332). This AIP forms the basis of the proceeding 
regulatory circuit, where upon reaching a critical AIP threshold, dependent on the 
bacterial density, the agr system is activated. AgrC is a transmembrane protein, 
consisting of several extracellular loops which interact with the AIP and a 
cytoplasmic C-terminal histidine kinase domain. This protein acts as the sensor 
component of the agr system, undergoing homodimerisation after AIP binding, 
leading to trans-phosphorylation of the histidine domain (333). This phosphate is 
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transferred to the response regulator, AgrA, leading to a conformational change 
permitting binding of this protein to the promoter regions of P2 and P3 (also binds to 
the promoter region of psm operons (215)). This activation of the P2 and P3 
promoters drives the expression of the two transcripts in a positive feed-back loop 




Figure 1.8: The accessory gene regulator (agr) system. The agr regulatory circuit consists of two 
divergently transcribed transcripts, RNAII and RNAIII. The RNAII transcript contains agrACDB 
operon. agrB encodes a transmembrane protein responsible for processing the autoinducing peptide 
(AIP), encoded from agrD. After reaching a critical threshold, AgrC (sensor kinase) senses AIP 
concentration, resulting in the phosphorylation of AgrA (response regulator) which interacts with 
promoter regions, resulting in expression of RNAIII and other genes. RNAIII is a regulatory RNA 
composed of 14 stem-loops and modulates the expression of virulence factors in S. aureus. RNA 
molecule was taken from (334). 
 
 
The regulatory RNAIII molecule is the pleiotropic effector of the agr regulon and 
encodes a toxin gene, delta (hld) toxin, (335). The RNAIII molecule has a complex 
secondary structure containing 14 stem-loops which are important in the up-
regulation of extracellular toxin transcripts and repression of cell surface proteins 
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during transition into the late-exponential phase of growth (335). RNAIII directly 
targets three specific mRNA encoding virulence factors, hla, spa and coa mRNA. 
Binding of the 5’ end of RNAIII to the Shine-Dalgarno (SD) sequence of hla mRNA 
results in conformational changes, conducive to translation of hla mRNA (336). In 
contrast, RNAIII represses the synthesis of protein A via direct binding of the 3’ end 
of stem-loop 13 to spa mRNA preventing ribosome interaction and initiating mRNA 
degradation by activation of the RNaseIII specific endoribonuclease (337). For coa 
inactivation, RNAIII utilises two distal regions which base-pair with nucleotides in 
the coa SD sequence forming an imperfect duplex complex, preventing protein 
activation and causing mRNA degradation through RNaseIII (338).  
 
Genome wide analysis of several S. aureus strains suggest that there are at 
least sixteen two-component systems present in the S. aureus genome (339). After 
AgrCA, there are four major two-component systems which have been implicated in 
virulence gene expression: SaeRS (S. aureus exoprotein expression), SrrAB 
(Staphylococcal respiratory response), ArlRS (Autolysis-related locus) and LytRS 
(Lytic-related genes).   
 
1.3.4.2 Two-component systems 
 
The sae locus contains four open reading frames, two of which illustrate strong 
homology to response regulators (SaeR contains an aspartate phosphorylation site) 
and histidine kinases (SaeS contains an aspartate autophosphorylation site) (340). 
Upstream of the saeRS genes exist two additional genes, saeP and saeQ, likely to 
contribute to saeRS activity (341). Four transcripts are expressed from two 
promoters, P1 and P3, with P1 being strongly activated by hydrogen peroxide and α-
defensins, suggesting a role of saeRS in activation of virulence factors important for 
neutrophil killing (342), with other factors such as high salt, low pH and 
subinhibitory antibiotics also affecting sae activity (329). Interestingly, the activation 
by α-defensins is strain specific, therefore other factors either interacting with sae 
leading to activation, or activation being a result of structural changes in the cell 
envelope between the different strains may be responsible for this activity (342).  
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The most abundant transcript, T2, has been suggested to be processed from transcript 
T1, following endoribonucleolytic cleavage, possibly acting as an important method 
of enhancing the half life of this transcript (342).  
 
sae mutants are deficient in α-, β-, γ-toxins, proteases, DNase, coagulase, and 
surface proteins such as fibronecting binding protein A and protein A, and do not 
affect the transcription of agr, sarA or sigB. (343, 344). Sae locus is activated by agr, 
but repressed by sigB highlighting the possibility that it acts downstream in the 
global regulatory cascade (340, 342, 344). Inactivation of sae or agr has a reduced 
effect in virulence in animal models, however the respective virulence genes they 
regulate are different (341, 343). For example, inactivation of agr causes an increase 
in the expression of certain surface proteins whereas sae mutation has the opposite 
effect on identical proteins (345). Recently, it has been reported that a methionine 
residue (M31) in the predicted extracellular loop domain of SaeS is essential for 
transcription of toxins genes (hla, lukA/B/lukG/H and hlgA), mutation of which 
drastically reduces cytotoxicity to neutrophils, signifying its importance as a 
virulence regulator (346). 
 
 The srr locus consists of two overlapping open reading frames srrA and srrB 
with one transcriptional start site, producing either srrA or full length srrAB 
transcript (347). This system also shows homology to the B. subtilis resDE system, 
which is important for global regulation under both aerobic and anaerobic conditions 
(348). The srrAB system acts as a global regulator of virulence, down regulating 
RNAIII, toxic shock syndrome toxin -1(tst), icaR and protein A, particularly in low-
oxygen environments (348) but enhances the level of these transcripts (except 
RNAIII) under aerobic conditions (349). SsrA is the response regulator of this 
system, and SrrA binding sites have been discovered at the agr P2 and P3, spa, tst, 
icaA and srr promoters regions highlighting a direct method of regulation by SrrA 
(347, 350).  
 
Polysaccharide intracellular adhesion (PIA) molecule is an important factor 
involved in biofilm formation and is regulated by the icaADBC locus (124). IcaA 
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acts as an N-acetylglucosaminyl transferase important in PIA production (124). 
SrrAB significantly increases icaA transcription leading to a PIA-positive phenotype 
during anaerobic growth (350). This mechanism of ica expression is proposed to 
function through inactivation of icaR, the repressor of the ica locus, by both 
phosphorylated SrrA and SarA (350). This expression of PIA under anaerobic 
conditions has been shown to confer a survival advantage during in vitro anaerobic 
phagocytosis assays (350).  SrrAB also plays a major role in resistance to hypoxia 
and radical nitric oxide, with mutants in ssrAB becoming hyper-sensitive to 
nitrosative stress (351). Under conditions of nitrosative stress srrAB induces the 
expression of genes required for anaerobic metabolism and nitric oxide (NO
°
) 
detoxification (352), conveying the importance of srrAB as a global regulator 
affecting genes important in virulence, stress adaptation and metabolism.   
 
The arl locus consists of two co-transcribed genes, one coding for the 
histidine kinase sensor protein, ArlS, while the other for the response regulator, 
ArlR, which belongs to the PhoB-OmpR family (353). This locus is expressed during 
the transition from the exponential to post-exponential growth phase (353). 
Inactivation of arlS causes autolysis due to an increase in peptidoglycan hydrolase 
activity, suggesting its involvement in cell growth and division (353). The arl locus 
is also intimately involved in global virulence regulation, illustrated by mutation in 
either arlS or arlR increasing the secretion of specific exoproteins (α-, β-haemolysin, 
lipase, coagulase, serine protease) and protein A, in contrast to an agr mutation 
(354). An agr/arl double mutation retains the overall increased exoprotein 
expression, suggesting it regulates certain exoproteins upstream of agr (353, 354). 
The effect on spa expression is through arlRS alteration of DNA supercoiling, where 
relaxed DNA leads to increased spa expression (355). Recently, the involvement of 
arlRS in agglutination and development of infective endocarditis (IE) has been 
investigated, illustrating a positive association between arlRS activity and clumping 
in the presence of human plasma (356). ArlRS negatively effects the expression of 
the extracellular binding homologue, Ebh protein, allowing the formation of stable 




 The lytRS locus comprises two overlapping, co-transcribed genes, lytS and 
lytR (357). In an analogous fashion to the arl genes, mutation of lytS increases 
autolysis (358). Both lytS and lytR positively regulate the expression of lrgA and 
lrgB, proteins which are important in regulating autolysis, inhibiting the activity of 
murein hydrolases by structurally modifying the bacterial cell wall (359). Reduced 
expression of these proteins leads to increased autolysis and increased susceptibility 
to cell wall acting antibiotics (359).  
 
Other, less well characterised two-component systems (TCS) which affect 
virulence regulation in S. aureus include the KdpDE and GraRS regulatory circuits. 
KdpDE senses external K
+ 
concentrations and regulates virulence genes in response 
to this stimulus (360). DNA microarray analyses revealed a multitude of genes were 
up and down-regulated in a kdpDE mutant, with some of these genes being important 
virulence factors (360). Coupled with the fact that this system is up-regulated by agr, 
the KdpDE system represents an exciting new TCS important in virulence regulation. 
The GraRS system is important for the induction of several genes which determine 
the net positive charge on the bacterial surface, where mutation of graRS leads to 
increased killing by host and bacterial antimicrobials peptides (361, 362). 
 
1.3.4.3 The SarA protein family 
 
The SarA family represents an array of regulatory proteins which are fundamental in 
coordinated virulence expression in S. aureus. The founding member of this family is 
the SarA protein, a 14.7 kDa DNA binding protein encoded from the sarA locus 
(363).  The sarA locus consists of three overlapping transcripts derived from three 
different promoters which are activated during different times of in vitro growth, 
each encoding the SarA protein (364). The P1 and P2 promoters are σA dependent 
while P3 activation relies on σB and is activated post-exponentially (364). SarA acts 
as a dimeric, winged helix protein with contains multiple helix motifs allowing for 
efficient DNA binding to AT-rich sequences (365). SarA promotes the synthesis of 
fibronectin and fibrinogen binding proteins and a suite of toxins (α-, β- δ- toxins) 
whereby inactivation of sarA leads to attenuation in multiple models of infection, 
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(366). SarA expression peaks at late exponential phase coinciding with activation of 
agr and RNAIII in particular, and it has been observed that the intergenic region 
between agr P2 and P3 promoters contains SarA binding sites (367). Both SarA and 
SarR, a Sar homolog, can bind these sites, influencing agr activation (368). SarR is a 
13.6 kDa protein which binds P1, P2 and P3 promoters, and when inactivated leads 
to a higher expression of sarA and translated SarA protein (369). AgrA is central for 
P2 and P3 activation, whereby SarA can interact with and enhance AgrA-mediated 
P2 expression, while SarR displaces this protein from the agr promoter region, down 
regulating the combined activation of SarA-AgrA (368).  
 
Through a series of genetic investigations, comparative sequence alignments 
and structural data it was deduced that the SarA family consists of an another 8 
homologs including Sar T, U, V, X, Y, Z, Rot and MgrA (370). The SarA protein 
family can be divided and classified based on structure and size, with the larger 
proteins such as SarS, SarY and Sar U classed as two-domain proteins, with each 
domain homologous to SarA, and single domain proteins, such as SarA, SarR, SarT, 
SarV, SarX and Rot). A further subclass is used based on the sequence similarity of 
MgrA and SarZ to the MarR protein family of Gram-negative bacteria (370). 
 
Rot (repressor of toxins) is a SarA homologue, and acts as a global regulator 
that negatively regulates the expression of several important virulence genes, such as 
lipase, haemolysins, and certain proteases, and positively regulates the expression of 
a number of surface adhesins and genes involved in teichoic acid biosynthesis (371). 
Considering the opposing influences both Rot and RNAIII have on virulence, it was 
hypothesized that these two global regulators must interact at some level. It has been 
observed that RNAIII can represses rot mRNA translation through an anti-sense 
mechanism, base-pairing between multiple RNAIII hairpins and the sequence of 
mRNA leading to rot repression and the upregulation of toxin genes (334). Rot 
directly regulates the expression of sarS, a transcription factors important in 
modulating virulence expression (372). Additionally, rot directly represses the P3 




SarS represents another SarA homolog, consisting of a monomeric, rather 
than dimeric structure, with two similar, but non-identical halves, important in 
functioning as winged helical protein (372). SarS is a 29.9kDa protein, important in 
the upregulation of protein A, binding directly to the spa promoter (372). SarS is 
repressed by both agr and another SarA homolog, MgrA and is activated by the 
ClpXP proteases (370).  
 
 SarT acts a regulatory mediator between genes regulated by SarA and agr. 
SarT represses hla transcription by binding directly to hla promoter region and is 
itself repressed by SarA and agr (374). SarT can positively influence the expression 
of SarS (374). Interestingly, repression of SarT by agr, is the proposed method of spa 
reduction observed in agr activated cells (374). Neighbouring sarT but divergently 
transcribed is sarU, which is repressed by SarT and is a positive activator of agr, 
observed by a significant decrease in RNAII and RNAIII transcripts in a sarU mutant 
(375). Activation by SarU may represent a secondary amplification of the agr 
regulatory cascade, strengthen by the fact that sarT is down regulated by agr (375).  
 
SarX functions to represses agr activity and is up regulated by MgrA, as two 
consensus MgrA binding sites are embedded within the sarX promoter region (376). 
This highlights the only known SarA protein which negatively affects agr activity 
directly, highlighting another potential regulatory loop complementing the already 
complex interplay surrounding virulence gene regulation. SarZ positively affects agr 
activity as a sarZ mutant results in the reduction of RNAIII transcripts (377). sarZ 
mutant also leads to a decrease in transcription of mgrA, hla and sspA (encoding the 
V8 protease) and  increased spa transcription (377) underpinning its importance in 
virulence gene regulation. The inactivation of sarZ also resulted in an increase in 
sarA, suggesting that both the effect of hla and spa in a sarZ mutant is via agr, and 
that activation of agr by SarZ is through a SarA-independent method (377). SarZ 
also represses biofilm formation through its actions on agr and mgrA, both of which 




MgrA is a key transcription factors which modulates virulence factors in an 
agr-like fashion (378). MgrA also affects autolysis through its repressive affect on 
SarV (378). SarV is a key transcription factor in modulating autolysis, whereby 
mutation of sarV results in an increased resistance of cells to detergents and beta-
lactam mediated lysis compared to wild-type levels (370, 379). This decrease in 
susceptibility maybe due to sarV acting as a positive regulator of murein hydrolase 
(379), a decrease of which would render cells more resistance to autolysis. Mutation 
in mgrA increases autolysis, sarS and spa transcripts and decreases agr, highlighting 
its global regulatory activity (380). mgrA causes increased hla transcription through 
interaction with agr, leading to its enhanced activation, but also through direct 
binding at the hla promoter (380). MgrA downregulation of spa transcription occurs 
through increased agr activity as stated above, but also by direct repression of sarS, 
whereby MgrA binds directly to the sarS promoter (380). MgrA is also a regulator of 
antibiotic resistance, activated through the oxidation of a critical cysteine residue 
located at the interface of the protein dimer (381). Antibiotic therapy can introduce 
oxidative stress which leads to the downstream activation of resistance genes by 
MgrA.   
 
1.3.4.4 Other regulatory proteins 
 
Several other factors are important in virulence regulation in S. aureus including, but 
not limited to, CodY, rsr, ClpXP and alternative sigma factor (σB). In many gram-
positive organisms CodY has been shown to be a global regulator, controlling the 
expression of genes involved in metabolism, nutrient adaptation and virulence (382). 
The deletion of codY in S. aureus causes the over-expression of several virulence 
genes and RNAIII, highlighting its potential role as a repressor of virulence (383). 
CodY acts as a link between metabolism and virulence owing to is activation by 
branch-chained amino acids (BCAAs), particularly isoleucine, leading to strong 
repression of target genes (383). Interestingly, under conditions of isoleucine 
limitation, the agr system is not repressed and becomes activated prematurely. This 
activation of agr has been hypothesised to work as an escape mechanism for S. 
aureus, as the expression of toxins and other spreading factors are unregulated during 
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times of nutrient limitation (383). The exact mechanism in which CodY regulates agr 
is not known, however it has been observed that CodY can regulate certain cell 
surface proteins independently of agr (383).  
 
 rsr (repressor of sarR) is located adjacent to sarR and acts as a repressor not 
only to sarR but also to agr (384). Not surprisingly, deletion of rsr confers a hyper-
virulent phenotype in a murine abscess model due to the upregulation of virulence 
genes associated with agr activation (384). Little is known about this regulator, and 
whether its repressive functions act directly on agr or through an as of yet-unknown 
mediator is under investigation; however this repression is independent of sarR.  
 
 Clp proteolytic complexes are very well conserved in bacteria, playing a vital 
role in cell physiology, and recently, observed to be important in virulence regulation 
(385). Clp proteases consist of an ATPase factor determining substrate specificity 
(ClpX in S. aureus) and a core protease barrel-like structure (ClpP). Comparisons of 
DNA microarray experiments between wild-type (8324-5) and ΔclpP illustrate the 
global regulatory activity of this protein, conferring a strong impact of genes 
involved in virulence, stress response, DNA repair and cell homeostasis (385). 
Recently, a whole spectrum of ClpP substrates were identified using the ‘clpPTRAP’ 
system, which uses a ClpP variant which can retain the substrate but not degrade it, 
highlighting central regulators such as CodY and PerR as targets (386). Specifically, 
mutants illustrate reduced RNAIII, hla, and sspA (serine protease) transcription and 
reduced virulence in a murine skin abscess model (387). Hypothetically, the link 
between agr and ClpXP may involve the degradation of virulence regulators after 
interaction with RNAIII. ClpX can function as an independent chaperone and is 
essential for spa transduction. Rot induces the transcription of spa directly by 
binding to the spa promoter and indirectly by positively activating sarS (388). 
Deletion of clpX results in a 3-fold reduction of Rot, abolishing Protein A 
production. This reduction of Rot was due to ClpX involvement in Rot translation, 





 Sigma (σ) factors are highly conserved transcription initiation factors 
working in concert with RNA polymerase (RNAP) to promote expression from 
specific genes under specific conditions (390).  σB is the most studied σ factor in S. 
aureus and plays a role in cell physiology, stress survival and virulence (391). σB is 
transcribed from a four gene operon, rsbUVWsigB encoding anti-sigma factor 
(RsbW), an anti-anti-sigma factor (RsbV) and RsbU, an anti-RsbV phosphatase. 
Under certain environmental conditions, RsbU removes the phosphate group of 
RsbV allowing RsbV to bind RsbW, removing RsbW from sig B, freeing its 
interaction with RNAP to transcribe target genes (390).  
 
Deletion of sigB also affects virulence. Historically, studies investigating the 
role of sigB were hampered due to use of 8325-4 strain and derivatives which 
contained an rsbU mutation. Studies have now revealed that sigB does play a role in 
repressing agr, hla and sspA (391). Microarray analysis of three phylogenetically 
distinct strains revealed sigB influence in excess of 200 genes, with many adhesins 
upregulated while many toxins and exoproteins were repressed (392). Interestingly, 
this data also showed sigB increases the activity of sarA, particularly during late 
exponential to early stationary phase (392), in contrast to Horsburgh et al (391). σB 
also modulates the transcription of a downstream operon, yabJ-spoVG, whereby 
inactivation leads to the repression of a set of enzymes, nuclease, lipase and certain 
proteases (393) again conveying sigB importance as a virulence regulator.   
 
 Virulence regulation in S. aureus is complex and involves a major cross-talk 
of virulence regulators comprising TCS and DNA binding proteins which can all be 
altered depending on growth conditions and environmental stimuli. Figure 1.9 
illustrates an overview of some of the interactions of the known regulators and how 
communication between these elements affects overall virulence, divided on the 
outcome on overall toxicity (T), adhesiveness (A) and evasiveness (E) (96). Adding 
to the complexity of these interactions is the strain specific activities of certain 
regulators. Therefore, we need a greater understanding of how these regulators act in 
different genetically distinct clinical strains, while evaluating the inactivation of 
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regulators in specific animal models of infection will help fully comprehend their 




Figure 1.9: Virulence regulatory network of S. aureus. The known virulence regulators (sRNAs are 
omitted) are illustrated inside the oval shapes, where their respective effect on one another is 
represented by arrows (positive effect) or bars (negative effect). The outside of the circle represents 
the known effect each regulator has on adhesiveness (A), toxicity (T) and evasiveness (E). A question 
mark illustrates that either there is no information regarding its effect on a particular phenotype or the 
information regarding this effect is conflicting. Image taken from (96). 
 
 
1.3.4.5 RNome  
 
As stated previously, S. aureus adapts to a wide variety of environments using 
multiple TCS and transcription factors to modulate gene expression in response to 
several environmental cues. Another layer of regulatory complexity is added through 
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the use of a wide spectrum of small, non-coding RNAs (sRNAs) (394, 395). For 
clarity, these have been omitted from figure 1.9, however they are extremely 
important in rapid regulation of genes, including those coding for virulence factors. 
The classic representative of this group, RNAIII, which couples quorum sensing 
regulation to the expression of virulence genes, is the most widely studied member of 
this group and has been discussed in the previous sections. psm-mec represents 
another important sRNA located on certain SCCmec elements and exhibits virulence 
inhibitory properties, and has been reviewed in section 1.3.1.2. This section will 
discuss three other recently discovered sRNAs (sprD, SSR42 and artA) and their 
impact on virulence.  
 
 The SprD (small pathogenicity island rNAs) molecule is an interesting 
example of a sRNA, as it is encoded within a pathogenicity island, but regulates the 
expression of genes found on the core genome. SprD is expressed during the 
exponential phase of growth, and is independent of RNAIII (396). The Sbi immune 
evasion protein was identified as a target for SprD and molecular analysis revealed 
that SprD interacts with the sbi mRNA specifically covering (SD) sequence 
preventing the initiation of translation (396). The deletion of sprD caused a 
significant decrease in mouse lethality in a sepsis model of infection, highlighting the 
role SprD in overall virulence (396).  
 
 Another important regulatory RNA involved in virulence alteration is the 
891-nt S. aureus regulatory RNA, SSR42, molecule (397). This molecule is part of a 
family of small stable RNAs (SSRs) which are produced and/or stabilised in 
response to specific growth phases and harsh conditions, hypothesised to help enable 
the organism to adapt to unfavourable conditions (398). SSR42 is expressed and 
predominantly stabilised during stationary phase of growth with deletion of SSR42 
(in a UAMS-1 (USA200) strain) affecting the expression of 82 transcripts during this 
phase of growth (397). Interestingly, deletion of SSR42 resulted in the upregulation 
of cell surface virulence determinants such as spa and sbi. Deletion of SSR42 in 
strain LAC (USA300) resulted in a different set of genes being modified; 
highlighting specific genes are affected depending on their genetic background. In 
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LAC, SSR42 contributes to pathogenicity in a SSTI mouse model of infection, is 
important in lysing erythrocytes and confers a survival advantage against 
polymorphonuclear cells through its positive effect on hla, hlgC and lukF-PV 
expression (397).  
 
 A recently discovered sRNA affecting virulence has been shown to interact 
with other virulence regulators to modulate toxin production. The ArtA (AgrA-
repressed, toxin regulating sRNA) sRNA represents another RNA molecule that is  
regulated, in this case repressed, by AgrA through direct binding to the artA 
promoter (399). Deletion of artA resulted in a decrease in α-haemolysin, which was 
mediated via increased sarT expression (399). It was shown that the regulatory 
activity of ArtA centred on the repression of sarT, via stable interaction with sarT 
mRNA providing a substrate for RNaseIII (399). This sRNA illustrates how 
important these regulatory molecules are in overall pathogenicity and provide clues 
on how the complex interplay between known regulators occurs.   
 
1.3.5 Virulence determinants 
 
S. aureus expresses a plethora of virulence determinants, a Swiss-army knife of 
surface proteins, toxins, enzymes, immune inhibitory proteins, superantigens and 
biofilm specific components, resulting in an extremely formidable pathogen. These 
factors are differentially expressed depending on growth phase and environmental 
conditions. Expression patterns are strain-dependent, with certain factors specific in 
particular diseases. Table 1.1 illustrates the known virulence factors and their 
primary function. In the proceeding section an overview of some of the most 
important virulence factors and their relevance in disease will be discussed, sectioned 
into the two main categories of virulence investigated in this thesis, adhesion and 






1.3.5.1 Cell wall proteins  
 
S. aureus comprises an impressive reservoir of 24 different cell wall-anchored 
(CWA) proteins which are differentially regulated depending on the environmental 
conditions (for example, IsdA is up-regulated during iron-limiting conditions (400)) 
and growth phase (98). CWA proteins exhibit conserved features. An amino-terminal 
secretory signal is required for Sec-dependent protein secretion, while the carboxyl-
terminal end contains several domains: a wall-spanning element rich in either proline 
or glycine residues, or composed of serine-aspartic acid repeats, an LPXTG motif, 
followed by a membrane-spanning hydrophobic domain and lastly a region 
composed of a series of positively charged residues (401). Cleavage of the LPXTG 
motif between the threonine and glycine residues results covalently linkage of the 
protein to the peptidoglycan cell wall, carried out by the transpeptidase activity of the 
sortase A enzyme (402). 
 
 The most predominant proteins are those that belong to the microbial surface 
component recognizing adhesive matrix molecules (MSCRAMMs), which are 
defined by their tandemly linked IgG-like folded domains in the A region (98). A 
large degree of functional redundancy exists between CWA proteins, whereby 
multiple proteins can bind the same host ligand (at least 5 CWA proteins bind 
fibrinogen). CWA proteins are fundamental for the initial attachment phase, which is 
a precursor for colonization and infection. These proteins are important virulence 
factors which can promote adhesion to the extracellular matrix, mediate invasion of 
specific host cells, and evasion and inhibition of the innate and adaptive immune 
system. 
 
Virulence Factor Function 
Secreted Factors  
Superantigens  
Toxic Shock Syndrome Toxin -1 (TSST-1) Immunomodulation 
Staphylococcal enterotoxins (SE) SEA to SEG Immunomodulation, gastrointestinal 
toxicity 




Cytolytic Toxins Cytotoxicity/Membrane requirement 
α-haemolysin (hla) Monocyte, erythrocyte - ADAM-10, 
inflammation 
β-haemolysin (hlb) Monocyte, erythrocyte - sphingomyelin 
γ-haemolysin (hlgACB) Erythrocyte and neutrophil - unknown 
δ-haemolysin (hld) Neutrophils, erythrocytes, monocytes 
lymphocytes, biofilm * 
PSMα1  Neutrophils, erythrocytes, monocytes 
lymphocytes, biofilm * 
PSMα2 Neutrophils, erythrocytes, monocytes 
lymphocytes, biofilm* 
PSMα3 Neutrophils, erythrocytes, monocytes 
lymphocytes, biofilm* 
PSMα4 Weakly cytotoxic- erythrocytes, 
lymphocytes, biofilm* 
PSMβ1 Weakly cytotoxic - erythroctyes, biofilm* 
PSMβ2 Weakly cytotoxic - erythroctyes, biofilm* 
PVL (lukSF-PV) Neutrophil, monocyte cytotoxicity - C5aR 
LukAB/GH Neutrophils - CD11b 




Coagulase (coa) Clotting and abscess formation 
Hyaluronidase (hysA) Hyaluronic acid degradation - 
dissemination  
Catalase (katA) Inactivates H2O2 - defence  
DNase Degrades eDNA – biofilm 
Elastase  Degrades elastin - dissemination 
V8 protease  Serine protease - protein degradation 
Superoxide dismutase Defence against reactive oxygen species 
Exfoliative toxin (eta, etb) – serine protease Cleavage of desmosomal cadherins  
Glycerol ester hydrolases (lip, geh) Degrades triacylglcerols 
Fatty-acid modifying enzyme (FAME) Inactivates bactericidal fatty acids 
O-aceyltransferase (oatA) Lysosome resistance 





ACME enzymes,  (arc, opp, speG) Colonisation, resistance to polyamines 
  
Immune evasins  
Staphylokinase (sak) Anti-opsonic  
Aureolysin - metalloprotease (aur) Cleavage of C3 - inhibition of phagocytosis 
 
Staphylococcal complement inhibitor (SCIN) 
protein 
 
Binds C3 convertases, inhibits C3b 
deposition 
Extracellular fibrinogen binding protein (Efb) Binds, Fb, C3b and C3d, inhibits 
opsonisation 
Formyl-like 1 inhibitory protein (FLIPr) Inhibits chemotaxis 
Staphylococcal immunoglobulin-binding 
protein (Sbi) 
Binds IgG and C3 protein 
Chemotaxis inhibitory protein (CHIPS)  Inhibits chemotaxis and extravasation 
Extracellular adherence protein (Eap) Interferes with neutrophil recruitment and 
extravasation 
Staphylococcal superantigen-like protein 5 
(SSL-5) 
Inhibits PMN recruitment  
Staphylococcal superantigen-like protein 7 
(SSL-7) 
Binds C5, inhibits complement 
Extracellular complement binding protein, 
Ecb 
Inhibits C3 convertase 
  
Cell wall associated virulence factors:  
Surface proteins/polymers/polysaccharides  
Fibronectin binding proteins A and B, 
FnBPA/B 
Binds ECM proteins - colonisation and 
invasion 
Clumping factor A, ClfA Binds Fb - Inhibits phagocytosis 
Clumping factor B, ClfB Binds Fb, Ln and C10 - nasal colonisation  
S. aureus protein A (Spa) Binds multiple proteins - inhibits 
phagocytosis 
Serine-aspartic acid-rich proteins (SdrC, D) Binds ECM - nasal colonisation  
SdrE Binds complement factor H 
S. aureus surface proteins (Sas) Binds ECM - nasal colonisation  
SasG Binds ECM - nasal colonisation and biofilm 
Collagen binding protein (Cna) Binds type I and IV collagen - septic 
arthritis  
Iron surface determinants (Isd) A Binds ECM proteins - Nasal colonisation 
IsdB Binds haemoglobin and hemin 
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IsdC Binds hemin 
IsdH Binds haptoglobin and haptoglobin-
hemoglobin complex 
Bone sialoprotein-binding protein (Bbp) Binds sialoprotein and Fb 
Elastin binding protein (EbpS) Binds elastin and tropoelastin 
Serine-rich surface protein (SraP) Binds platelets  
Von Willebrand factor binding protein 
(vWbp) 
Binds and activates prothrombin, Fb and 
vW factor 
Wall Teichoic acids (WTA) Binds ECM - Nasal colonisation 
Capsular polysaccharide (CPS) Anti-phagocytosis  
  
Miscellaneous   
Staphyloxanthin  Protect against reactive oxygen species  
Dlt operon (dltABCD)  D-alanylation of teichoic acids  
Mulitple peptide resistance factor F (MprF) Lysinylation of phospholipids - prototects 
against neutrophil killing 
 
Table 1.1 
Abbreviations: Fb, fibrinogen; IgG, immunoglobulin; PMN, polymorphonuclear 
leukocyte; ECM, extracellular matrix; Ln, loricrin; C10, cytokeratin 10;  
*No receptor required 
 
 
Arguably the most important CWA proteins involved in pathogenicity are the 
fibronectin-binding proteins A and B (FnBPA/B), clumping factor A and B (ClfA/B) 
and S. aureus protein A (Spa).   
 
1.3.5.1.1 Fibronectin binding proteins  
 
The majority of S. aureus clinical strains (77%) encode both fibronectin binding 
proteins (FnBPs), FnBPA and FnBPB (403). FnBPs exhibit similar structural 
characteristics, and along with Clf, Sdr and Cna proteins, belong to the MSCRAMM 
family of surface proteins (404). FnBPs are composed of an amino-terminal A 
domain, which is subdivided into three subdomain N1, N2 and N3, and a region 
distal to the A domain composed of 11 and 10 non-identical repeats in FnBPA and B 
respectively (405, 406). The A domain of FnBPs are surface exposed and can interact 
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with ECM proteins such as fibrinogen (Fb) and elastin (407). The FnBP binding of 
Fb and elastin is hypothesised to occur through an elegant ‘dock, lock, latch’ (DLL) 
mechanism, which is based on the predicted binding of ClfA to Fb (407). This 
involves the docking of the γ-chain domain of Fb to region between the N2 and N3 
domains of the A domain, inducing residues in the N3 C-domain to undergo a 
conformational change resulting in the formation of an extra β-strand, locking and 
trapping the Fb molecule (408). Interestingly, the N23 subdomains of FnBPB are 
also capable of binding an extra ECM protein, fibronectin (Fn), by an as of yet 
unknown mechanism (409). Fn binding by the FnBPs is also mediated by the 
multiple repeat regions (410). Fn acts as a molecular bridge, allowing S. aureus to 
interact with and induce clustering of host surface expressed α5β1 integrins (411). 
Clustering of integrins triggers intracellular phosphorylation activating a signalling 
cascade resulting in the alteration of the cellular architecture and uptake of S. aureus 
(412). In FnBPA, it has been shown that at least one high-affinity fibronectin-binding 
repeat is required for rapid and efficient invasion of non-professional phagocytes 
(410).  
 
This invasive phenotype mediated by FnBPs is important in immune and 
antibiotic avoidance and for promoting dissemination to other anatomical sites (404). 
FnBPs have been shown to be important in numerous animal models of infection 
particularly in sepsis and endocarditis development (410, 413). Finally, FnBPs have 
been implicated in MRSA biofilm development under specific environmental 
conditions, where residues which are central for ligand binding do not play a role 
(414), highlighting another potential protein-protein interaction activity of these 
already multifunctional proteins. 
 
1.3.5.1.2 Clumping factor proteins  
 
ClfA and ClfB contain a series of Serine/Aspartic acid dipeptide repeats linking the 
subdomains of the A-domain to the carboxyl-terminal cell wall anchoring region 
(415). These proteins share significant sequence similarity, 41% and 47% identity at 
the N- and C- terminal respectively, while the A domain shares only 26% similarity 
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(415). ClfA and ClfB are expressed during different stages of growth with maximum 
clfA expression occurring during stationary phase, whereas clfB expression is highest 
during early exponential phase and is undetectable during stationary phase (415, 
416). Given the low level similarity of the A domain it was surprising that ClfB also 
bound fibrinogen promoting adhesion and clumping (415). However, both proteins 
bind different regions of the Fb molecule, with ClfA interacting with the γ-chain of 
Fb, while ClfB binds with the alpha chains, both predicted to occur through the DLL 
mechanism (404). The ability of two related proteins binding the same molecule but 
to different regions is not uncommon in S. aureus and may be important in binding 
firmly to ECM proteins or thrombi when under flow.  
 
 ClfA has been shown to confer resistance to neutrophil-mediated 
phagocytosis, involving the binding of Fb molecules, preventing the deposition of 
oposins on the bacterial surface or masking any recognition of opsonins by immune 
cells (417). Recently it was shown that ClfA mediates this bacterial resistance in a 
Fb-dependent and independent manner, highlighting another role of ClfA in immune 
evasion. Subsequently, it was revealed that the A-domain of ClfA could trigger the 
cleavage of C3b to iC3b by interacting with and inducing the action of serum factor I 
(418). C3b is an important opsonin, central in the elimination of microbes, whereby 
cleavage of C3b to iC3b reduces the impact of this important clearance mechanism. 
ClfA can stimulate the activation of platelets leading to aggregation, an important 
prerequisite to the onset of infective endocarditis (419). This activation requires the 
binding of several Fb molecules by ClfA aided by the simultaneous interaction with 
immunoglobulin G (IgG) molecules leading to the clustering of platelet receptors 
GPIIb/IIIa and FcγRIIa inducing intracellular signalling cascades culminating in 
platelet aggregation (419). This multifunctional protein has been shown to be 
important in rat endocarditis (420), murine septic arthritis (421) and infective 
endocarditis (422) models of infection. ClfB plays an important role in adhesion and 
nasal colonisation, through its interaction with cytokeratin 10 and loricin as 




1.3.5.1.3 Protein A 
 
S. aureus protein A (SpA) is structurally distinct from the other CWA proteins, 
containing five homologous modules, designated EABC and D. Each of the modules 
contains a separately folded three-helical bundle structure which can interact with 
multiple ligands (404). Separating this region and the cell wall domain is the Xr 
region composed of octapeptide repeats which vary in number followed by a 
constant region known as Xc (404). SpA is best known for its ability to bind to the 
Fcγ region of the IgG, decorating the bacterial surface with IgGs orientated in the 
incorrect fashion, preventing recognition by neutrophils and activation of the 
classical complement pathway impairing phagocytosis (423). However, SpA also 
performs an immunomodulatory function, interacting with the Fab variable regions, 
VH3, of IgM molecules which are exposed on the surface of B cells (424). This 
interaction can lead to the cross-linking and stimulation of B cells resulting in 
apoptosis, leading to B cell depletion and immunosuppression (424).  
 
 S. aureus is a primary cause of pneumonia in infants and the 
immunocompromised and evokes an intense host response characterised by high 
recruitment and infiltration of PMNs to the site of infection (425). This effect is 
mediated by the expression of SpA and its interaction with tumour necrosis factor 
receptor-1 (TNFR-1) on lung epithelium, inducing TNF-α like pro-inflammatory 
responses resulting in PMN mobilisation and recruitment (425). This hyper-
recruitment has an adverse effect on lung epithelia resulting in cell damage, 
respiratory dysfunction and pneumonia. 
 
 SpA enables S. aureus to bind directly to the essential blood glycoprotein, 
von Willebrand factor (vWF) (426). The main function of vWF is to interact with 
exposed collagen and capture and direct circulating platelets for immobilization at 
the site of damaged blood vessels, promoting the formation of blood clots (426). 
Thus, binding of SpA to vWF allows S. aureus to adhere to damaged blood vessels 
and exposed sub-endothelial tissue when under flow conditions (426). This adhesive 
feature may play a role in enhanced survival in the blood and, in conjunction with 
66 
 
ClfA, attachment and induction of platelet aggregation, important features in the 
development of infective endocarditis.  
 
1.3.5.2 Cytolytic proteins 
 
A key component in the S. aureus artillery is the secretion of membrane-damaging 
proteins, essential in colonization and pathogenesis. S. aureus strains are capable of 
expressing numerous polypeptides which can be classified into haemolysins (α- and 
β-haemolysins), bi-component leukocidins (gamma-(γ-) haemolysin, leukocidins 
LukAB and LukED and Panton-Valentine Leukocidin PVL) and small amphipathic 
lytic peptides (δ-haemolysin and Phenol Soluble Modulins (PSMs)). The vast 
majority of clinical S. aureus strains contain the genes for the haemolysins and PSM 
peptides (312, 427). In contrast the genes for PVL are observed in approximately 5% 
of clinical strains and are highly associated with CA- S. aureus strains. The true 
distribution of LukAB and LukED genes in clinical isolates is unknown but has been 
suggested to be between 30-70% (100). It is important to note that the presence of 
the gene does not mean the protein is expressed as SNPs within toxin genes, 
mutations in virulence regulators and environmental conditions can impact on the 




α-haemolysin is the model pore-forming toxin (PFT) and research into its structure, 
mechanism of action and role in disease from the last forty years has made it one of 
the most well-characterized virulence factors. α-haemolysin is composed of seven 
monomers which initially form a homoheptamer prepore, transitioning into a mature 
β-barrel transmembrane pore on the surface of susceptible cells (314). This causes an 




 in and 
out of the cell, resulting in cell death. Historically, the deposition of α-haemolysin 
monomers was shown to occur on phosphatidylcholine containing liposomes, 
underlining the requirement of these phospholipids (153). However, the differences 
in susceptibilities of rabbits and human erythrocytes to purified α-haemolysin 
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suggested another important receptor required in α-haemolysin activity. Recently, the 
identification of A Disintegrin and Metalloprotease Domain-containing protein 10, 
(ADAM10) highly expressed on rabbit erythrocytes (among other cell types) was 
shown as an important receptor for α-haemolysin activity (428).  
 
 α-haemolysin is responsible for the lysis of several other cell types including 
lymphocytes and monocytes (309, 314, 429) and binding with ADAM-10 activates 
the intrinsic metalloprotease activity of this protein resulting in degradation of E-
cadherin and disruption of the epithelial barrier (100). Sub-lytic concentrations of 
this toxin can induce pro-inflammatory responses through activation of the 
inflammasome, a complex signalling platform, resulting in necrotic tissue injury 
(430). The cytolytic, immunomodulatory and barrier disruptive activity conferred by 
this single toxin confirms α-haemolysin as a main virulence factor in in vivo 
experiments. This toxin has been implicated as a critical factor in S. aureus 
pneumonia (315), sepsis (431), brain abscess (432) and SSTI (311).  
 
 The β-haemolysin is a neutral sphingomyelinase, which targets 
sphingomyelin, a specific type of membrane lipid resident in the plasma membrane 
(433). This lipid is highly associated with cholesterol and is enriched in lipid ordered 
membrane microdomains (433). This enzyme hydrolyses sphingomyelin into 
ceramide and phosphorylcholine leading to aggregation of microdomains, possibly 
affecting the fluidity and stability of the membrane resulting in cell lysis, although 
the exact mechanism is poorly understood (433). The classic hot-cold lysis assay to 
investigate β-haemolysin activity highlights the relative inactivity of this toxin to 
erythrocytes, compared to other cytolytic peptides. Similarly, β-haemolysin is toxic 
to monocytes, but at a reduced level, about 50% activity compared to α-haemolysin 
(100). The gene for β-haemolysin, hlb, is also a site for bacteriophage insertion, 
which results in disruption of the gene. The majority of phages which integrate at this 
site carry with them components of the immune evasion cluster (IEC) such as 
staphylokinase and chemotaxis inhibitory protein (CHIPS) (434) and the majority of 
clinical strains carry components of the IEC and thus are β-haemolysin negative 
(435), questioning the relevance of this toxins contribution to overall virulence.    
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 In spite of the low prevalence of hlb clinically, it has been shown to be 
important in promoting lung epithelial damage and inflammation in a mouse model 
(436) most likely through the release of ceramide after hydrolysis of the cell 
membrane. Ceramide is believed to activate the inflammasome through interaction 
with NLRP3 receptor, promoting pro-inflammation and resulting tissue damage.  
 
1.3.5.2.2 Bi-component toxins 
 
Bi-component toxin activity requires the involvement of two polypeptides, 
designated S (slow) and F (fast) based on their electrophoretic mobility. The most 
studied of these toxins is the γ-haemolysin, but the mechanism of action is believe to 
be similar for all, consistent with the significant homology shared among these 
proteins (437). In a similar fashion to α-haemolysin, each monomer of the bi-
component toxins binds to the cell membrane before oligomerizing into a pre-pore 
composed of four S components alternatively arranged with four F components 
(438). Prepore transition into a mature homo-octamer transmembrane β-barrel results 
in host cell lysis. 
 
 There are four members of this family of PFTs: γ-haemolysin, composed of 
two S subunits, HlgA or HlgC, and F subunit HlgB; PVL, consisting of LukS-PV 
and LukF-PV; LukAB and LukED. These toxins are responsible for the lysis of a 
broad spectrum of host cells. γ-haemolysin and LukED are haemolytic whereas PVL 
and LukAB are not (439). The specific binding requirements of these toxins to 
erythrocytes is not fully understood, however for γ-haemolysin the architecture and 
membrane components plays a major role in pore-formation (440). γ-haemolysin and 
PVL are very toxic to neutrophils and macrophages, but LukAB is only toxic at the 
same level when the concentration is increased 100-fold (437), suggesting that this is 
not the primary target for LukAB. Recently, LukED has been shown to bind to the 
CCR5 receptors and efficiently lyse T-lymphocytes, ending a decade long 
investigation into its specific cell target (441). Recent works has also elucidated the 
specific receptors required for binding of the other bi-component toxins to 
susceptible cells. The common theme among these receptors is their importance in 
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immune function. LukAB lyses neutrophils by binding to the CD11b subunit of the 
integrin Mac-1, an important receptor involved in leukocyte adhesion and 
chemotaxis (442). Recent work has shown that after exposure to neutrophils, 
USA300 preferentially activates the expression of the promoter of lukAB operon 
(443). This pre-emptive attack on ensuing neutrophils is coupled with the continued 
expression upon phagocytosis promoting escape, underlying the dual role played by 
this toxin (443). Spaan et al showed that PVL targets the human complement 
receptors C5aR and C5L2, possibly underlying the reason why murine PMNs were 
more resistant to PVL than human or rabbit PMNs (308). CCR5, C5aR and C5L2 are 
G-protein coupled receptors involved in cytokine sensing and response to 
inflammatory mediators resulting in neutrophil recruitment to the site of infection 
(444).  
   
 Toxins’ acting on the same cell types highlights the degree of redundancy 
which exists within this family, in an analogous fashion observed with some of the 
CWA proteins binding the same ECM proteins. However, investigating the effects of 
sub-lytic concentrations of these toxins opens up a new area of investigation, 
potentially uncovering new functions for these virulence factors (100). For example 
sub-lytic concentrations of PVL can lead to neutrophil activation, or priming, 
resulting in the secretion of potent inflammatory mediators such as IL-8 and 
leukotriene B4 (445). The resulting release of such chemicals triggers massive 
inflammation, and when occurring within the lung, contributes to the development of 
pneumonia, a disease in which PVL plays a central role (310). Clinical PVL positive 
strains also displayed enhanced adhesion to collagen and laminin, two important 
matrix proteins, enabling the attachment to damaged airway epithelium, potentially 
playing a significant role in the development of necrotizing pneumonia (446). The 
ability to confer the observed increased adhesion was attributed directly to the signal 
peptide of the LukS-PV (446).  
 
The importance of these toxins is further shown using isogenic deletion 
mutants and assessing the impact in animal models. These experiments illustrate the 
direct role of toxins in specific diseases, further distancing the idea that these toxins 
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are redundant in S. aureus. As described above, PVL has been shown to be a key 
virulence factor in rabbit pneumonia model but also in rabbit osteomyelitis (447). 
The importance of the leukocidins in immune evasion and destruction of neutrophils 
is highlighted by their role in human blood survival (437) and murine model of 
bacteraemia (448).  
 
1.3.5.2.3 Small amphipathic lytic peptides 
 
The δ-haemolysin and PSM peptides represent a class of small amphipathic 
membrane damaging toxins affecting a broad repertoire of host cells, requiring no 
proteinaceous receptor for activity. The δ-haemolysin is encoded with the rnaIII 
gene while the PSM peptides form two classes encoded on the core genome; psmα 
operon encoding the small (20-25 amino acid) PSMα1-4 peptides and psmβ operon 
expressing the larger (44 amino acids) PSMβ1-2 (312).  
 
 The exact mechanism of action of the PSM peptides is unknown but assumed 
to be similar to that proposed for δ-haemolysin (449). The hypothesis is based on 
whether the toxin is expressed at low or high concentration. At low concentration, it 
is suggested that δ-haemolysin dimers lie horizontal to the surface of the membrane, 
at the interface of the polar head groups and acyl chains. These dimers can either 
aggregate forming small and large channels resulting in osmotic imbalance, or can 
self assemble on the surface causing a bilayer curvature strain leading to membrane 
instability in a ‘sinking-raft like’ model (450). At high concentration, δ-haemolysin 
seems to act like a detergent, leading to the rapid solubilisation of the membrane 
forming micelles, resulting in cell lysis (449).  
 
 PSM peptides are multifunctional and are influential in many aspects of S. 
aureus pathogenesis. These peptides have been shown to lyse neutrophils and 
erythrocytes (312, 316), and in this thesis, lymphocytes (T cells) (Chapter 6). 
Intriguingly, although the PSM peptides are very similar, possibly arising through 
sequential gene duplication events, PSMα3 has a significantly higher lytic activity to 
neutrophils than the other peptides (70). This peptide has been implicated as a key 
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element responsible for the highly virulent phenotype of CA-MRSA strains (312). 
However, the same pattern of lysis observed with PSMs and neutrophils is not 
observed with erythrocytes or vesicles, most likely due to differences in the 
membrane composition. One of the key features of highly virulent CA-MRSA is the 
ability to survive and lyse neutrophils following phagocytosis (296). The role of 
PSMs in intracellular escape from the phagosome was predicted after it was shown 
that serum lipoproteins reduced the cytolytic activity of PSMs (451). In an 
experiment similar to that illustrating the activation of the lukAB promoter in the 
presence of neutrophils, it was shown through psmα promoter-GFP constructs that 
PSMs were expressed after phagocytosis (451). The fact that S. aureus employs two 
toxins to mediate escape and lysis of neutrophils after phagocytosis illustrates the 
importance of neutrophils for controlling S. aureus survival.  
 
 At sub-lytic concentrations PSMs attract, stimulate and induce the release of 
cytokines from neutrophils through their interaction with the formyl peptide receptor 
2 (FPR-2) (312, 452). At first this activation may seem counter-productive to 
survival, however overexpression of neutrophil mediators may lead to the tissue 
destruction and future dissemination. The FPR receptor is also present on mouse 
dendritic cells, whereby PSM can bind to these receptors and modulate the activity of 
these cells, reducing the expression of proinflammatory cytokines such as TNFα and 
IL-6 but inducing anti-inflammatory cytokines such as IL-10 (453). This 
immunomodulation results in a decreased activation of CD4
+ 
T cells and reduced 
Th1 differentiation, hypothesized to contribute to S. aureus immune evasion (453).  
 
 PSMs are instrumental in biofilm formation, particularly in facilitating 
intricate channel development important for nutrient and waste transport (128). The 
biophysical characteristics of these molecules, namely their amphipathic property, 
suggest that they play a central role in the release of cells or cell clusters from the 
biofilm surface (128). In vivo animal experiments highlight the importance of PSM is 
specific infections. Deletion of the psmα operon exhibited reduced virulence in a 
mouse bacteraemia model, whereas deletion of psmβ operon displayed no effect 
(312). In analyzing the main virulence factors involved in SSTIs, PSM and α-
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haemolysin were highlighted as the main contributors in a rabbit skin infection 
model (311). Considering their presence in virtually all clinical S. aureus strains in 
addition to the many roles played in pathogenicity, it has been proposed that PSMs, 
along with α-haemolysin, are the primary virulence factors responsible for S. aureus 


























1.4 Summary, aims and objectives of PhD 
___________________________________________________________________________________________ 
 
This thesis consists of an interdisciplinary approach to understanding, measuring and 
identifying factors important for bacterial virulence. For clarity in highlighting the 
aims and objectives of this project, the thesis is divided into two main parts:  
 
1)  Investigating bacterial mediated lysis of phospholipid vesicles: implications 
for the development of ‘smart’ burn wound dressings and novel assays to 
measure specific surface acting virulence factors. 
 
2) Examining factors and identifying virulence loci which alter toxicity in 
Staphylococcus aureus 
 
1.4.1 Investigating bacterial mediated lysis of phospholipid vesicles 
 
The main objective of the Bacteriosafe project (European Commission, Seventh 
Framework Programme) was the development of a ‘smart’ or ‘active’ burn-wound 
dressing. This project consisted of a pan-European consortium, composed of 
interdisciplinary scientists from the fields of cell biology and wound healing, 
physical and nano-chemistry and microbiology. The basis of the wound dressing is 
illustrated in figure 1.10 and consists of a phospholipid vesicle containing a 
fluorescent dye. Importantly, the fluorescent dye used in this system is self-
quenchable at high concentrations, as is the case within the aqueous cavity of the 
phospholipid vesicle. The ‘activity’ of the wound dressing depends on the lysis of 
these vesicles by ‘active’ bacterial exofactors (toxins, enzymes, glycolipids) causing 
a switch from a non-fluorescent to fluorescent state, signalling an infection, 
highlighting the ‘smart’ aspect of the dressing. Our role at the University of Bath was 
to develop these phospholipid vesicles as sensors for bacterial detection. Briefly, this 
required the identification of several vesicle types which met the criteria for stability 
at different pH, temperatures, and in specific polymer matrices or hydrogels, while 
monitoring the sensitivity to bacterial exofactors (165, 455, 456). My primary 
objective was to identify these ‘bacterial lytic agents’. The identification of these 
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exofactors lead to the development  of two assays to actively measure important 
virulence factors expression in two of the most important burn wound colonisers, 
Staphylococcus aureus and Pseudomonas aeruginosa, highlighted in Chapters 3 and 




Figure 1.10: Concept behind Bacteriosafe burn wound dressing. The Bacteriosafe prototype 
dressing consists of self-quenchable fluorescent dye encapsulated phospholipid vesicles, which are 
immobilised within a protective polymeric hydrogel. Burn wounds are susceptible to infection 
particularly by S. aureus and P. aeruginosa. After colonisation, bacteria at the burn site express 
certain exofactors which are lytic to membranes. The phospholipid vesicles mimic biological 
membranes and are lysed by these exofactors, releasing the dye which is no longer quenched and 
fluoresces, signalling an infection.  
 
 
1.4.2 Examining factors and identifying virulence loci which alter 
toxicity in Staphylococcus aureus 
 
Staphylococcus aureus is a versatile human pathogen and this second project 
intended to gain a better understanding of how internal and external factors can 
modulate virulence factor expression. Keeping with the theme of the first project, 
one objective was to investigate the lytic activity of toxic shock syndrome toxin-
1(TSST-1) positive S. aureus strains, as discussed in chapter 5. This was preformed 
as previous results suggested that TSST-1, as well as modulating its own regulation, 
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also down-regulated overall exoprotein expression (457), and therefore may hinder 
the trigger for vesicle lysis and early bacterial sensing.  
 
 Medical intervention of bacterial infection historically consists of treatment 
of the infection with antimicrobial agents. This comes at a cost, as antimicrobial 
intervention imposes a positive selection on bacteria to mutate and become resistant. 
Another treatment avenue is to prevent bacteria producing virulence factors by 
interrupting with virulence gene regulation. Chapter 6 investigates the potential of 
using subinhibitory oxacillin to attenuate virulence in community-acquired 
methicillin resistant S. aureus CA-MRSA (CA-MRSA) strains.  
 
Due to the advancement in sequencing technology in the last decade, there 
has been an explosion of genomic data made available for various bacterial species, 
particularly S. aureus. The objective in Chapter 7 was to investigate whether it was 
possible to utilise the genomes sequences of 90 closely related ST239 S. aureus 
strains to identify novel virulence loci by associating genetic polymorphisms with 
phenotypic traits, specifically toxicity and adhesion, using a genome-wide 
association study (GWAS) approach. This work was done in collaboration with Dr. 
Mario Recker from the College of Engineering, Mathematics & Physical Sciences, at 














A list of all materials can be found in Table 2.1.  
Product Description Supplier 
Acetic acid  Solvent Sigma 
Acetone Solvent Sigma 
Agarose DNA/RNA gels Promega 
Anhydrous tetracycline Used for pRMC2 induction Sigma 
Ampicillin Beta-lactam; cell wall inhibitor Sigma 
APS Ammonium persulfate Sigma 
BHI Brain heart infusion Fluka 
Bis-polyacrylamide 40% polyacrylamide solution Bio-Rad 
Bovine Serum Albumin Used as a blocking reagent in binding 
assays 
Sigma 
Bradford reagent Protein quantification Sigma 
1-butanol Solvent Fisher Scientific 
CaCl2 Calcium chloride Sigma 
Chloramphenicol Broad-spectrum, protein synthesis inhibitor Sigma 
Chloroform HPLC-grade Solvent Fisher Scientific 
Costar 96-well plate 96-well plate used in vesicle studies Costar 
Crystal violet Bacterial stain Sigma 
DMEM Dulbecco’s Modified Eagle’s Medium Invitrogen 
Dream Taq DNA polymerase and PCR reagents Fermentas 
EDTA Ethylenediaminetetraacetic acid Sigma 
Erythromycin Macrolide antibiotic; protein synthesis 
inhibitor 
Sigma 
Ethanol Solvent Fisher Scientific  





Cell counting slide Immune Systems 
FBS Foetal bovine serum Gibco 
Fibrinogen Extracellular matrix protein Sigma 
Fibronectin Extracellular matrix protein Sigma 
Gene Jet Midi Kit Plasmid purification midi kit Fermentas 
Gene Ruler 1 kb DNA ladder Fermentas 
Gentamicin Aminoglycoside; protein synthesis inhibitor Gibco 
Glycerol Used in -80°C bacterial stocks Sigma 
Goat anti-spa Goat polyclonal against protein A (HRP) Abcam 
GPS solution L-Glutamine-Penicillin-Streptomycin Sigma 
Guava ViaCount Viability stain Millipore 
HyClone DMEM Culture media Fisher Scientific 
Isopropanol Solvent Fisher Scientific 
LB Luria-Bertani agar/broth Fluka 
Lysostaphin Glycyl-glycine endopeptidase  Cell Sciences 
Mouse anti-lukS Monoclonal antibody against LukS-PV IBT bioservice 
NaCl Sodium chloride Sigma 
NaOH Sodium hydroxide Sigma 
Nap-25 columns Sephadex G-25 DNA grade packed 
columns 
GE Healthcare 
Nunc 24-well plates Tissue culture plates Nunc 
Nunc 96-well plates Binding assay plates Nunc 
Olive oil Substrate in lipase plate assay Sigma 
Opti4CN substrate kit Colorimetric (HRP) substrate  Bio-Rad 
Oxacillin Beta-lactam, cell wall inhibitor Sigma 
Page Ruler Plus Pre-stained protein ladder Fisher Scientific  
Paraformaldehyde Fixative in binding assay Sigma 
PBS Tissue grade phosphate-buffered saline Gibco 
PCR purification kit Purification of PCR products Fisher Scientific 
Mouse anti-mecA Mouse monoclonal antibody to PBP2a Abnova 
peqGreen DNA/RNA dye peqLab 
Phusion DNA 
polymerase 
High-fidelity DNA polymerase New England 
Biolabs 
Proteinase K Broad-spectrum serine protease Sigma 





PSM peptides Peptide toxins Severn Biotech 
Rabbit anti-hla Polyclonal whole antiserum against α-
haemolysin 
Sigma 
Rabbit anti-tst Polyclonal antibody against TSST-1 Abcam 
Raffinose Trisaccharide; used in sphaeroplast buffer Sigma 
Random Hexamer Primers used in reverse transcription  Qiagen 
Reverse transcriptase Superscript II reverse transcriptase Invitrogen 
Rhamnolipid R-95 Pure rhamnolipid; glycolipid Sigma 
Rhodamine B Fluorescent dye, used in lipase plate assay Sigma 
RNAprotect Immediate stabilisation of RNA Qiagen 
RNeasy Midi Kit RNA purification kit Qiagen 
RPMI 1640 Roswell Park Memorial Institute cell 
culture media 
Gibco 
SDS Sodium dodecyl sulphate Sigma 
Skim milk powder General blocking reagent Sigma 
T-75 Tissue culture flask Corning 
TAE Tris-acetate EDTA buffer Sigma 
TEMED N, N, N, N’-tetramethylethylenediamine Sigma 
Triton X-100 Detergent Sigma 
Trypan Blue Vital cell stain Sigma 
Trypsin-EDTA (0.25%) Cell detachment solution Gibco 
TSA Tryptic Soy Agar Sigma 
TSB Tryptic Soy Broth Sigma 
TSST-1 Toxic shock syndrome toxin-1  Sigma 
Turbo DNAse Fast acting DNAse Ambion 
Qubit RNA assay kit Fast and accurate RNA quantification Invitrogen 
Virkon Disinfectant Fisher Scientific 
 
Table 2.1: List of materials used 
 
 
2.2 Lipid vesicle development 
___________________________________________________________________________________________ 
 
Aqueous buffer solutions used in the development of phospholipid vesicles are given 
in Table 2.2 and 2.3. These compounds were dissolved in deionised water, sonicated 




    
    
                                                                   
 
Table 2.2: HEPES buffer solution, pH 7.4 
Abbreviations: HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; NaCl, 








Table 2.3 50 mM 5(6)-carboxyfluorescein buffer  
 
 
Stock solutions of vesicle components were separately dissolved in 1 mL of 
chloroform and stored in glass vials at -20°C, according to Table 2.4.  
 
Compound Mr (g mol
-1
) Mass (mg) Concentration (mol dm
-3
) 
TCDA 346.55 34.6 0.10 
DPPC 734.04 73.4 0.10 
DPPE 691.96 69.1 0.10 
CHO 386.65 38.6 0.10 
 
Table 2.4: Stock solutions of vesicle components: Abbreviations: TCDA, 10, 12-
Tricosadiynoic acid; DPPC 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine; DPPE 1, 
2-dipalmitoyl-sn-glycero-3-phosphoethanolamine; CHO, cholesterol.  
 
 















Vesicle suspensions were prepared by mixing lipid and fatty acid components in 
chloroform at a 3 X concentration: 1 X concentration was prepared by using 25 
mol% of 10, 12-tricosadiynoic acid (TCDA), 53 mol% 1, 2-dipalmitoyl-sn-glycero-
3-phosphocholine (DPPC), 2 mol% 1, 2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine (DPPE) and 20 % of cholesterol (CHO). This mixture of lipids 
and fatty acid in chloroform was dried under nitrogen. Figure 2.1a and b illustrate the 
various steps in the production and determination of lipid vesicles formation. The 
dried lipid was (1) rehydrated using 5 mL of 5(6)-carboxyfluorescein (CF) 
(molecular structure shown in figure 2.1) buffer solution, vortexed and heated in a 
hot water bath at 75°C for 10 min. CF is self-quenched at high concentrations (i.e. 
encapsulated within vesicles), but fluoresces when diluted to lower concentrations 
(i.e. when vesicles are lysed). Three freeze/thaw cycles were carried out by initially 
immersing the lipid-containing vial in liquid nitrogen and then heating the vial back 
to room temperature to homogenize the solution (164). A turbid solution was an 
indication of vesicle formation. Vesicles were then (2) extruded five times at 55°C 
using a Liposofast vesicle extruder (Avestin, USA) through 2 × 0.1 μm 
polycarbonate filters under nitrogen pressure. The initial opaque vesicle solution 
becomes translucent after extrusion. The vesicle solution was then (3) purified using 
Illustra Nap-25 columns to remove any un-encapsulated CF dye. The columns were 
washed with 15 mL of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
buffer to remove the 0.15% Kathon CG/ICP biocide. 2 mL of vesicle solution was 
added to each column and allowed to load. 1 mL of HEPES buffer was then added 
and left to drain. After this a further 2 mL of HEPES buffer was added and the 
resultant pure vesicle was collected and stored at 4°C overnight. These 
polydiacetylene containing lipid vesicles were then (4) cross linked and photo 
polymerised using a CL1000 Ultraviolet cross linker (Hamamatsu, Japan) on setting 
one for 6 s. Section (4) of figure 2.1 illustrates a TCDA molecule undergoing a 
conformational change after exposure to UV. The cross linking of the TCDA 
molecules leads to higher stability, while retaining sensitivity to bacterial  







Figure 2.1: Development and validation of lipid vesicles. A)  Steps in the production of vesicles 
beginning with 1) rehydration of the lipid film using the 50 mM carboxyfluorescein (chemical 
structure shown), 2) extrusion through 100 nm polycarbonate filters, 3) purification using sephadex 
columns and 4) UV cross linking lipid-polydiacetylene vesicles. B) Size distribution of the vesicles 
using nanosight tracking analysis and dynamic light scattering illustrates vesicle size between 90-110 
nm. Use of 0.01% Triton X-100 and HEPES buffer as positive and negative controls showing 
maximum fluorescence release with the addition of 0.01% Triton X-100.  
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Size distribution and concentration of vesicle was measured via dynamic light 
scattering (Malvern) and nanosight tracking analysis (Nanosight Ltd) respectively, 
producing a size distribution of 90-110 nm and concentration of 1 x 10⁸ particles/μL. 
All chemicals were purchased from Sigma-Aldrich, UK, and lipids and cholesterol 
from Avanti Polar Lipids, USA. These vesicles were stored at 4°C and were stable 






2.3.1 Bacterial strains and culture conditions 
 
Bacterial strains used are listed in Appendix A. Bacterial strains were routinely 
stored at -80°C in 15% glycerol/broth stocks until required. Unless stated otherwise, 
S. aureus strains were streaked onto Tryptic Soy agar (TSA) and single colonies 
transferred to 5 mL Tryptic Soy broth (TSB). Pseudomonas aeruginosa and 
Escherichia coli strains were routinely plated onto Luria Bertani (LB) agar and 
single colonies transferred to 5 mL of LB broth. All bacterial cultures were 
propagated in a shaking incubator for 18 h at 37°C at 180 rpm. For detection of 
Panton-Valentine Leukocidin, bacterial strains were grown in casein hydrolysate and 
yeast-extract containing medium (CCY) (458). Bacterial strains were grown in 25 
mL glass universal tubes which were decontaminated using Virkon disinfectant, 
washed thoroughly to prevent any residual disinfectant remaining and subsequently 
autoclaved. Single point bacterial growth measurements were analysed using a micro 
plate reader (BMG LABTECH) at OD600.  Where continuous bacterial growth curve 
analysis and/or dual absorbance/fluorescence was required, bacteria were measured  
at OD600 at 37°C and shaking at 300 rpm in Costar 96-well round-bottomed plates 
using a dual absorbance/fluorescence script. To identify specific roles of 
toxins/enzymes/glycolipids in vesicle lysis, bacterial supernatants were heated to 
95°C for one hour. Where appropriate antibiotics were used with the following 
concentrations; S. aureus strains: tetracycline (10 μg/mL), oxacillin (0.5 μg/ml); 
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chloramphenicol (10 μg/mL), erythromycin (5 μg/mL).  P. aeruginosa strains: 
tetracycline (200 μg/mL), gentamicin (100 μg/mL). E. coli DH5α: ampicillin (100 
μg/mL).       
 
 
2.4 Cell culture 
___________________________________________________________________________________________ 
 




In the cell toxicity assay, immortalized human T2 cells (459) were used in 
accordance with guidelines form the American Type Culture Collection. T2 cells are 
derived from a mutant TxB hybrid cell line T cells were grown in T75 tissue culture 
flasks containing Roswell Park Memorial Institute (RPMI) 1640 cell culture media 
supplemented with 10% heat-inactivated foetal bovine serum (FBS), 1 μM L-
glutamine, 200 units/mL penicillin and 0.1 mg/mL streptomycin (GPS), at 37°C in a 
humidified incubator with 5% CO2 in air. Cells were routinely viewed 
microscopically and split every 48-60 hours. Cells were harvested by centrifugation 
at room temperature for 10 min at 1500 g, gently washed and resuspended in tissue-
culture grade phosphate buffered saline (PBS) to a final concentration of 1–1.5 x 106 
cells/mL using a FastRead counting chamber. This procedure typically yielded > 95 





T cells were subjected to three types of treatment: 1) Bacterial supernatant (active 
and heat-inactivated), 2) purified phenol soluble modulin (PSM) and δ-haemolysins 
and 3) purified rhamnolipid. For the first two treatments, 20 μL of cells were 
incubated with 20 μL of staphylococcal supernatant or toxin for 12 min at 37°C. 
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Following incubation, 260 μL of Guava ViaCount viability strain was added and left 
to incubate for 5 min at room temperature. Viability of cells was then analysed using 
the Guava easyCyte flow cytometer (Millipore) under the following conditions: flow 
rate of 0.59 μL/s, with 250-300 cells/μL; adjustment of FSC threshold and viability 
marker to correct for cell debris and for increased discrimination between viable and 
non-viable cells, according to manufacturer’s instructions. For treatment 3), P. 
aerugionosa supernatants and purified rhamnolipid, 15 μL of cells and 15 μL of 
supernatant or purified rhamnolipid were incubated for 12 min. 15 μL of 0.4% trypan 
blue was added and mixed with the above solution and added to a FastRead counting 
chamber and viability assessed through trypan blue exclusion and examination under 
an Olympus CX31 light microscope. This method was preferred in this treatment as 
neat P. aeruginosa supernatant and high concentrations of purified rhamnolipid 
caused total cell lysis and release of genomic DNA (addition of DNAse caused 
viscous cell mixture to return to normal fluid solution) inhibiting viability counts 
using the flow cytometer. Cell toxicity experiments were done in duplicate three 
times. 
 
2.4.2 Erythrocyte and polymorphonuclear leucocytes harvesting and 
lysis assay 
 
Polymorphonuclear leukocytes (PMNs) were isolated from heparinized venous blood 
obtained from healthy adult volunteers. Whole-blood samples were layered onto 
density gradient medium (Lympholyte cell separation medium) and centrifuged as 
described by the manufacturer (Cederlane). The PMN-containing band was harvested 
and diluted with an equal volume of culture medium (HyClone Dulbecco’s modified 
Eagle’s medium [DMEM]–10% fetal calf serum [FCS] cell medium) at a 
concentration of 0.5 N to restore normal osmolality. The cells were further diluted 
with 2 volumes of culture medium and washed by centrifugation for 10 min at 400 g. 
The cells were suspended in 5 mL of 0.2% NaCl and incubated for 120 s to lyse 
erythrocytes by osmotic shock, followed by the addition of 5 mL of 1.6% NaCl for 
120 s to normalize the osmolality and centrifugation at 400 g for 10 min. Purified 
PMNs were then washed in PBS and enumerated by using a haemocytometer. Purity 
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was assessed by trypan blue and flow cytometric analyses. The final PMN count was 
adjusted to 1-2 x 10
6
 cells/mL with culture medium. 30 μL of PMNs were incubated 
with 30 μL of bacterial supernatant for 30 min, and cell viability was assayed by 
using Guava ViaCount and easyCyte flow cytometer as above. Experiments were 
done in duplicate three times.  
 
Erythrocytes were isolated from the same blood samples and washed twice by 
gentle resuspension with a 10 mL volume of sterile saline (0.9% NaCl) and 
centrifugation at 1,000 g for 10 min. Erythrocytes were diluted to 1% (vol/vol), and 
200 μL of cells were incubated with 50 μL of 30% bacterial supernatant for 30 min, 
using free saline as a negative control and 1% Triton X-100 as the positive control. 
Intact cells and cellular debris were removed by centrifugation at 1,000 g for 10 min. 
RBC lysis was assayed by determining the absorbance of the resulting supernatant at 
an OD404 nm using a micro plate reader (BMG LABTECH). These assays were 
performed in duplicate three times. 
 




The EA. Hy926 cell line was constructed by the fusion of human umbilical 
endothelial cells (HUVEC) and the permanent lung epithelial carcinoma cell line 
A549 (460).  EA. Hy926 cells were routinely cultured in DMEM media 
supplemented with 10% FCS and GPS at 37°C and 5% CO2. These cells were 
cultured in T75 flasks to approximately 95% confluency and routinely observed 
microscopically. Cells were liberated using trypsin-EDTA, resuspended in culture 
medium and approximately 5x10
5 
cells (in 0.5 mL medium) were seeded into each 
24-well tissue culture plates. Following incubation for 48 h, cell culture medium was 
aspirated and cell monolayers were washed gently in PBS. New cell culture medium 







 To each well, 50 μL of washed bacteria were added (approximately 1x107 CFU/mL) 
and incubated for 15-60 min. After the specific time point, the medium was aspirated 
and wells gently washed once in PBS and replaced with 500 μL DMEM/10% FBS 
supplemented with 200 μg/mL gentamicin and incubated at 37°C in 5% CO2 for 60 
min. This medium was removed and wells gently washed twice in PBS. 500 μL of 
0.5% Triton X-100 was added and resuspended to fully lyse the endothelial cells and 
the CFU was enumerated by serial dilution and plating onto TSA agar plates and 
incubated overnight at 37°C. Invasion assays were perfomed in duplicate three times. 
 
 
2.5 DNA/RNA  
___________________________________________________________________________________________ 
 
2.5.1 RNA isolation 
 
Overnight cultures of S. aureus were diluted 1:1000 into fresh TSB and grown at    
37 °C for 8 h (late exponential phase), at which time, samples were collected for 
RNA isolation after normalisation of optical densities. Cultures were treated with 
two volumes of RNAprotect, incubated at room temperature for 10 min, centrifuged 
and resuspended in Tris 0.05 M (pH 7.5). The pellet was further treated with 300 μL 
of 0.5 M EDTA/ lysostaphin (5 mg/mL) and incubated for 1 h. RNA was then 
isolated using the Qiagen RNeasy Midi Kit according to the manufacturer’s 
instructions with the addition of Turbo DNase after the purification step. RNA purity 
was checked by running 5 μL of sample on a 1% agarose gel and absence of DNA 
further verified by PCR using standard primers. Typical RNA samples are shown in 





Figure 2.2: RNA isolation. Four representative RNA samples isolated from S. aureus cultures after 
DNAse treatment. 23S and 16S ribosomal RNA are indicated. 
 
 
2.5.2 Reverse transcription and qRT-PCR 
 
Reverse transcription of messenger RNA to complementary DNA (cDNA) was 
generated using the SuperScript II Reverse Transcriptase according to 
manufacturer’s instructions using random hexamers. Primers were designed using 
Primer 3 software (http://bioinfo.ut.ee/primer3/) to produce a PCR product between 
80-120 bp with an annealing temperature of 60 °C. Primer binding sites were 
constructed on the RNA sequence in areas with no complex secondary structure 
using mfold software (http://mfold.bioinfo.rpi.edu). Primers used for gyrase B (gyrB) 
and RNA III are listed in Appendix A. Standard curves were generated for both 
primer sets on serial dilutions of cDNA to determine primer efficiency. The reverse-
transcriptase PCR (RT-PCR) was performed as follows: 5 mL cDNA, 7.5 mL SYBR 
reagent, 0.5 ml forward and reverse primer and RNase-free water to a total volume of 
15 mL. The cDNA was subjected to real-time PCR using the Applied Biosystems 
Step-One Real Time PCR detection system (Applied Biosystems). Cycling 
conditions were 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for 
1 min and a dissociation step 95°C for 15 s and 60°C for 1 min. Cycle threshold 
values were determined for 3 biological repeats in duplicate. For each reaction, the 
ratio of RNA III and gyrB transcript number was calculated as follows: 2
(Ct gyrB – Ct 
RNAIII)






2.5.3 PCR and cloning techniques 
 
In order to examine the effect of single nucleotide polymorphisms (SNPs) on 
virulence factor expression, plasmid constructs were created containing wild type 
sarS (amplified from N315, psarS1) and sarS containing two amino acid 
substitutions, N221D and N243D (amplified fromMRSA252, psarS2). Plasmid 
constructs were also created to examine the effect of SNP presence in mecA, 
containing wild type mecA (amplified from TW20, pmecA1), and mecA containing 
two SNPs at nucleotide positions T78097C (E736G) and C78222A (K611N), or the 
‘CA’ SNPs, (amplified from strain HU24, pmecA2), mecA containing the ‘CA’ SNPs 
and SNP T78396A (K437N), or the ‘A’ SNP, (amplified from strain IU11, pmecA3) 
and mecA containing the ‘CA’, ‘A’ and SNP C78119T (E714K), (amplified from 
strain HU13, pmecA4).  
 
Primers designed to amplify the whole sarS and mecA genes with the 
respective restriction enzyme cleavage sites are listed in Appendix A. Polymerase 
chain reaction (PCR) conditions were similar for all PCR reactions, apart from 
annealing temperature and duration and elongation duration. General PCR 
parameters consisted of: 1) initial denaturation (95°C, 1 min), 2) denaturation (95°C, 
30 s), 3) annealing temperature (dependent on primers (sarS (62°C) and mecA 
(65°C)) 4) elongation (72°C, duration dependent on PCR product; sarS (45s) mecA 
(1.5 min), 30 cycles of step 2-4, 5) final elongation (72°C, 5 min) and 6) storage 
(4°C, unlimited). High-fidelity phusion polymerase was used to generate PCR 
products. PCR products were cleaned using PCR purification kit, subjected to double 
digest using BglII and KpnI in NE buffer 2 for sarS and KpnI-HF and SacI-HF in 
CutSmart buffer for mecA. Digested PCR products were cleaned in PCR purification 







2.5.4 Production of competent cells 
 
Two 50 mL conical flasks of LB broth were inoculated 1:1000 with an overnight 
culture of E.coli DH5α and incubated for 2-4 h at 37°C with shaking at 180 rpm until 
an OD600 of 0.5-0.7. Cells were chilled on ice for 30 min before centrifugation at 
3,000 rpm for 10 min at 4°C. Cells were washed in ice-cold deionised H2O, 
centrifuged and gently resuspended in 15 mL of ice-cold, sterile 0.1M CaCl2. Cells 
were left on ice for 1-2 h, centrifuged at 4°C and resuspended in 500 μL ice-cold, 
sterile 0.1M CaCl2 containing 15% glycerol. 50 μL aliquots were snap frozen using 
1.5 mL Eppendorfs previously placed in dry ice and stored at -80°C until use.  
 
2.5.5 Plasmid transformations 
 
Following ligation reaction, 5 μL of mixture containing ligated plasmid/PCR product 
was transformed into CaCl2 competent DH5α by heat shock at 42°C for 2 min. Cells 
were recovered in 900 μL of LB and incubated for 45 min after which they were 
centrifuged and resuspended in 100 μL and plated onto LB agar plates containing 
100 μg/mL ampicillin. 
 
 Transformation of plasmid into S. aureus requires initial transformation into 
the restriction and modification deficient S. aureus RN4220 strain (462). 
Transformation of plasmids into RN4220 and all subsequent S. aureus strains was 
performed by electroporation using a Micro Pulser (Bio-Rad) and 1mm gap pre-
sterilised electroporation cuvette (Molecular BioProducts). Overnight cultures were 
subcultured 1:500 and were grown in BHI for 2-4 h to an OD600 of 0.4-0.6. Bacterial 
cells were washed three times in ice-cold 500 mM sucrose to remove salts. After 
centrifugation at 4°C, the pellet was resuspended in 500 μL of 500 mM sucrose and 
left on ice for 30 min. Cells were further centrifuged and resuspended in 100 μL of 
500 mM sucrose. 100 μL of bacterial cells were added to a pre-chilled cuvette with 
5-10 μL of plasmid and pipette mixed. Cells were electroporated using the settings 
for S. aureus (25 μF, 2.5 KV and 100 Ω; pulse time of 2.5 msec), and recover cells in 
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750 μL of BHI. Cells with plasmid were incubated for 1 h at 37 °C, centrifuged for 1 
min and resuspended in 100 μL and plate on TSA containing chloramphenicol (10 
μg/mL).  For bacterial cells transformed with pRMC2 plasmid, 0-100 ng/mL 
anhydrous tetracycline was added to the growth medium. 
 
 
2.6 Protein and Glycolipid Analysis 
__________________________________________________________________________________________ 
 
2.6.1 Protein extraction techniques 
 
Whole cell lysate 
 
Overnight bacterial cultures were grown and optical densities normalised. 20 mL of 
culture was harvested by centrifugation for 10 min at 5,000 rpm after which cells 
were washed with 50 mM Tris, 150 mM NaCl and 5 mM MgCl (pH 7.5) and 
resuspended in 500 μL of the same buffer. Lysostaphin (200 μg/mL), RNase          
(10 μg/μL) and DNase (20 μg/μL) were added to the cell suspension and incubated at 
37°C for 45 min. The cells were disrupted by sonication on ice and the insoluble cell 
fraction was pelleted by centrifugation at 14,000 rpm for 15 min at 4°C. Supernatant 
was then transferred to a new Eppendorf and protein concentration calculated using 
Bradford reagent after generation of a standard curve using known concentrations of 
bovine serum albumin. 5 μL of sample and 250 μL of prewarmed Bradford reagent 
were mixed and left for 30 min at room temperature after which the absorbance was 
read at OD595nm.  
 
Surface expressed proteins 
 
Bacteria were grown to specific growth phases; either to exponential phase (OD600 of 
0.45-0.55) or stationary phase, which was defined as 18 h growth. Cultures were 
normalised and 25 mL of exponential phase or 10 mL of stationary phase were 
harvested by centrifugation as above. Bacterial pellet was washed twice in PBS and 
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resuspended in 500 μl of sphaeroplasting buffer (SB) and incubated for 1 h at 37°C 
with shaking at 180 rpm. SB consisted of: 30% raffinose, 0.05 M Tris (pH 7.5), 
0.145 M and 200 μg/mL. Bacterial cells were centrifuged for 15 min at 5,000 rpm, 
after which supernatant was transferred to a new eppendorf and further centrifuged 
for 10 min at 14,000 rpm. Protein concentrations were calculated using Bradford 




Bacteria were grown for 18 h and optical densities were normalised as above. 
Bacteria were removed by centrifugation at 14,000 rpm for 10 min and supernatant 
was transferred to a new eppendorf. Supernatant proteins were precipitated using 
trichloroacetic acid (TCA) at a final concentration of 20 % for 1 h on ice. Samples 
were centrifuged at 14,000 rpm for 20 min at 4°C and washed three times in 300 μL 
of ice cold acetone. Protein pellet was resuspended in 80 µL of solubilising buffer    
(8M urea with 6.25 mM NaOH).  
 
2.6.2 Western blot 
 
For analysis of α-haemolysin, toxic shock syndrome toxin-1 (TSST-1), LukS-PV 
(Panton-Valentine Leukocidin), protein A and penicillin binding protein 2a (PBP2a), 
20 μL sample protein was mixed with 10 μL 2X concentrated sample buffer and 
heated at 95°C for 5 min before 10 μL of sample was subjected to 12% SDS-PAGE. 
Separated proteins were electroblotted onto nitrocellulose membrane using a semi-
dry blotter at 25V for 30 min (BioRad). Membranes were blocked overnight at 4°C 
with 5 % semi-skimmed milk and then incubated with rabbit polyclonal antibodies 
specific for TSST-1 (1:1000) or α-haemolysin (1:3000) or mouse monoclonal 
antibodies specific for LukS-PV (1:500), or PBP2a (1:1000) or goat polyclonal 
antibodies specific to protein A (1:1000) for 2 h at room temperature. Immunoblots 
were washed 5 times in PBS and incubated with horseradish peroxidise-coupled 
protein G (1:1000) for 1 h at room temperature (apart from antibodies directed 
against protein A as these were HRP-conjugated). Proteins were detected using the 
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Opti-4CN detection kit and left to develop for 30 min. Band intensities were 
measured using Image J software (version 1.43). Experiments were done in triplicate 
and the mean band intensity was used for statistical analysis.  
 
2.6.3 Peptide extraction and quantification 
 
Overnight S. aureus cultures were diluted 1:1000 into 50 mL TSB in a 250-mL 
conical flask and grown for 20 h at 37 °C to an OD600 of 2.0. Bacteria were removed 
by centrifugation at 5,000g for 10 min and supernatant passed through a 0.22 μM 
pore. 30 mL of cell-free supernatants was mixed with 10 mL 1-butanol. Extraction 
was performed by shaking mixed solutions for 3 h at 37 °C. Samples were then 
centrifuged for 3 min for complete separation, and the upper organic phase was 
collected, aliquoted into 1.5-mL eppendorf tubes, and concentrated by using a 
vacuum overnight. Dried samples were dissolved in 200 μL of 8 M urea. Proteins 
(10 μL of each sample) were mixed with 2X-concentrated sample buffer and heated 
at 95°C for 5 min before SDS-PAGE (12% acrylamide) was performed. The 
individual PSMs were quantified by using mass spectroscopy as described previously 
(317) . This assay was performed in triplicate. 
 
2.6.4 Circular dichroism and helical wheel analysis 
 
The structures of synthetic PSM peptides were analyzed by circular dichroism (CD) 
using a Chirascan spectrometer (Applied Photophysics) and a path length of 0.2 cm. 
Solutions of PSMs were prepared in 1 mL PBS at concentrations between 30-60 μM. 
Due to the hydrophobic nature of the PSMβ1 and 2 peptides, they were dissolved in 
10 μL DMSO initially and then to the required concentration with PBS. This buffer 
was also used in subsequent studies with these respective peptides. PSMβ peptides 
were also dissolved in DMSO 50% Trifluoroethanol to induce secondary structure. 
Experiments with PSMβ peptides in 50% TFE were conducted using a 0.5 mm 
cuvette. Measurements were converted to mean residual molar ellipticity (θ) and 
were performed in triplicate and the resulting scans were averaged, smoothed, and 
the buffer signal was subtracted. Analysis of secondary structure content was 
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performed using the Pro-data and CDNN software (463). Helical wheel projections 
were constructed using helical wheel analysis software (http://rzlab.ucr.edu/) and the 
primary amino acid sequence of the PSMs in Appendix A.  
 
2.6.5 Thin layer chromatography  
 
Rhamnolipids were extracted from filtered culture supernatants using ethyl acetate in 
a 1:1 v/v ratio. Samples were mixed by vortexing with subsequent phase separation 
by centrifuging for 1 min at 14,000 rpm. The upper, rhamnolipid containing phase 
was transferred to a new Eppendorf tube and the procedure repeated three times. The 
organic solvent was removed by evaporation using a vacuum centrifuge. For 
detection of rhamnolipids, this dried pellet was dissolved in 10 μL of ethanol. 5 μL 
of this solution was spotted on silica 60 TLC-plates (Fisher). In addition, 5 μl of a 
0.1% rhamnolipid solution containing mono- and di-rhamnolipid (R-95) was used as 
a standard. TLC was performed using chloroform/methanol/acetic acid in a ratio of 
65:15:2 as a running buffer. For visualisation, the dried plate was briefly submerged 
in a detection agent composed of 0.15 g orcinol, 8.2 mL sulphuric acid (60% v/v) 
and 42 mL deionised H2O. The plate was left to dry at room temperature and then the 
sugar moieties were stained by incubating the plates at 110°C for 10 min.  
 
2.6.6 Dry weight analysis of rhamnolipids 
 
Dry weight analysis was based on the procedure by Gunther et al (464). Briefly, 
supernatant was separated from overnight culture (100 mL) by centrifugation at 
7,000 rpm. Supernatant was then acidified to pH 2.0 by the drop-wise addition of 12 
M hydrochloric acid. This solution was then centrifuged at 13,000 rpm and the RL 
containing precipitate was extracted three times with a chloroform-ethanol (2:1) 
mixture. This was then evaporated away leaving the characteristic honey-like 
appearance. This oily residue was dissolved in methanol and transferred to a 
previously weighted container, where the methanol was evaporated giving the total 




2.7 Phenotypic assays 
___________________________________________________________________________________________ 
 
2.7.1 Vesicle lysis assay 
 
The vesicle toxicity assay was designed de novo were experimental conditions were 
optimised before use. Fluorescence intensity was measured at excitation and 
emission wavelengths of 485–520 nm respectively on a FLUOROstar fluorimeter 
(BMG Labtech). Depending upon the experiment, two different assays were 
employed, one utilising whole bacterial cells and the other using bacterial culture 
supernatant/purified PSM/pure rhamnolipid. In the first method, bacterial culture was 
normalised to a specific CFU/mL achieved through correlation with optical density. 
250 μL of bacterial culture was added to 50 μL of vesicle solution in triplicate. The 
fluorescence of each sample was then measured at 5 min intervals for 18 h. Positive 
and negative controls were pure vesicles with 0.01% Triton X-100 and HEPES 
respectively.  
 
For the second assay, bacteria were grown for 18 h, supernatant (neat and 
heat-inactivated) was harvested by centrifugation at 14,000 rpm for 10 min and filter 
sterilized through a 0.22 mm filter. 50 μL of vesicle solution was incubated with     
50 μL of bacterial supernatant or differing concentrations of purified PSMs 
(Biomatik; 99% purity) or rhamnolipid and measured for 30 min with the above 
parameters. Normalised fluorescence was achieved using the equation                   
(Ft–F0) / (Fm/F0) where Ft is the average fluorescence value at a specific time point, 
F0 is the minimum and Fm is the maximum fluorescence value in that particular 
experiment. All vesicle lysis assays were performed in triplicate three times.  
 
2.7.2 Solid-phase fibrinogen/fibronectin binding assay 
 
The adhesion of bacteria to human fibronectin (Fn) and fibrinogen (Fb) was assessed 
using a protocol adapted from Edwards et al (410). Fn or Fb (1 μg/100 μL PBS per 
well) was immobilised onto Nunc Maxisorp Immuno plates and incubated at 4°C 
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overnight, with the remaining binding sites blocked with 300 μL 5% bovine serum 
albumin (in PBS) at room temperature for 2-3 h. Well contents were discarded, and 
100 μL of bacteria corresponding to approximately 1x108 CFU/mL (and 
corresponding to a specific phase of growth, section 2.6.1) were added to wells and 
incubated at 37°C for 1 h. Non-adherent bacteria were removed through three rounds 
of washing with PBS. Adherent bacteria were fixed with 50 μL per well of 2.5% 
paraformaldehyde for 5 min. Wells were washed a further two times before the 
staining of fixed bacteria with 50 μL of 0.5% crystal violet for 2 min. After a further 
three PBS washes, adherent, fixed bacteria were enumerated by solubilisation of 
crystal violet with 100 μL of 7% acetic acid. Quantification was achieved through 
measurements of well absorbance at 595nm using a microplate reader. Both Fb and 
Fn reading were blanked against bacteria bound to BSA coated wells. Absorbance 
measurements were converted to bacterial numbers by use of standard plots of 
known bacteria numbers against absorbance 595nm reading (410). All adherence 
assays were perfomed in duplicate three times. 
 
2.7.3 Lipase plate assay 
 
Lipase plate assay was designed as described previously with some minor 
modifications (465). Olive oil (1 %) and rhodamine B (0.001 %) were used as 
substrate and added to the agar medium after sterilization and cooling to 60°C. 3-
mm-diameter holes were punched into the agar and 50 mL of cell-free supernatant 
harvested from 18 h stationary phase bacterial cultures were added and left to 
incubate for 18 h at 37°C. Plates were irradiated with a UV light and images captured 
on a Nikon camera. 
 
2.7.4 CAMP assay 
 
The conventional method to determine or measure Agr activity is via δ-haemolysin 
production. This was determined by streaking the β-haemolysin positive S. aureus 
RN4220 strain on washed sheep blood agar (SBA) plates. The test strains were 
streaked perpendicular to this strain and any enhanced zone of haemolysis where the 
96 
 
δ-haemolysin (466) or PSMs (316)  overlaps with the β-haemolysin zone was scored 
Agr positive. 
 
2.7.5 Beta-haemolysis assay 
 
Haemolysis plates consisted of TSA with 5% defibrinated Sheep blood (Thermo 
Scientific). Sheep blood was added under sterile conditions after TSA was 
autoclaved and cooled to 40-45°C. Bacterial strains, previously plated onto TSA 
plates, were streaked to achieve single colonies on blood plates and incubated 
overnight at 37 °C. After overnight incubation at 37°C, plates were incubated and 
4°C for 2 h.  
 
2.7.6 Orcinol assay 
 
Culture supernatants were obtained by centrifugation and 300 μL of this was 
extracted twice with 1 mL of diethyl ether. The samples were pooled and evaporated 
to dryness using a vacuum centrifuge and then 0.5 mL of sterile H2O was added. To 
each 100 μL sample, 900 μL of a solution containing 0.19% orcinol (in 53% H2SO4) 
was added. This solution was heated to 80°C for 30 min, after which the samples 
were cooled at room temperature for 15 min. The absorbance of the samples were 
measured at 421nm (BMG labtech) and concentration of rhamnolipids compared to 
those generated using a standard (R-95 Sigma). These assays were performed in 











2.8 Statistical and genotypic analysis 
___________________________________________________________________________________________ 
 
2.8.1 Statistics  
 
For adhesion, invasion, cell and vesicle lysis assay and protein expression 
experiments, statistical analyses were performed with a Student’s t test. Values that 
were stastically significantly different than the wildtype or control values are 
indicated by asterices in the figures. Error bars indicate the mean average ± the 95% 
confidence interval of multiple independent experiments.  
 
2.8.2 Genome wide association studies using PLINK 
 
We conducted a quantitative association study on a set of 90 isolates of the S. aureus 
clone ST239 to identify single nucleotide polymorphisms (SNPs) that were 
significantly associated with toxicity, using the PLINK software package 
(http://pngu.mgh.harvard.edu/purcell/plink/) (467). From the original set of 3060 
intragenic SNPs we identified 102 SNPs with a statistical significance of p < 0.05 
after quality control (using PLINK options -geno 0.9 and -maf 0.05, which restricted 
SNPs which were present in 90% of isolates or less than 5%). Association study was 




where all files were in .map format. SNPs were only chosen that has a statistical 
significance of  p<0.05 after Bonferroni correction. P-values are used todetermine the 
significance of a result. These values allow the interpretation of the result based on 
rejecting the null hypothesis, the default position where there is no relationship 
between two measured factors. Bonferroni correction undertakes an assessment of 
the statistical significance of multiple assessments. With multiple assements there is 
a higher probablility that one of the assessments is statistical significant by pure 
chance. Therefore in cases with multiple assessments a lower p-value is used to 
assess whether something is stastically significant and this is achieved by using 
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Bonferroni correction, where .05 is divided by the number of tests that are done. A 
similar association study was performed using the insertion and deletion 
polymorphism data (InDel), where inserts, deletions, and wild types were coded as 
+1, -1, and 0, respectively. This identified 22 unique InDels quantitatively associated 
















Staphylococcus aureus Interaction with Phospholipid 
Vesicles – A New Assay to Determine Accessory Gene 





Accurate and sensitive measurement of Agr activity is central in understanding the 
virulence potential of Staphylococcus aureus, especially in the context of Agr 
dysfunction, which has been linked with persistent bacteraemia and reduced 
susceptibility to glycopeptide antibiotics. Agr function is typically measured using a 
synergistic haemolysis CAMP assay, which is believed to report on the level of 
expression of one of the translated products of the Agr locus, δ-haemolysin. In this 
study we develop a vesicle lysis test (VLT) that is specific to small amphipathic 
peptides, most notably delta and Phenol Soluble Modulin (PSM) toxins. To 
determine the accuracy of this VLT method in assaying Agr activity, we compared it 
to the CAMP assay using 89 clinical Staphylococcus aureus isolates. Of the 89 
isolates, 16 were designated as having dysfunctional Agr systems by the CAMP 
assay, whereas only three were designated as such by VLT. Molecular analysis 
demonstrated that of these 16 isolates, the 13 designated as having a functional Agr 
system by VLT transcribed RNAIII and secreted δ-haemolysin, demonstrating they 
have a functional Agr system despite the results of the CAMP assay. The Agr locus 
of all 16 isolates was sequenced, and only the 3 designated as having a dysfunctional 
Agr system by the VLT method contained mutations, explaining their Agr 
dysfunction. Given the potentially important link between Agr dysfunction and 
clinical outcome, we have developed an assay that determines this more accurately 
than the conventional CAMP assay. Additionally, this study provides an insight into 
how the PSMs differ in lytic potentials against specific vesicles, confirming that 






taphylococcus aureus expresses many different secreted and surface -
associated virulence factors which are utilised during all stages of infection 
(276). The staphylococcal accessory gene regulator (Agr) quorum sensing 
system is central in the ability of this organism to promote infection, through 
coordinated, temporal expression of specific virulence genes, in which cell surface 
adhesins are synthesised and expressed before secreted toxins and enzymes (329, 
468). Previous studies have shown that a functional Agr system is important in 
several infection models including a murine arthritic (469) and subcutaneous 
abscesses model (470) as well as rabbit endocarditis (471). The shift in gene 
expression is tightly correlated with population density and sensing of a diffusible 
signal molecule by the Agr two-component system (see section 1.3.4.1 and Fig 1.8 
for more details). This complex alteration in expression of virulence genes occurs in 
conjunction with many global regulators namely the DNA-binding Sar family of 
proteins (363, 370), the alternative sigma factor (472) and other two component 
systems such as saeRS (340) and arlRS (354) (see section 1.3.4 for more details). 
 
 Recently, there has been much research into Agr dysfunction, particularly on 
the outcomes of infection with isolates containing mutations in the Agr locus, which 
can range in prevalence from 10-20% of S. aureus clinical isolates (473, 474). These 
mutations can occur during infection in a patient (475) and have been implicated in 
an increased mortality for patients suffering from bacteraemia (474, 476). The 
increased survival of Agr defective strains observed in persistent bacteraemia has 
been hypothesised to involve a defect in autolysis (477), owing to the fact that 
several murein hydrolase genes are regulated by Agr (358). This phenotype has been 
implicated in the increased survival of Agr dysfunctional strains in the presence of 
platelet derived antimicrobial peptides and reduced sensitivity to gylcopeptide 
antibiotics, namely vancomycin (477).  
 
The conventional method of assessing Agr function is to demonstrate the 




with a β-haemolysin positive strain, usually RN4220 (466). Additionally, Agr 
activity can be monitored through other methods such as Northern blotting or 
quantitative reverse transcriptase-PCR (qRT-qPCR) with probes or primers directed 
at RNA III, and recently, by whole-cell matrix assisted laser desorption ionization-
time-of-flight (MALDI-TOF) mass spectrometry (478). However, Northern blotting 
and qRT-PCR are time consuming and expensive, but considerably more sensitive 
than the CAMP assay, and a MALDI-TOF mass spectrometer costs several hundred 
thousand dollars to purchase, although running costs are low (479).  
 
Here we describe the development of a new methodology that determines Agr 
activity in a fast, high throughput, sensitive and quantitative manner. This method is 
based on the interaction of delta and Phenol Soluble Modulin (PSM) toxins, both 
used as surrogate markers for RNAIII and RNAII activity respectively, with lipid 
vesicles containing encapsulated self-quenched fluorescent dye. One fundamental 
element in the transition from inactive toxin monomers into fully functional 
membrane-damaging agents is the lipid and protein composition of the target 
membranes, particularly important in artificial membranes. We have formulated a 
lipid vesicle system that is responsive to specific peptide toxins; the small alpha 
helical, amphipathic delta and PSM toxins. When compared to the conventional 
CAMP assay this method proved more accurate, identifying all the isolates in a 
collection of 89 clinical S. aureus isolates that had mutations in the Agr locus, unlike 
the CAMP assay that had 13 false positives. As such, if Agr dysfunction becomes 
more widely accepted as being a critical determinant in the clinical outcome of 
infection, the accuracy of the VLT assay suggests that it should be used ahead of the 
plate based CAMP assay.  
 
In additional experiments, we observed differences in the lytic potentials 
between the different PSM peptides (alpha and beta classes) and within the PSMα 
class, contrary to previous studies (316). In an attempt to understand this observation, 
experiments were designed to investigate peptide amphipathic properties and 
secondary structure. Ultimately, the nature of peptide secondary structure and lipid 
bilayer composition dictate the lytic capacities of these peptides. Here we highlight 
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differences in the degree of alpha helicity through circular dichroism experiments 
and hypothesize how this structural property explains why certain PSM are less, or 
non-cytolytic.   
 
3.3 Results and Discussion 
___________________________________________________________________________________________ 
 
3.3.1 Vesicle breakdown correlates with early stationary phase 
growth  
 
Methicillin-susceptible S. aureus strain MSSA476 is a community-acquired invasive 
isolate for which a genome sequence is available (480). To determine if and at what 
stage of growth MSSA476 lysed lipid vesicles, a range of concentrations of bacteria 
were used to inoculate broth containing vesicles. Toxin production in bacteria is 
strictly growth-phase regulated and density dependent, with bacteria relying on the 
secretion of auto-inducing peptides to communicate and regulate genes (330). Figure 
3.1 shows the vesicle breakdown/fluorescence response, observed for the three start 
inocula were growth phase dependent; being triggered in the early stationary phase in 
each case.  
 
 







 CFU/mL) of MSSA 476 were used to assess vesicle lysis during bacterial growth. 
Bacteria were grown for 18 h with lipid vesicles and by monitoring optical density and fluorescence it 
was evident that vesicle lysis occurs at early stationary phase. Experiments were done in triplicate 
three times and error bars represent the 95% confidence interval.  
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3.3.2 Identification of the toxins lysing the lipid vesicles 
 
S. aureus expresses a number of toxins that are up-regulated in the stationary phase 
by the Agr system. These toxins differ in their mode of action and host receptor 
specificity, resulting in different toxins lysing different cell types. To determine 
which staphylococcal toxins were causing vesicle lysis, a number of isogenic 
mutants were assayed.  
 
α- and β-haemolysin 
 
The S. aureus 8325-4 laboratory strain and the isogenic hla (α-haemolysin) and hlb 
(β-haemolysin) mutants were used to assess the role of these two toxins (Fig 3.2a). It 
has been known that α-haemolysin damages protein free liposomes and that 
phosphatidylcholine head groups play a vital role in initial association (149, 314). α-
haemolysin mediated lysis requires the clustering of phosphatidylcholine head 
groups within membrane microdomains enriched in cholesterol and sphingomyelin 
while the absence of either membrane proteins or the absence of sufficient clustering 
lead to the inhibition of monomer heptamerization (149) and therefore no lytic event. 
1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) is a major component of the 
vesicles under study (53%) and for this reason we explored the role of α-haemolysin 
mediated breakdown of vesicles. Figure 3.2a clearly shows that both the alpha and β-
haemolysin knockout strains caused vesicle lysis at virtually identical levels as the 
wild type strain, showing that neither toxin were critical in vesicle lysis or caused 
maximum fluorescence release in these experiments.  
 
Importantly, in the lipid vesicles used here, 10, 12-tricosadiynoic acid 
(TCDA) was included to stabilize the membrane via cross-linking of the acyl chains 
of DPPC, and this is believed to prevent such head group clustering, rendering the 
monomers incapable of binding and penetrating the membrane. The β-haemolysin is 
an enzyme which acts as on sphingomyelin (481) and consistent with its activity, no 






The Panton-Valentine leukocidin (PVL), γ-haemolysin and the leukocidin family 
(notably LukAB and LukED) belong to the bi-component pore-forming family of 
toxins. In a similar fashion to the α-haemolysin, these leukocidins require specific 
receptor(s) for lysing biological membranes (150, 308, 441, 442) but may still lyse 
artificial membranes (151). Therefore, we wanted to investigate whether any 
measurable difference could be seen between supernatants derived from USA400 
MW2 wild type and isogenic PVL mutant and strain Newman and the respective 
lukAB, lukED and hlgACB mutants. Due to the reported high levels of toxin 
production by these strains and sensitivity of vesicles, a series of dilutions of 
supernatants were tested. No measurable difference was observed between wild type 
and mutant strains with our vesicle type.  
 
It has been shown previously that γ-haemolysin can permeate liposomes 
composed of PC head groups (151); however our results are consistent with two 
pieces of evidence which also proves that this toxin does not have the capacity to 
bind and permeabilize our vesicle type. Firstly, the lipid composition is crucial for 
this toxins’ activity with short (less than 13 carbon atoms) acyl chains being vital for 
pore-forming ability (440). The vesicles in question are composed of longer (16 
carbon atoms) chains causing cholesterol to integrate below the DPPC head groups 
permitting packaging not conducive to monomer binding (440). Secondly, this toxin, 
as with α-haemolysin, is susceptible to heat-inactivation at 65°C for 30 minutes (152)  
and since heat inactivated supernatants were still able to lyse vesicles with the same 
ability as un-treated supernatant (Fig 3.2e) over a defined period (20 min exposure), 







Figure 3.2: Characterising the toxins and enzyme involved in vesicle lysis. A) Deletion of α-or β-
haemolysin had no measurable effect on vesicle lysis. B) 5-fold dilutions of MW2 and MW2Δpvl 
mutant and C) Newman, NewmanΔlukAB, NewmanΔlukED and NewmanΔhlgACB illustrate the lack 
of involvement of the Panton-Valentine leukocidin and leukocidin AB, leukocidin ED and the γ-
haemolysin in lysis of vesicles. D) Phospholipase plate assay showing phospholipase activity as an 
orange halo around un-treated supernatant filled wells in contrast to no activity with heat-inactivated 
supernatants. E) 95°C Heat-treatment of supernatants retains vesicle lysis ability, suggesting no 
involvement of either phospholipases or γ-haemolysin in vesicle lysis (see text for details). Lipid 
vesicles were incubated with bacterial supernatants for 30 min. Vesicle lysis experiments were 







S. aureus also produces a number of enzymes, some with lipolytic activity such as 
(phospho) lipases. These enzymes are heat-sensitive and to investigate whether these 
enzymes had an effect on vesicle lysis, we first demonstrated the inactivation of 
these enzymes in the bacterial supernatant of a selection of clinical isolates following 
heat treatment using a lipase plate assay (Fig 3.2d). These heat-treated supernatants 
retained their vesicle lytic activities, demonstrating that these enzymes were not the 
main lytic agent of this system. 
 
Delta and PSM peptide toxins 
 
It has been previously shown that δ-haemolysin can retain its alpha helical structure 
in phosphatidylcholine bilayers and causes membrane perturbation and lysis in a 
concentration dependent manner (449). Therefore, we examined the effect of δ-
haemolysin and related PSM toxins on the vesicles described in this chapter. Lysis of 
vesicles was observed with δ-haemolysin and also for the PSMα1, 2 and 3 toxins 
whereas PSMα4 and PSMβ1 and 2 had reduced lytic activity (Fig 3.3a). Given the 
effect of δ-haemolysin and PSMα3 in our assays and their published effect on 
polymorphonuclear leukocyte cells (312) we focused on their activity in greater 
detail.  
 
Above a concentration of 2.5 μM and 1.5 μM for δ-haemolysin and PSM3α 
respectively, vesicle lysis occurs rapidly, whereas below this magnitude, lysis is 
reduced by approximately 20–30 % of maximum fluorescence (Fig 3.3b and d). The 
concentration of δ-haemolysin and PSM3α required to lyse 50 % of vesicles (V50) is 
1.5 μM and 0.25 μM respectively. By comparing this to the LD50 for biologically 
relevant T cells which are derived from an immortalized T cell line (482) the 
sensitivity of the vesicles to these peptides is illustrated. A 50-fold (δ-haemolysin) 
and 16-fold (PSM3α) increase in toxin concentration is required to cause lysis of 50 
% of T cells (Fig 3(c) (e). It has been shown previously that PSM concentrations of 
greater than 30 μg/mL were required to cause lysis of human neutrophils [41]. When 
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using PSM3α as an example, this roughly equates to a concentration of 
approximately 11.5 μM, whereas for the immortalized T cells, a concentration of 
approximately 5 μM results in lysis of 50% of T cells, highlighting the differences in 




Figure 3.3: Effect of purified toxins on lipid vesicles and T – cells. A) Vesicle rupture as a result of 
incubation with 10 μM synthetic PSM and δ-haemolysin peptides for 30 min B) Lysis of vesicles and 
C) T cells subjected to selected concentrations of purified δ-haemolysin. D) Lysis of vesicles and E) T 
cells subjected to selected concentrations of purified PSM3α toxin. The vesicle system is highly 
sensitive to both toxins at low concentrations, while PSM3α is more potent at lysing both vesicles and 
T cells than δ-haemolysin. T cells were incubated for 15 min at 37 °C with purified toxins. 




3.3.3 Comparison of two assays in measuring Agr activity 
 
Having developed an assay that responds to the activity of δ-haemolysin, we next 
wanted to establish how this vesicle lysis test (VLT) assay compared to the 
conventional δ-haemolysin plate CAMP assay in determining Agr function. 89 
clinical S. aureus strains were tested including 51 hospital acquired and 38 
community acquired isolates from diverse genetic backgrounds (427). (The strains 
used in this study are derived from CC1 (n=7), CC5 (n=5), CC8 (n=5), CC9 (n=1), 
CC12 (n=4), CC15 (n=6), CC16 (n=5), CC22 (n=7), CC25 (n=10), CC30 (n=24), 
CC39 (n=5), CC45 (n=9) and CC51 (n=1)). Of the 89 strains assayed using the 
CAMP assay, 17.98% (16 of 89) exhibited no synergy between δ- and β-haemolysins 
on the blood agar plates (Fig 3.4a) and as such were designated as having a 
dysfunctional Agr system. Using the VLT only 3.3 % (3 of 89) had no lytic activity, 
as measured by fluorescence comparable to the negative control (HEPES buffer) and 
were classified as Agr dysfunctional (Fig 3.4b). Using LAC and its isogenic hld 
mutant it was also shown that the synergistic effect of haemolysis could also be 
observed in the absence of translated δ-haemolysin (Fig 3.4a), an observation also 
made by that Cheung et al (316) where other PSMs were shown to be involved. Of 
the CC used, CC30 showed the highest percentage of agr dysfunction when 
examined using the CAMP assay, with 13 of 24 strains showing no haemolysis, 
however no association between CC type and agr dysfunction is shown when using 





Figure 3.4: Differences in Agr activity observed using two methods. A) δ-haemolysin plate assay 
of agr positive (RN6390B) and negative (RN6911) strains, 17 S. aureus clinical isolates, 16 which are 
designated as agr negative, one agr positive isolate (MRSA325) and agr positive LAC and its 
corresponding isogenic hld mutant strain, signifying the effects of δ-haemolysin and PSMs on the 
haemolysin plate assay. B) Normalized fluorescence measurements of 89 clinical S. aureus strains 
using the vesicle-supernatant method, highlighting the three strains causing no vesicle lysis. 




3.3.4 Validation of the sensitivity of the VLT test 
 
To determine which of the two assays (CAMP or VLT) were assaying Agr activity 
accurately we measured the level of expression on RNAIII in all 16 isolates defined 
as Agr dysfunctional by the CAMP assay by qRT-PCR (Fig 3.5). Only the three 
isolates defined as Agr dysfunctional by both the CAMP and the VLT assays were 
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impaired in the expression of RNAIII (MSSA71, MRSA378 and MSSA707). We 
also qualitatively assayed the secretion of small amphipathic peptides (i.e. δ-
haemolysin and the PSMs) by these isolates (Fig 3.6). Although variability existed in 
the secretion of these peptides across all 16 isolates, only the three designated as 
being Agr dysfunctional by VLT had no detectable amount of peptide. One of the 
limiting factors of using this extraction technique is that it doesn’t differentiate 
between the PSMs and may not be sensitive enough to detect them all, especially if 
they are expressed at a low-level. Therefore, we extracted the sample and analysed it 
by liquid chromatography mass spectrometry (LC/MSMS) where only δ-haemolysin 
was detected in this band. (LC/MSMS was done at the Central Proteomics Facility at 




Figure 3.5: Measurement of RNAIII transcription. Real - time qPCR results of 19 strains 
consisting of the positive and negative control RN6390B and RN6911 respectively, the 3 negative 
vesicle lysis test strains (MSSA 71, MRSA 378 and MSSA 707), 13 non-haemolytic strains and the 
haemolytic strain MRSA 325. RNAIII transcription is observed in those strains designated agr 









Figure 3.6: SDS-PAGE of concentrated Agr regulated peptides. Concentrated and extracted 
proteins using 1-butanol from several S. aureus strains, showing the presence of protein bands, 
indicating δ-haemolysin. Purified δ-haemolysin and RN6390B used as a positive control and RN6911 




3.3.5 Agr sequencing 
 
The Agr loci of all the 16 isolates, designated as having dysfunctional Agr system by 
the CAMP assay, were sequenced. We aligned the agr sequence of these isolates to 
the known sequence of the agr locus in the respective clonal complex (Fig 3.7). Only 
the three designated as Agr negative by both VLT and CAMP were found to have 
mutations in this locus and the mutational effect on the protein sequence is 
summarised in figure 3.9. All three isolates had 1 bp deletions occurring within a run 
of adenine (MSSA71 and MRSA378) or thymine (MSSA707) residues. In MSSA71, 
this lead to a premature stop codon in AgrA truncating the protein at amino acid 
position 49; in MRSA378 this caused a frame shift mutation and the addition of 22 
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amino acids at the C-terminal end of AgrA protein; and in MSSA707 this lead to the 
truncation of the AgrC protein at position 176. With regards to the other non-
haemolytic but VLT positive strains, (MSSA41, MRSA69, MSSA101, MRSA119, 
MSSA144, MSSA215, MRSA252, MSSA304, MRSA312, MRSA354, MRSA393, 
MSSA406, and MRSA448) and one haemolytic strain (MRSA325), had the same 
Agr sequence apart from MRSA69 and MRSA325 which were identical with each 
other and of a different Agr group (Agr-1 as opposed to Agr-3) from the rest of the 
strains. Therefore Agr dysfunctional strains were resolved only by the VLT assay 




Figure 3.7: Mutations in VLT negative isolates. Isolates MSSA71, MRSA378 and MSSA707 all 
contained 1 bp deletions (red bold) which led to truncation or alteration of essential Agr proteins. The 
reference strain is given (top) along with the strain in which the mutation was shown to occur in 













MSSA41 30 Negative 0.71±.04 5.7±1.4 Identical to 
MRSA252 
MRSA69 30 Negative 0.95±.09 8.9±2.1 Identical to 
MRSA325 
MSSA71 1 Negative 0.05±.01 0.02±.01 -1bp(nt147) AgrA 
MSSA101 30 Negative 0.98±.07 11±3.1 Identical to 
MRSA252 
MRSA119 30 Negative 0.85±.02 10.9±3.7 Identical to 
MRSA252 
MSSA144 30 Negative 0.99±.07 11.2±4.6 Identical to 
MRSA252 
MSSA215 30 Negative 0.80±.09 9.7±1.4 Identical to 
MRSA252 
MRSA252 30 Negative 0.73±.11 9.5±4.2 MRSA252 
MSSA304 39 Negative 0.91±.03 9.4±3.1 Identical to 
MRSA252 
MRSA312 30 Negative 0.65±.05 5.9±1.7 Identical to 
MRSA252 
MRSA325 30 Positive 0.92±.05 8.8±1.4 Identical to 
MRSA69 
MRSA354 30 Negative 0.73±.11 4.8±1.6 Identical to 
MRSA252 
MRSA378 30 Negative 0.03±.01 0.05±0.03 -1bp(nt705) AgrA 
MRSA393 30 Negative 0.64±.16 4.64±1.2 Identical to 
MRSA252 
MSSA406 30 Negative 0.92±.07 10.6±2.9 Identical to 
MRSA252 
MRSA448 30 Negative 0.95±.14 7.4±1.9 Identical to 
MRSA252 
MSSA707 16 Negative 0.05±.02 0.83±.3 -1bp(nt487) AgrC 
 
Table 3.1: Key characteristics of CAMP and VLT assayed strains 
Abbreviations: CC; clonal complex, CAMP; synergistic haemolysis plate assay, 
VLT; vesicle lysis test 
¶ Values shown in normalised fluorescence  
* qRT-PCR after 8 hour 
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3.3.6 Secondary structure and alpha helical wheel analysis of PSM 
peptides 
 
The differences in PSM mediated vesicle lysis observed in section 3.3.2 and PSM 
cytotoxicity assays shown in section 6.3.1 and by others (312), highlights that 
different PSMs have the different lytic activities. PSMs are generally classified as 
small, amphipathic, alpha helical peptides which can target cell indiscriminately, not 
requiring a proteinaceous receptor. For these reasons we sought to investigate which 
structural parameters are important in determining PSM lytic activity.  
 
Studies of antimicrobial peptides (AMPs) suggest that there are two 
functional requirements needed for active membrane destabilisation: a net positive 
charge to facilitate interaction with the negatively charged phospholipid membrane; 
and the potential to form amphipathic structures which allow incorporation into the 
membrane (483, 484). Other parameters which can strengthen the incorporation of 
peptides into lipid membranes include the overall hydrophobicity of the peptide, the 
ratio of hydrophobic to charged residues (h:c) and the degree of structuring (485-
487). In light of these parameters and using the hypothesis that PSMs act in a similar 
fashion to AMPs and δ-haemolysin, we investigated these properties in an attempt to 
understand the observed different lytic activities of these related peptides.  
 
The δ-haemolysin and PSMα1-3 peptides consist of 46-54% hydrophobic 
residues, which is consistent with the requirement for an amphipathic helical 
structure (483). However, the PSMα4 peptide contained 70% hydrophobic residues, 
giving the highest hydropathicity score using the Kyte and Dolittle algorithm, where 
a high hydropathicity value indicates high hydrophobicity (Table 3.2) (488). 
Previous studies using short AMPs observed that increased hydrophobicity lead to a 
decrease in interaction with negatively charged membranes and under certain 
conditions the more hydrophobic a peptide, the lower its membrane lytic capability 
(483, 489).  PSMα4 also has the highest hydrophobicity to charge (h:c) ratio among 
the PSM peptides, which may further explain its lower lytic capacity. Overall charge 
on the δ and PSMα1-4 toxins was positive, (Table 3.1) PSMα2> 
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PSMα1=PSMα3=PSMα4> δ, within the limits of charge typical for lytic peptides, as 
excessive charge is potentially damaging towards lytic activity by preventing suitable 
structuring (490). The PSMβ1 peptide has an overall negative charge whereas 
PSMβ2 displays a neutral charge while both peptides have a high h:c ratio which 
may in part explain the low lytic phenotype.  
 
PSM Hydropathicity Charge 
Delta 0.135 0 
PSMα1 0.957 +2 
PSMα2 0.890 +3 
PSMα3 0.305 +2 
PSMα4 1.700 +2 
PSMβ1 0.570 -1 
PSMβ2 0.607 0 
 
Table 3.2 Hydropathicity and charge of PSM peptides 
 
 
Helical wheel projections of these peptides (Fig 3.8) illustrate that like δ-haemolysin, 
all the PSMα peptides have a predicted helical structure with a high degree of 
amphiphilicity, with PSMα3 showing the largest hydrophobic moment (PSMα3 > δ > 
PSMα4 > PSMα2 > PSMα1, ranging from 9.16 to 5.96) and PSM1 and 2 
relatively lower (6.23 and 4.29, respectively). PSMα3 is the most toxic towards 
polymorphonuclear leukocytes (PMNs) (312) and in this thesis, is most lytic to lipid 
vesicles and T cells (Figure 6.3b). It has been observed that ionic or salt bridges may 
form when negatively charged residues are spaced 3- to 4- positions from positively 
charged residues, which may promote helix formation (491). PSMα3 shows the 
largest number of charged residues (positive and negative) on the hydrophilic phase 
of the predicted helix, indicating the potential formation of helix stabilizing ionic 
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bonds. This coupled with the large hydrophobic moment for PSMα3 will likely 
increase both peptide agglomeration in solution and partitioning of the peptide into 
the lipid bilayer (492).  
 
 Circular dichroism (CD) spectroscopy can be used to investigate the alpha 
helicity of proteins. CD measures differences in the absorption of left-handed 
circularly polarized light and right-handed polarized light over a range of 
wavelengths, generating a distinct CD spectral signature for specific biological 
molecules, such as proteins. CD spectral analyses demonstrate that the PSM peptides 
that were highly lytic (PSMα1-3) displayed a higher degree of alpha helical 
secondary structure (Fig 3.9a), whereas PSMα4 and particularly PSMβ1-2 showed 
reduced helical characteristics (Fig 3.9b) (alpha helical content is shown by the peaks 
at 190 and 210 nm). Alpha helicity is important in the ability of small peptides to 
integrate within the lipid membrane and cause disruption as this type of structure 
allows for the formation of both hydrophilic and hydrophobic faces (493-495). The 
structuring is influenced by both the overall hydrophobicity of the peptide, which 
will govern initial interaction with the bilayer surface and subsequent interactions 
between individual residues on the hydrophobic face of the peptide and the bilayer 
interior. It is worth noting that the PSMα1-3 peptides possess helix stabilizing 
alanine residues at position 5 whereas PSMα4 contains a helix destabilizing glycine 
in this position which may reflect the observed difference in alpha helicity.  
 
δ-haemolysin displays high a degree of amphipathicity and alpha helicity, 
with well defined hydrophobic and hydrophilic phases, but had a lower cytolytic 
activity than PSMα2-3 (Figure 6.3b). The lower lysis activity is intriguing and may 
be due to the low hydropathicity value and a neutral charge affecting efficient initial 
interaction and insertion within the membrane. Previous studies have demonstrated 
that aliphatic residues decreasingly promote alpha helix stability in the order 
Leu>Ile>Ala>Val> in a lipid environment (496, 497). The combined number of all 
aliphatic residues within each peptide (discounting glycine), varies in the order; 6 
(PSMα3), 8 (PSMα2), 9 (PSMα1), 9 (δ toxin) and 12 (PSMα4). Of those residues 
PSM alpha 3 has proportionately the highest leucine content while PSMα4 has the 
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lowest. The number of aliphatic residues a peptide contains therefore shows an 





Figure 3.8: Helical wheel projections of δ-haemolysin (top), PSMα1, α2, α3, α4 (middle, from left to 
right) and PSM1 and 2 (bottom, from left to right). Hydrophobicity is color coded from dark green 
(most hydrophobic) to yellow (zero hydrophobicity). Hydrophilic amino acids are shaded from red 
(most hydrophilic) to yellow, charged residues are shown in light blue (reference; 
http://rzlab.ucr.edu/). The arrows indicate the directions of the hydrophobic moments. 
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It is important to note that δ-haemolysin and PSMα1-3 illustrated good alpha helical 
spectra in the absence of lipid membranes and alpha helical inducing solvents such as 
2, 2, 2- trifluoroethanol (TFE). The PSMβ1-2 peptides, which show the lowest lytic 
potential, are relatively unstructured in the absence of TFE. The negative peaks at 
202nm and minimal negative peaks at 220nm indicate random coil secondary 
structure, a property which is not amenable to lysis. However, under our conditions, 
PSMβ1-2 shows increasing alpha helicity with 50% TFE as shown in figure 3.9b 
table 3.3b. Previous results have shown that all PSM possess alpha helicity, however 
these peptides were dissolved in 50% TFE (312) which is known, and observed by 
us, to induce alpha helicity. Our results suggest that the ability to form alpha helical 
structure is extremely important in lysing CHO containing lipid vesicles, as those 








Figure 3.9: Circular dichroism (CD) spectra of synthetic PSMs. A) CD spectra of PSMα1-4 and δ-
haemolysin prepared in PBS. B) CD spectra of PSMβ1 peptide in 50% TFE (trifluoroethanol), PSM 
β1 peptide in PBS buffer, PSM β2 peptide in 50% TFE and PSM β2 peptide in PBS buffer. The peaks 
at 190 and 210nm are indicative to alpha helicity. The negative peaks at 202nm and minimal negative 






Lipid vesicles have been extensively used to study toxin membrane interactions 
(149-151, 153, 440). Synthetic lipid vesicles allow different membrane components, 
such as cholesterol, glycolipids and phospholipids to be incorporated at varying 
concentrations allowing the possibility of being able to tune the vesicles response to 
different lytic toxins (455). In this study we formulate a lipid vesicle that is lysed by 
a specific group of small, amphipathic, alpha-helical peptides, regulated by the 
staphylococcal Agr system but unresponsive to other known Agr regulated toxins. 
This vesicle contains some features consistent with certain eukaryotic membranes, 
most notably comprising a percentage of cholesterol reflecting that of erythrocyte 
membranes (20–25% (498)) and featuring two very common membrane 
phosphoglycerides, phosphatidylcholine and phosphatidylethanolamine. However, 
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our vesicles lack any glycolipids or sphingomyelin, which can be in high proportion 
in certain cell types (498).  
 
The similarity in composition of our vesicle system to some eukaryotic 
membranes is reflected in the similar concentrations of purified toxins required to 
lyse erythrocytes and our vesicles. In general, erythrocytes lysis occurs after 
incubation with 10 mg/mL (approximately 3.85 μM) of individual PSMs (316), 
whereas our vesicles require in the range of 1.5–2.5 μM depending on the peptide 
toxins, both systems requiring incubation at 37°C for 30 min. If we compare this to 
the results of PSM interaction with 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC) vesicles used by Duong et al we see a stark difference in the 
concentration of PSMs used and incubation time required to cause lysis (499). For 
POPC vesicles, PSM concentrations were in the range of 0.5–1.0 μM and incubated 
for 200 s to reach maximum lysis. Moreover, the order in which the PSM peptides 
caused lysis of POPC vesicles is quite different to the order for normal cellular lysis 
and order of our vesicles, with the PSM β1 and β2 peptides and PSM4α causing the 
highest degree of lysis in POPC vesicles whereas these peptides have the lowest lytic 
capabilities under physiological conditions (312) and our vesicles (Fig 3.3a). The 
increase in time and toxin concentration required to lyse our vesicle type in 
comparison to pure POPC is based a number of factors, but largely dependent on the 
cholesterol composition in our vesicle type. Cholesterol plays a major role in 
membrane fluidity and the transition temperature of lipids, which has an overall 
impact on the mechanical rigidity of the lipid membrane (500) and which we have 
shown has a profound effect on toxin-mediate lysis of vesicles (Laabei, M et al. 
2014: Investigating the lytic activity and structural properties of Staphylococcus 
aureus Phenol Soluble Modulin (PSM) peptides, under review). The POPC vesicles 
are also unsaturated and are therefore packed less tightly which may influence toxin 
binding and disruption of the membrane; unsaturation also lowers the transition 





Agr dysfunction is an increasingly important issue due to its relevance with 
regard to persistent bacteraemia and decreased antibiotic glycopeptide susceptibility 
such as to vancomycin (476, 477). Loss of Agr activity is also implicated in 
increased biofilm formation and attachment to inert surfaces, which is important as 
the majority of bloodstream hospital acquired infections are catheter associated (502, 
503). However, the majority of these studies looking at correlations between Agr 
dysfunction and clinical outcomes use the CAMP assay. We suggest that the use of 
the CAMP assay for determining Agr activity may not be sufficiently sensitive in 
determining Agr function. Using our VLT assay we correctly identified the only 3 
isolates from a collection of 89 that had mutations in the Agr locus (summarised in 
Table 3.1). A possible confounder of the VLT method is their sensitivity to the other 
PSM toxins. It has been shown previously that psm genes can be regulated in an 
RNAIII independent manner, with AgrA being important in this upregulation (215). 
However, this also affects the outcome of the CAMP assay, as we show in figure 
3.4a, where the LAC δ-haemolysin mutant exhibits a positive CAMP assay. We must 
also keep in mind that the vast majority of strains that produce detectable levels of 
PSMs are the highly toxic community acquired type IV SCCmec strains, which 
produce considerably higher concentrations of δ-haemolysin than PSM (312). No 
examples of Agr dysfunction have been reported amongst this group, indeed Agr 
function is believed to be critical to their emergence and virulence (318), suggesting 
that neither the VLT or the CAMP assay will be of use clinically for these types of 
infection. The question that this study also touches on is how much Agr activity is 
required in determining a strain to be functional, semi-functional or have complete 
inactivity? We have suggested that those strains which were VLT negative and non-
haemolytic were the only true Agr inactive isolates, acquiring mutations leading to 
truncation of essential proteins. This VLT is a sensitive, rapid assay which is quick 
and easy to perform and amenable to 96-well plate high-throughput analysis and may 
help us in redefining the Agr activity of clinical isolates. 
 
 Physico-chemical properties of peptides affect their ability to both penetrate 
and lyse phospholipid membranes. On the basis of the results presented here, the 
degree of alpha helicity is the most important property for correct insertion and lysis 
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of membranes for PSM peptides. The PSMβ1-2 peptides, which show the lowest 
lytic potential, are relatively unstructured in the absence of TFE, instead possessing a 
random coil structure which is not conducive to high lytic activity. Why the PSMα4 
or PSMβ1-2 peptides have lower alpha helicity is not completely understood as yet 
but maybe due to the presence of helix breaking residues. Therefore, we suggest 
refining this class of peptides, as not all of the members have alpha helicity, which is 
an important factor in membrane lysis.  
 
The ability of these PSM to act synergistically with other toxins has been recently 
reported and shown to be involved in S. aureus escape from epithelial and 
endothelial phago-endosomes (504). This study reported the synergistic effect of δ-
haemolysin or PSMβ1-2 with the sphingomyelinase β-haemolysin in disrupting the 
endosomal membrane. Interestingly, no synergistic effect was observed with the 
PSMα peptides, which are more related to δ-haemolysin than the PSMβ peptides. 
Currently, it is unknown if PSMs can act synergistically with each other, and what 
molecular interaction may dictate such effects. Experiments designed to investigate 
how PSMs acting in synergy affect different phospholipid vesicle membranes and 
how they influence the structure of one another are ongoing and will hopefully shed 
















A New Assay for Rhamnolipid Detection – 






Rhamnolipids [RL] are heterogeneous glycolipid molecules that are composed of one 
or two L-rhamnose sugars and one or two β-hydroxy fatty acids, which can vary in 
their length and branch size. They are biosurfactants, predominantly produced by 
Pseudomonas aeruginosa and are important virulence factors, playing a major role in 
P. aeruginosa pathogenesis. Here, the ability to detect RL producing P. aeruginosa 
strains with high sensitivity, based on an assay involving phospholipid vesicles 
encapsulated with a fluorescent dye is shown. This vesicle-lysis assay is confirmed to 
be solely sensitive to RL, confirming the importance of the expression of this 
virulence factor for sensing in a putative smart dressing application. We illustrate a 
half maximum concentration for vesicle lysis (EC50) of 40 μM (23.2 μg/mL) using 
pure commercial RL, and highlight the ability to semi-quantify RL directly from the 
culture supernatant, requiring no extra extraction or processing steps or technical 
expertise. We show that this method is consistent with results from thin layer 
chromatography detection and dry weight analysis of RL, but find that the widely 
used orcinol colorimetric test significantly underestimated RL quantity. This assay 
was used to compare RL production among strains isolated from either chronic or 
acute infections. We confirm a positive association between RL production and acute 









Pseudomonas aeruginosa is an opportunistic human pathogen, ubiquitous in the 
environment and capable of causing a multitude of infections in the immune-
compromised host (505, 506). The ability of this organism to cause such a wide array 
of infections is based in part on the large arsenal of virulence factors it produces 
(507). Virulence factor regulation in P. aeruginosa is achieved through a density-
dependent cell-to-cell communication network, involving two acylhomoserine 
lactone (AHL)-mediated quorum sensing (QS) systems; the las, rhl (508, 509)  and 
Pseudomonas quinolone signal system (82, 510). The las and rhl systems are LuxRI 
homologues, where lasI and rhlI direct synthesis of  N-3-oxododecanoylhomoserine 
lactone (3-oxo-C12-HSL) and N-butanoylhomoserine lactone (C4-HSL) 
respectively; these are diffusible signalling molecules which activate their respective 
DNA binding response regulators LasR and RhlR, which in turn induces the 
expression of a wide range of genes, approximately 6% of the genome (509, 511-
513). The other cell-to-cell signalling system responds to the quinolone compound 2-
heptyl-3-hydroxy-quinolone (the Pseudomonas quinolone signal, PQS), acting with 
the transcriptional activator, PqsR (82, 514). An elegant hierarchy system 
predominates in this global regulatory network, with the las system positively 
regulating both the rhl and quinolone signalling systems (82, 83, 515).  
 
One of the most interesting extracellular factors produced by P. aeruginosa are 
rhamnolipids [RL]. RL are surfactant-acting molecules, composed of a hydrophilic 
head, of one or two rhamnose molecules, defining mono- and di-rhamnolipid, and a 
hydrophobic tail portion of one or two fatty acids (Fig 4.1). RL have been utilised in 
a wide variety of industrial applications involving emulsification, detergency, 
wetting, foaming and solubilisation procedures, bioremediation and food additives 
(516). The amphiphilic nature of RL allows these biosurfactants to partition into 
biological and artificial membranes altering their biophysical properties, previously 
shown in model membranes using 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine POPC vesicles and purified RL (517, 518). RL are also very 
important virulence factors for P. aeruginosa, central in immune cell and erythrocyte 
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destruction (519, 520), swarming and twitching motility (90, 91), biofilm formation 
and protection (120, 521). Furthermore, they have been implicated in the 
deterioration of patients with ventilator associated pneumonia (522) and disruption 
and permeablization of epithelial cells, a prerequisite to P. aeruginosa invasion 




Figure 4.1: Molecular structure of rhamnolipid. RL are composed of a one or two hydrophilic 
rhamnose sugar head groups attached to either one or two hydrophobic fatty acid chains.  
 
 
Clearly an accurate and rapid method to assess RL production is important. Current 
methods can be qualitative; the cetyltrimethylammonium bromide (CTAB) 
methylene blue (MB) agar test (524), which signals RL expression through the 
formation of blue halos due to the complexation of the anionic RL and cationic 
CTAB and MB. Although this method is quick, it suffers from a time delay of 
incubation for 48 h for best results and also through distortion of halo formation due 
to fluorescent pigments produced naturally by certain P. aeruginosa strains. Other 
methods measure the tensioactive properties of the surfactant (525) however these 
methods employ sensitive instruments and are laborious, and not amenable to being 
utilised in a high-throughput manner. Quantitative methods consist of 
spectrophotometric analysis, using the orcinol test (526), chromatographic methods 
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including thin layer chromatography (TLC), high performance liquid 
chromatography (HPLC) (527), infrared spectroscopy (IR) (528) and dry weight 
analysis of rhamnolipids following solvent extraction (464). 
 
In this chapter, a new methodology in detecting and quantifying RL using 
carboxylfluorescein encapsulated phospholipid vesicles is presented, which came to 
light through my attempts to identify the factors produced by P. aeruginosa to lyse 
vesicles as part of the larger Bacteriosafe project. In this report we confirm that RL 
can be detected and quantified directly from overnight culture supernatants using the 
vesicle lysis assay, decreasing preparation time, hazardous extraction techniques or 
expert analysis.  
 
 
4.3 Results and Discussion 
__________________________________________________________________________________________ 
 
4.3.1 Bacterial mediated lysis of vesicles occurs during early 
stationary phase of growth 
 
To investigate at what stage of growth P. aeruginosa PAO1 wild type lysed lipid 
vesicles, a range of starting inocula were used to initiate growth in a combination of 
nutrient rich broth and lipid vesicles (Fig 4.2a). Expression of specific genes is 
essential at different stages of growth, particularly in the expression of virulence 
factors (529), capable of lysing lipid vesicles. Therefore, we investigated the ability 
of P. aeruginosa to break down vesicles and correlated this with the respective 
growth rate with and without vesicles within the media (Fig 4.2b). Differences in 
optical density (OD600) observed between the two experiments are most probably due 
to the vesicles impacting on light scattering, resulting in higher absorbance values. 
Nonetheless, vesicles did not have a negative impact on bacterial growth (Fig 4.2b). 




CFU/mL we determined that a 
time delay exists in lysis of vesicles with respect to smaller starting inoculum. With a 
starting inoculum of 1x10
6
 CFU/mL bacteria reach late exponential/early stationary 
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phase of growth after approximately 400 min (Fig 4.2b) (blue line in both Fig 4.2a 
and b represent 400 min time point) the approximate time point when vesicles begin 
to breakdown followed by increasing fluorescence release over the next 150 min (Fig 
4.2a). This signifies that bacterial mediated breakdown of vesicles occurs during 
early stationary phase, when the local concentrations of bacteria reach a critical 
threshold, leading to the expression of quorum sensing (QS) regulatory genes known 




Figure 4.2: Lysis of vesicles occurs during early stationary phase of growth of Pseudomonas 
aeruginosa. A) The breakdown of vesicles by different starting inoculums (10⁶-10⁴ CFU/mL) was 
measured over 18 h of growth, shown here by the detection of carboxyfluorescein released from lysed 
vesicles. B) The growth curves of P. aeruginosa, with and without vesicles added to the medium, are 
illustrated over 18 hours from a starting inoculum of 10⁶ CFU/mL. Experimetns were performed in 
triplicate three times with error bars representing the 95% confidence interval. 
 
 
4.3.2 Identification of rhamnolipids as the vesicle lysing agent 
 
The production of toxins/enzymes in P. aeruginosa is governed by a hierarchical cell 
to cell QS system, which when activated, leads to the production of a whole suite of 
virulence factors, some of which are excreted into the extracellular environment. 
Therefore, we investigated the ability of QS mutants to lyse lipid vesicles (Fig 4.3a), 
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to determine the factor(s) involved. The quinolone signalling system contains the 
pqsABCDE operon, in which the pqsABCD section is required for the synthesis of 
the hydrophobic quinolone signal which interacts with a LysR-like regulator PqsR, 
modulating the expression of genes known to function in virulence (79, 530). 
Therefore, we assayed the culture supernatant of a pqsA mutant to identifying any 
deleterious effects on lipid vesicle lysis; however no difference between WT and 
mutant strain was evident (Fig 4.3a). It has been shown previously that a pqsE 
mutant, although not impacting on the production of the PQS signal, negatively 
affects PQS-controlled virulence factors (80, 531) and has been shown to enhance 
the rhl system (532). However, no difference was seen in lysis of lipid vesicles with 
culture supernatants derived from the pqsE mutant (Fig 4.3a). Unlike the signalling 
molecules of the las and to an extent, rhl system, the PQS is very hydrophobic, 
inhibiting free diffusion between bacterial communities (533). To circumvent this, 
these PQS signals are encapsulated within membrane vesicles (MVs), derived from 
the outer membrane of the bacterial cell envelope (534). Interestingly, PQS has been 
shown to induce membrane curvature in erythrocytes, leading to haemolysis (535). 
The formation of bacterial MVs requires the expression of PqsH, which is a 
monooxgenase, essential for the conversion of 2-heptyl-4-quinolone (HHQ) to PQS 
(531). Therefore, in a pqsH mutant there is a reduced capacity to form membrane 
vesicles due to reduced quinolone formation to induce membrane blebbing and 
structural perturbations. However, no difference was seen in vesicle lysis with 
culture supernatants derived from this mutant and WT, suggesting that the quinolone 
signalling system did not play a role in lysis of this specific vesicle type (Fig 4.3a).  
 
The lasRI and rhlRI regulatory systems are the most well characterised QS 
systems in P. aeruginosa. To investigate which secreted factor(s) caused lysis we 
examined culture supernatants from deletion mutants of the signal synthase (lasI and 
rhlI) and the response regulators (lasR and rhlR) (Fig 4.3a). The results demonstrated 
that an active rhlRI system was required for vesicle lysis. P. aeruginosa expresses 
three quorum-regulated phospholipases C (PLC) enzymes: a haemolytic PLC (PlcH), 
a non-haemolytic PLC (PlcN) (536) and a PLC involved in phospholipid chemotaxis 
(537) (PlcB). PlcH causes cytolysis, with a preferred substrate affinity for 
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phosphatidylcholine (PC) and sphingomyelin (536), importantly PC is the most 
abundant lipid in our vesicle. For this reason, we examined the effect of a plcH 
deletion mutant on the capacity to lysis the vesicle (Fig 4.3b). By using serial 
dilutions of supernatants, it was evident that PlcH did not have any effect on lysis. 
Most proteins are denatured and inactivated at high temperatures, therefore to 
understand what was causing vesicle breakdown, supernatants were heat treated and 
compared to non -treated supernatants (Fig 4.3b), however, no difference in vesicle 
lysis activity was observed. This suggested that a heat-resistant glycolipid could be 
involved in overall vesicle lysis.  
 
 RL are biosurfactant glycolipids, in which the synthesis of these molecules is 
under the control of the rhlABC operon, where the rhlA gene is itself directly 
regulated by the rhl QS system (538). We performed TLC on solvent extracts of the 
supernatant in order to detect RL from P. aeruginosa strains that were either vesicle 
lysis positive or negative (Fig 4.3c and Table 1). In all cases where strains caused 
vesicle lysis, RL was detected by TLC, whereas the opposite was true in those strains 
which were vesicle lysis negative. To understand conclusively what caused P. 
aeruginosa mediated breakdown of lipid vesicles, culture supernatants from an rhlA 
mutant were used and no vesicle lysis was observed (Fig 4.3d). The rhlA gene is 
critical in the formation of RL precursors (90) and thus without this neither mono- 







Figure 4.3: Identification of vesicle lysing agent. A) Culture supernatants of several quorum-sensing 
mutants (ΔpqsA, ΔpqsE, ΔpqsH, ΔlasR, ΔlasI, ΔrhlR, ΔrhlI) were tested against lipid vesicles, 
highlighting the important role of the rhlRI QS system in vesicle lysis. B) Culture supernatants of 
wild-type (WT) PAO1, a lipase mutant PAO1ΔplcH and heat treated (HT) PAO1 culture supernatant 
at various dilutions (neat, 75, 50, 25, 10, 1) were tested against lipid vesicles, with no significant 
differences observed. C) TLC was used to detect the presence of rhamnolipid from two strains, PAO1 
(vesicle lysis positive) and PA45100 (vesicle lysis negative) D) Comparison of WT PAO1 and the 
isogenic rhlA mutant. Experimetns were performed in triplicate three times with error bars 
representing the 95% confidence interval. 
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4.3.3 Estimation of secreted rhamnolipid concentration from P. 
aeruginosa  
 
To investigate whether this vesicle-lysis assay could be used to quantify RL secreted 
from culture supernatants, we created a standard curve (Fig 4.4a) incubating vesicles 
and purified R-95 rhamnolipid, a mixture of the highly abundant mono- and di-
rhamnolipids congeners from P. aeruginosa. This graph illustrates the EC50, the 
concentration of purified rhamnolipid to cause 50% lysis of vesicles, as 23.2 μg/mL 
(40μM). Using this value, the quantity of RL from culture supernatants can be 
estimated (Fig 4.4b), by graphing the respective normalised fluorescence obtained 
from serial dilutions of culture supernatants, using a sigmoidal curve fit, generating 
the best fit line, giving the dilution constant required for EC50 and multiplying to give 
an estimation of RL in the original culture (92.8 μg/mL for PAO1). This PAO1 RL 
value generated from the vesicle-lysis assay was relatively consistent with that of our 
dry weight analysis of PAO1 RL (172.5 ±56.4 μg/mL). It is important to note that 
quantity and structure of RL is dependent on many factors, including carbon source, 
reaction vessel and conditions, temperature and strain-specific details and that very 
high concentration of RL have been recorded using optimised growth medium and 
bioreactors (539, 540). The growth conditions and reaction conditions we have 
employed are not conducive to high levels of RL production, as this was not the aim 







Figure 4.4: Estimation of rhamnolipids in culture supernatants. A) Vesicle-purified rhamnolipid 
interaction illustrating the EC50, the amount of purified rhamnolipid required to cause 50% of vesicle 
lysis as measured by fluorescence release. B) Estimation of rhamnolipid concentration via serial 
dilutions of PAO1 culture supernatant exposed to vesicles, generating different fluorescence values. 
EC50 value obtained using 25% supernatant, thus EC50 times 4 giving the estimated starting RL 
quantity (23.2 μg /ml x 4 = 92.8 μg /ml). Experimetns were performed in triplicate three times with 







4.3.4 Comparison of vesicle assay with orcinol and TLC assays 
 
A comparison was made between the vesicle-lysis assay and the orcinol and TLC 
methods of RL detection and quantification. We selected 16 strains, 8 derived from 
acute infections and 8 derived from chronic infections and measured their respective 
RL content using the above methods (Table 4.1). The orcinol assay was chosen as 
this colorimetric assay is widely used. However, this method provided a significant 
underestimation of RL values compared to our results, perhaps due to loss of RL 
during the extraction procedure, which were produced at small quantities initially. 
This was not the first study which has highlighted erroneous results using the orcinol 
assay (540). The orcinol method can also suffer from contamination from the growth 
media and also other components of the cellular envelope which has rhamnose as a 
component in their structure, namely lipopolysaccharides.  
 
The TLC method was used qualitatively and complemented the results of our 
vesicle-lysis assay, whereby vesicle lysis positive strains were also shown to secrete 
RL (Table 4.1). The CTAB method can suffer from distortion of RL complexation 
circles due to pigment production (524) and we were not able to generate consistent 
results using this method. The RL values of clinical isolates examined here (Table 
4.1), are consistent with values shown by other groups (539). Although the vesicle-
lysis assay is dependent on fluorescence detection from lysed vesicles, this is not 
influenced by fluorescent molecules being expressed by P. aeruginosa (data not 
shown): pyoverdine is typically excited by low wavelength light (UV) whilst 


























44883 21.7 125.4 + PA00856 22.2 85.5 + 
44981 8.6 25.6 + PA00887 20.83 30.9 + 
45197 16.7 86.9 + PA00889 21.7 91.1 + 
45445 32.5 150.2 + PA00935 16.2 90.1 + 
45076 2.3 NL - PA00261 3.2 NL - 
45100 15.2 NL - PA00848 3.9 NL - 
45122 1.88 NL - PA00918 3.4 NL - 
45394 2.83 NL - PA00929 3.7 NL - 
 
Table 4.1 Detection and quantification of rhamnolipids 
* Quantification of rhamnolipids derived from these techniques in μg/mL; No lysis, NL. 
 
 
4.3.5 Rhamnolipid expression is associated with acute infections 
 
It has been shown previously that RL are important virulence factors as they have 
been implicated in cell death and essential in correct biofilm construction and 
protection. We wanted to explore the use of this assay to determine rhamnolipid 
expression among clinical isolates. We performed vesicle-supernatant experiments 
on a range of clinical strains (n=78), from a chronic (n=48; isolated from cystic 
fibrosis patients) and an acute (n=30; isolated from blood stream and wound 
infections) infection background to gain an understanding of the clinical importance 
of RL in these two classes of infection (Fig 4.5). There was a positive association 
between RL expression and acute infection isolates (Fisher test p = 0.0008), which 
suggests that RL play an active role during acute infections, and that this assay can 





Figure 4.5: Positive association between rhamnolipid expression and isolates from acute 
infections. Vesicle-supernatant assay exploring the rhamnolipid producing capacity of clinical P. 
aeruginosa isolates derived from either a A) chronic (blue; n=48) or B) acute infection (red; n=30). A 
positive association between rhamnolipid production and isolates from acute infections was observed, 
using an exact fisher test, p=0.0008. Experimetns were performed in triplicate three times with error 






The vesicle-lysis assay is responsive to QS regulated factors, which are expressed 
during the transition from late exponential to early stationary phase of growth (Fig 
4.2). P. aeruginosa expresses a wide spectrum of exofactors, some of which are 
important in membrane damage. Using isogenic mutants in key regulatory QS genes 
and virulence determinants we investigated which factor was important in the 
observed lysis. Due to their hydrophobic nature, PQS molecules induce the formation 
of MVs through an interaction with lipopolysaccharide on the bacterial outer 
membrane facilitating cell-to-cell communication, and this is dependent on the 
expression of the pqs operon (Mashburn and Whiteley 2005). Interestingly , it has 
also been reported that exogenously added PQS molecules can also induce 
membrane curvature in erythrocytes, lacking any of the receptors important for MV 
formation, leading to haemolysis in a concentration dependent manner (535). 
Additionally, after the blebbing of MVs from the bacterial cell envelope these 
structures are then able to fuse with recipient cells, transferring their cargo in an 
elegant transport mechanism (535). Considering these observations we investigated 
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whether the PQS signalling system was influencing lysis of vesicles used in this 
study. Genetic inactivation of pqsA, pqsE or pqsH conferred no reduction in vesicle 
lysis (Fig 4.3a), suggesting no role for the PQS system in disruption of these vesicles.  
 
Surprisingly, the phospholipase C enzyme (PlcH), a key component in the 
degradation of lipids due to their affinity for phosphatidylcholine head groups, did 
not play a role in lipid vesicle lysis as no reduction in fluorescence was observed in 
the plcH mutant or heat treated supernatants (Fig 4.3b). Work on phospholipase 2 
(PLA) has shown that the degree of saturation and most importantly, the acyl chain 
length of the phospholipids impact on the ability of this lipase to lyse lipid bilayers 
(542). The structure of the vesicles in this study are composed of DPPC and DPPE, 
which are saturated phospholipids containing 16 carbon chain length fatty acids 
which may not be efficient substrates for PLC activity.  
 
Inactivation of the rhl QS system leads to a reduction in vesicle lysis (Fig 4.3a). 
RL expression is under the control of rhlABC operon, where rhlA, a gene which 
encodes a rhamnosyltransferase which catalyses the transfer of L-rhamnose to 3-(3-
hydroxyalkanoyloxy) alkonic acid (HAA) and is required for subsequent RL 
formation, is regulated by the rhl system. RL are also heat-resistant molecules, and 
our results show heat-treatment was insufficient to inhibit the lytic function of 
bacterial supernatants derived from P. aeruginosa strain PAO1 (Fig 4.3b). Finally, 
deletion of the rhlA gene confers a non-lytic phenotype, consistent with TLC results 
showing no RL production in strains which do not lyse vesicles (Fig 4.3c-d), 
confirming RL as the sole vesicle lytic agent from P. aeruginosa, and fulfilling one 
of the objectives of the Bacteriosafe project.  
 
As a result of these experiments, we sought to develop a new method to quantify 
RL based on the lysis of carboxyfluorescein-encapsulated phospholipid vesicles. 
Here we illustrate that this assay is more rapid, sensitive and easier to perform than 
current methods. The vesicle-lysis assay requires no extraction procedure and 
therefore is not susceptible to contamination or sample loss. We have shown that this 
assay is semi-quantitative and can estimate the amount of RL present in culture 
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supernatants (Fig 4.4). We observe that our results are in contrast to the values 
generated using the orcinol assay but are consistent with TLC and dry weight 
analysis. However, the orcinol test relies on the extraction of RL from the 
supernatant, the measurement of the rhamnose content by use of orcinol and 
concentrated sulphuric acid and applying these absorbance values to a standard curve 
(526). This procedure can be susceptible to contamination from other rhamnose 
containing molecules such as lipopolysaccharides or from un-extracted media 
components and can also give erroneous results due to differences in incubation 
temperature and sample loss (540).  
 
RL production also had a positive association with isolates derived from 
acute infections; however this link is somewhat tenuous. It is difficult to determine 
any association between an infection and a specific bacterial factor, particularly 
when comparing between such different infections. A more informative study should 
include strains derived from different time periods during the length of specific 
chronic infection (e.g infection in cystic fibrosis patient) to evaluate whether a 
specific time point exists that leads to the reduction of RL expression. Equally, a 
more informative clinical history of the isolate derived from acute infections is 
necessary in order to make an accurate judgement on the above association. However 
the superficial association that is illustrated in figure 4.5 is used only as an example 
of how this novel phenotypic assay may be employed. Another important 
consideration would to use genotyped strains to examine any polymorphisms that 
may result in an alteration in RL expression, in an analogous fashion to the 
experiemtns designed in chapter 7. It is known that genetic changes occur during 
chronic infections, which can lead to the down regulation of extracellular virulence 
factors (84) with loss of function mutations in the central regulator lasR being most 
frequent in chronic infections, but other QS mutants involving the rhl system are 
evident (543-545). Since las and rhl system are intricately linked, with the las system 
controlling the rhl system at a transcriptional and post-translational level, it was 
conceivable that mutations in lasR were causing this RL negative-phenotype in 
certain clinical strains. However, in PAO1 we did not see any statistically significant 
difference in lysis potential between lasR mutant and WT strains. This leads us to 
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believe that mutations in either the rhl system or the rhlABC operon are the most 
likely reasons for RL negative phenotype. Novel point mutations in quorum 
regulators genes and mutations in the multitude of quorum regulators may also be 
responsible for the RL negative phenotype and work into elucidating this in ongoing. 
 
Following from these observations, we envisage that this vesicle lysis test 
may be applied as a rapid phenotypic assay, useful for screening large numbers of 
clinical strains in an effort to determine novel mutations that may affect the 
expression of this important virulence factor. Given the specificity of this assay it 
could be an important tool in analysing the highly complex and interconnected QS 
systems of P. aeruginosa. The effects of mutation on candidate putative regulatory 
genes or single base pair mutations of known regulators could be assayed quickly to 
in order to determine their effect on a key QS-regulated virulence factors.  
 
Determining whether an isolate is a strong- or weak-RL producer maybe 
important considering that specific concentration of RL are required to lyse 
important immune cells and disrupt the cellular barrier which prevent invasion and 
dissemination (519, 523). One limitation of this assay is that it is susceptible to other 
microbial surfactants, notably the phenol-soluble modulin (PSM) peptide toxins of S. 
aureus (546). Therefore, isolation of pure P. aeruginosa isolates is required before 















Investigating the effects of Toxic Shock Syndrome 






The main etiologic agent of toxic shock syndrome (TSS) is the toxic shock syndrome 
toxin-1 (TSST-1) protein secreted by Staphylococcus aureus. Diagnosis of TSS is 
difficult and is significantly under-reported in young children with burns, due to the 
nonspecific presentation coupled with a rapid deterioration in patient condition. 
Previous reports have observed a downregulation of exotoxin production mediated 
by the expression of the TSST-1 protein using a lab strain, RN4282. To investigate 
this further, the lytic and cytolytic activity of a number of clinical and laboratory 
TSST-1 positive strains of methicillin-susceptible S. aureus (MSSA) (101, 253, 279 
and RN4282) were tested in vitro using the phospholipid vesicle and T cell toxicity 
assay. In addition, the activity of lytic exotoxins such as the δ-haemolysin/ PSM 
peptide toxins, β-haemolysin, α-haemolysin and non-lytic TSST-1 toxin was 
measured over the 20-hour growth of RN4282 and the isogenic tst negative strain, 
RN6938, with both strains presenting toxic phenotypes. It is important to note that 
the clinical TSST-1 positive methicillin-susceptible S. aureus strains exhibited lytic 
exotoxin production as well as TSST-1 expression as confirmed by Western blot. We 
suggest that there is no correlation between the expression of TSST-1 and lack of 
exotoxin production which has been previously described. We also suggest that 
purulence in an S. aureus infected burn wound in a child should not be used to rule 








oxic shock syndrome (TSS) is a serious complication of burn infections, 
primarily affecting children less than 4 years of age due to a lower level of 
antibody-mediated protection (547-549). TSS presents clinically as a range 
of symptoms including shock, pyrexia, an erythematous rash, gastrointestinal 
disturbance and central nervous system signs including lethargy or irritability (550). 
TSS is often observed in infants with smaller partial thickness scalds, possibly due to 
more conservative treatment and the absence of surgical debridement (547). The TSS 
clinical picture is of a young child with a small burn who deteriorates and rapidly 
becomes moribund within hours unless treatment is started promptly. Untreated 
mortality rates are around 50% (551). A study by Guggenheim et al showed that the 
majority of children with burn infections had Staphylococcus aureus as the primary 
infective agent (73). Various strains of S. aureus are known to secrete the small        
22 kDa toxic shock syndrome toxin-1(TSST-1) protein, which is highly associated 
with menstrual TSS (mTSS) and, along with staphylococcal enterotoxin (SE) B and 
SEC, with non-mTSS which can develop during burn wound infection (283, 552, 
553). 
 
 The tst gene (which encodes TSST-1) can be found on one of three mobile 
staphylococcal pathogenicity islands (SaPIs) that can integrate close to tyrB gene 
(SaPI1), or within trp locus (SaPI2) (554). A third tst gene is found on SaPIbov, a 
pathogenicity island associated with certain bovine S. aureus strains (555). 
Approximately 20% of S. aureus strains carry a tst-containing pathogenicity island 
(554) however, TSS is fortunately rarely seen, occurring in approximately 0.6 cases 
per 100,000 people (556). This is most likely due to the tight control and complex 
regulation of this toxin. Multiple environmental factors and molecular mechanisms 
all play a role in modulating tst expression. Environmental stimuli such as elevated 
carbon dioxide and oxygen are associated with high levels of toxin production, 
possibly through the SsrAB two component system, which is hypothesised to 
differentially regulate certain virulence genes under aerobic and anaerobic conditions 




(558), and this has been demonstrated to be dependent on the binding of the 
catabolite control protein CcpA, with catabolite responsive elements (cre) situated in 
all known tst promoter regions (559). Other factors such as NaCl and magnesium 
concentration and the relative pH all play a role in altering production of this toxin 
(560-562), factors which were all implicated in the correlation observed between 
tampon use and mTSS. Furthermore, the role of vaginal mircobiota has been 
highlighted in the induction and suppression of TSST-1 production (563) and cyclic 
dipeptides produced by the human vaginal isolate, Lactobacillus reuteri RC-14, has 
been shown to interfere with the accessory gene regulator (Agr) quorum sensing 
system, resulting in reduced TSST-1 expression (564). Importantly, the most direct 
evidence of tst regulation is via the SarA DNA-binding protein, with SarA directly 
binding to at least one site within the tst promoter (565). Moreover, deletion of sarA 
leads to a more deleterious tst transcription than deletion of the effector molecule of 
the Agr system, RNAIII (565), highlighting the central role of SarA in tst regulation. 
 
TSST-1 is part of a class of proteins known as super antigens (SAg), due to 
their ability to massively and non-specifically over activate T cells. SAg can bridge 
the major histocompatibility complex (MHC) class II expressed on antigen 
presenting cells and surface attached T cell receptors on CD4+ T cells without the 
requirement of a specific antigen (Fig 5.1). This action stimulates a much larger and 
disproportional release of cytokines including tumour necrosis factor, interleukins 
and gamma-interferon. The downstream effect is the activation of up to 30% of the T 
cell population and interruption of normal immune surveillance (566). Recent studies 
have shown that a related staphylococcal enterotoxin, SEB, interacts with the CD28 
co-stimulatory molecule, which is required for full T cell activation and cytokine 
production (567). Such nonspecific cytokine release leads to rapid clinical 
deterioration which can result in capillary leakage leading to hypotension, shock and 
multiple organ failure. This activation of T cells and resulting ‘cytokine storms’ 
occurs only after induction of cytokine production from mucosal epithelial cells, a 
process known as ‘outside-in’ signalling. Pro-inflammatory cytokine and chemokine 
production is stimulated at the mucosal epithelial layers causing increased mucosal 
142 
 
permeability, allowing SAg penetration through these layers and subsequent 





Figure 5.1: Mode of action of superantigen TSST-1. The TSST-1 protein (SAg) generates powerful 
immune responses by binding to both the MHC II on the antigen presenting cell (APC) and TCR on 
the CD4+ T cell and is hypothesised to interact with the co stimulatory molecule CD28, which 
normally ligates with the B7 molecule. SAg mediated bridging bypass normal antigen (Ag) 
presentation (left) and results in the activation of downstream signalling cascades, leading to the 
massive stimulation and non-specific proliferation of T cells and secretion of cytokines. Figure 
adapted from reference (568).  
 
 
The work described in this chapter is important regarding the aims of the 
Bacteriosafe project; designing a bacterial sensor mechanism dependent on the 
expression of bacterial membrane damaging factors. As part of this project, TSST-
1producing S. aureus were studied to investigate whether exotoxins from such 
bacteria would lyse phospholipid vesicles. This was in relation to a proposed method 
of tst regulation described by Vojtov et al demonstrating that TSST-1 undergoes auto 
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repressive regulation and strongly represses the expression of virtually all 
exoproteins (457). As a consequence, we investigated the toxin production and 
vesicle lysis capabilities of the TSST-1 producing S. aureus strain, RN4282 and the 
isogenic tst deletion mutant, RN6938, which were used in the original study 
performed by Vojtov et al. Additionally, we also investigate the toxic activity of 
three other TSST-1 positive clinical S. aureus strains (community-acquired 
methicillin sensitive S. aureus strains 101, 253 and 279) while simultaneously 
analysing TSST-1 expression through western blotting.   
 
 
5.3 Results and Discussion 
___________________________________________________________________________________________ 
 
One of the primary modes of pathogenicity of bacteria such as S. aureus is via the 
action of their secreted exotoxins. Exotoxins such as δ-haemolysin target the 
eukaryotic cell membrane by adsorbing to target membranes and disrupting 
membrane integrity leading to osmotic shock and cell death. As described 
previously, the phospholipid vesicles used in this work were designed to roughly 
mimic the eukaryotic cell membrane and be susceptible to such toxins.  
 
5.3.1 Vesicle response to bacterial strains 
 
The dilution of self-quenched and ‘switch on’ of carboxylfluorescein (CF) is a 
simple way to follow vesicle membrane damage by toxins, as release and dilution of 
encapsulated dye switches on fluorescence, resulting in an easily observable / 
measureable response to vesicle lysis. Figure 5.2 shows the fluorescence response of 
vesicles to Triton X100 and HEPES buffer (positive and negative control 
respectively); and the strains under investigation as described earlier. RN6390B (Agr 
+) and RN6911 (Agr -) strains where used as positive and negative toxin producers 
as the Agr quorum sensing system plays a central role in general toxin expression 
and activates the expression of δ-haemolysin and phenol-soluble modulin (PSM) 
toxins, known to lyse the vesicles used in this study (Chapter 3). We investigated the 
potential of the TSST-1 secreting strain, RN4282, and the isogenic tst knockout 
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strain, RN6938, to lyse vesicles, in order to examine any influence that TSST-1 
expression may have on toxin mediated vesicle lysis.  Finally, three clinical 
methicillin sensitive S aureus (MSSA) strains which were annotated as tst positive 
by PCR (427) were also used to examine their vesicle lytic potential. BothRN4282 
and RN6938 and the three TSST-1 positive strains caused lysis of vesicles equal to 
that of the positive control, suggesting that this protein did not downregulate the 




Figure 5.2: Fluorescence response as a result of vesicle lysis by bacterial exotoxins after 
exposure to overnight bacterial culture supernatant. All strains, except the Agr deletion strain 
(RN6911) caused lysis of vesicles. Triton X100 and HEPES buffer were used as positive and negative 
controls respectively. Experimetns were performed in triplicate three times with error bars 
representing the 95% confidence interval.  
 
 
5.3.2 T cell cytotoxicity assay  
 
As discussed later (Chapter 6), the T cells used in the cytotoxicity assay are 
susceptible to a suite of toxins including the α-, β-, γ- and δ-haemolysin and PSMs. 
Using this assay we wanted to investigate any deleterious effect on these toxins 
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associated with the presence/expression of  the tst gene. T cell survival thus 
negatively correlates with bacterial pathogenicity / exotoxin production. Hence, the 
histogram shown in figure 5.3 is almost a mirror image of figure 5.2, with RN6390B, 
RN4282 and the clinical MSSA strains being toxic to T cells, whereas RN6911 




Figure 5.3: T cell toxicity assay. Bacterial supernatant mediated lysis of T cells illustrating toxic 
phenotype of all strains except RN6911 (Agr negative). Importantly, both the tst positive and negative 
strains show T cell lysis. Experimetns were performed in duplicate three times with error bars 
representing the 95% confidence interval 
 
 
5.3.3 Whole cell lysate and exoprotein analysis of RN4282 and 
RN6938 
 
The previous results have contradicted the role of TSST-1 in repressing global 
exoprotein secretion, as supernatants derived from both RN4282 and RN6938 caused 
vesicle and T cell lysis. An investigation into the effects of tst deletion on protein 
profiles was performed in these lab strains to understand if any specific toxins were 
repressed, as vesicle lysis and T cell death could have been caused by a single toxin 
and therefore this assay would not accurately reflect global exoprotein analysis. Prior 
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to further protein analysis, the growth curves of both strains were compared and no 
deviation in growth was observed (Fig 5.4a). Western blot analysis on TSST-1 
expression was also performed (Fig 5.4b), confirming expression of TSST-1 under 
these experimental culture conditions, as toxin expression can be affected by growth 
in different media (569). Whole cell lysate (Fig 5.4c) and tricholoroacetic acid 
(TCA) precipitated supernatant protein analysis (Fig 5.4d) was performed to 
investigate any global deleterious effects caused by TSST-1 expression. These results 
clearly show no decrease in exoprotein secretion associated with effect of TSST-1. 
Additionally, the potential effects of tst on specific toxin expression was examined 
by use of butanol-1 peptide extraction of peptide toxins (δ-haemolysin and PSMs), 
western blot analysis of the hepatameric pore-forming α-haemolysin and the 
detection of beta haemolysin on sheep blood agar through the ‘hot-cold lysis’ method 
(Fig 5.4 e-g). Again, no deleterious effect was observed in the TSST-1 producing 


















Figure 5.4: Protein analysis of RN4282 (tst positive) and RN6938 (tst negative). A) Growth curves, 
B) western blot analysis highlighting TSST-1 expression from the tst positive RN4282, C) whole cell 
lysate protein preparations and D) supernatant proteins analysis of RN4282 and RN6938. E), F) and 





5.3.4 Real-time analysis of S. aureus clinical isolates: Growth rates, 
exotoxin production and TSST-1 secretion 
 
The high degree of toxicity to T cells, the response of the phospholipid vesicles to 
the TSST-1positive S. aureus RN4282, and the positive expression of three exotoxins 
confirms that this strain, as well as producing the super-antigen TSST-1, also 
expresses and secretes lytic membrane-damaging agents. Although RN4282 was 
isolated from the clinic, it has been a laboratory strain since 1983 (462) and therefore 
maybe harbouring mutations that affect its virulence regulation. To fully confirm that 
the TSST-1 protein had no measurable effect on global exotoxin synthesis, we 
switched from the laboratory strain (RN4282) to clinical tst positive strains             
(S. aureus 101, 253 and 279). Further measurements were carried out, analysing the 
correlation between growth rate, vesicle lysis as a function of fluorescence and 
detection of TSST-1 (Fig 5.5). These results show that the lytic exotoxin secretion 
(not TSST-1) commences early in the bacterial growth phase, with a clear change in 
fluorescence being measureable (and observable by eye) within 6-8 hours from an 
initial starting inoculum of 10
5
 CFU / mL.  In all three strains (Fig 5.5a-c), vesicle 
lysis is observed during the post-exponential phase of growth, approximately 
corresponding to 10
8
 CFU/mL. TSST-1 secretion does not commence until later on 
in the growth phase, at approximately 7–11 hours (Fig 5.5a-c). The Western blot 
analysis therefore confirms not only that the three clinical strains tested here do 
secrete TSST-1, but are also highly lytic to vesicles and that in an in vitro 
experiment, the putative detection system will signal before or at the onset of   
TSST-1 expression. We also observed α-, β- and δ-haemolysin expression and 
explored the respective supernatant protein profiles of these three clinical strains, all 
illustrating no exotoxin repression (data not shown). This has important implications 
for the clinical arena and potential early diagnosis of infection via a putative smart 













Figure 5.5: Real time analysis of TSST-1 positive clinical strains. Strains MSSA 101, 253 and 279 
were analysed based on the association between TSST-1 production (B) and vesicle lysis (C) as a 
measure of growth rate (A). All three strains grew in a characteristic fashion and secreted TSST-1 at 
approximately 7-11 hr of growth. Vesicle lysis was significantly apparent between 6-8 hrs of growth. 







The results of this chapter suggest that TSST-1 expression does not have a negative 
or global repressive effect on overall exotoxin synthesis in S. aureus. Importantly, we 
see no significant difference in exotoxin profile between the TSST-1 positive and 
negative strains, which was substantial in the Vojitov et al study (457). It was noted 
previously that TSS causing clinical isolates had lower production of haemolysin, 
lipase and nuclease, than strains which were not producing the TSST-1 protein 
(formally known as pyrogenic exotoxin C) (571). However, these virulence genes are 
regulated by the Agr regulon, the two component SaeRS system and SarA DNA 
binding protein (329) . Therefore, any deleterious mutation in these regions could 
impact on the levels of virulence expression, which may have been misrepresented as 
151 
 
TSST-1 global regulatory effects. In this study we show that the presence of the tst 
gene has no repressive effect in the production of three main virulence genes; α-, β-
haemolysin and the δ-haemolysin/PSM peptides. Three more clinical strains were 
also tested (Fig 5.5a-c) with no indication of repressive effect by this SAg. These 
results are consistent with studies designed to assess the contribution of SAg’s in 
modulating the secretome expression in Streptococcus pyogenes (572). This study 
concluded that neither the streptococcal pyrogenic exotoxin A (SPEA) nor 
streptococcal mitogenic exotoxin Z (SMEZ) had any regulatory effect on protein 
expression (572).  
 
 An important element in the design of the smart dressings outlined in section 
1.4.1 is the role of toxins in damaging dye loaded vesicles for use in signalling 
responses. Considering that the overall aim was the development of a prototype for 
use in burn care, with a particular focus on paediatric burn patients, coupled with the 
fact that TSS can be potentially fatal in young children, highlighted the need for an 
investigation into whether these putative signalling system could respond to TSST-1 
positive S. aureus strains, at least in vitro. One important factor in disease 
progression is the speed at which the patient’s health declines. Children with TSS 
deteriorate rapidly (1–2 hours) and are unresponsive to antibiotics alone. In Figure 
5.5, vesicle lysis occurs after 6-8 hours of growth whereas TSST-1 production begins 
after 7-11 hours and is strain dependent.  Therefore, in this in vitro model, these 
vesicles could be used to signalling infection before or at the same time as TSST-1 
production begin. We are concerned that over interpretation of the article by Vojtov 
et al could lead to a potentially incorrect differential diagnosis of TSS because the 
authors suggest that S. aureus RN4282 downregulates exotoxin production, in 
contradiction to findings presented here. The in vitro data presented suggests that 
clinicians should not discount the possibility of toxic shock in a child with evidence 
of lytic exotoxin production/cytotoxic infection including direct tissue damage, 














Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is 
an emerging global concern. CA-MRSA strains are known to be highly virulent due 
to increased expression of core-genome-encoded and phage-encoded toxin genes. It 
has been shown previously than hospital-acquired (HA)-MRSA strains have high-
level expression of the alternative penicillin-binding protein, PBP2a, encoded by the 
mecA gene on type II staphylococcal cassette chromosome mec (SCCmec) elements. 
This high PBP2a expression caused a reduction in toxicity by interfering with the 
Agr quorum sensing system. CA-MRSA strains express significantly lower levels of 
PBP2a than other MRSA types, which is believed, in part, to explain their relatively 
high toxicity. We hypothesized that since oxacillin increases mecA expression, use of 
this antibiotic could attenuate virulence gene expression by interfering with global 
regulatory systems. This chapter illustrates the use of a subinhibitory concentration 
of oxacillin which induced PBP2a expression while repressing RNAIII expression. 
Consequently, this repression caused a decrease in phenol-soluble modulin (PSM) 
secretion, but increased α-haemolysin and Panton-Valentine Leukocidin (PVL) 
expression consistent with other studies. As oxacillin treatment had both positive and 
negative effects on toxin expression, the net effect of these changes on three different 
cell types were examined. Where PSM and α-haemolysin are important, oxacillin 
reduced overall lysis, but where PVL is important oxacillin increased lysis. We also 
examined the effect of oxacillin on bacterial binding to extracellular matrix proteins 
specifically fibrinogen and fibronectin, invasive capacity in an endothelial cell 
invasion assay and on the surface expression of the multifunctional protein A protein. 
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Where we found no difference in invasion capacity, a positive association between 
subinhibitory oxacillin treatment and binding to fibrinogen in strain LAC and 
decreased protein A expression in both CA-MRSA strains was recorded, 




6.2 Introduction  
___________________________________________________________________________________________ 
 
ince the mid-1940s, consecutive waves of antibiotic-resistant 
Staphylococcus aureus strains have posed difficult challenges to healthcare 
professionals (289). Infections caused by methicillin-resistant S. aureus 
(MRSA) have reached epidemic proportions globally and incidence rates are 
increasing, both in the health care and community environments (282, 573, 574). 
Historically, MRSA infections were associated with predisposed patients in a 
nosocomial setting, however, the recent emergence of MRSA infecting patients 
lacking any contact with hospitalisation or any healthcare individual/facility, lead to 
the introduction of the term, community-associated MRSA (CA-MRSA) (575, 576). 
There are specific factors which discriminate between these two MRSA groups 
which involve the acquisition of certain mobile genetic elements and virulence 
determinants (292, 296, 301) (see section 1.3.3.1 for more details). In the United 
States, the CA-MRSA USA300 clone (ST-8, PVL
+
, type IV SCCmec) has caused the 
most severe outbreak, in terms of frequency and infection severity (577, 578). CA-
MRSA strains are considered hyper-virulent, possessing extra virulence genes 
encoded on staphylococcal pathogenicity islands (SaPIs), such as the phage-encoded 
Panton-Valentine Leukocidin (PVL) and having increased expression of core-
genome encoded toxins genes, notably α-haemolysin and Phenol-soluble Modulin 
peptide toxins (PSMs) (313).  
 
 All MRSA strains possess staphylococcal cassette chromosome mec 
(SCCmec) elements (reviewed in section 1.3.1.2), which confer resistance to β-




content and metabolic burden (581-583), but share common features, namely the 
mecA gene, which encodes the alternative penicillin binding protein, PBP2a (584). 
Also contained within the SCCmec elements are recombinases (ccrA and ccrB) 
which permit correct integration and excision at orfX on the staphylococcal 
chromosome, other mobile genetic elements integrated within, which contribute to 
resistance to other antibiotics and heavy metals, and repressor (MecI) and signal 
transduction (MecR) proteins involved in mecA regulation and expression (585, 586). 
Based on their protein homology with BlaI and BlaR1 and experimental data, MecI 
and MecR are believed to regulate inducible transcription of mecA (587). MecR can 
detect and respond to the presence of β-lactam antibiotics through the penicillin-
binding domain, activating the cytoplasmic protease domain by autocatalytic 
cleavage, leading to the cleavage of the mecI repressor and inducing mecA 
transduction (588). The BlaRI S. aureus signal/transduction system directly acts 
against β-lactams, through the induction of β-lactamase expression (589) as shown in 
figure 6.1. The BlaR1 protein has three domains; C-terminal sensor domain, a trans-
membrane domain and a cytoplasmic domain which is hypothesised to possess a 
zinc-dependent protease (590). In a similar fashion to the mecA complex, in the 
presence of a β-lactam antibiotic, the surface domain of the BlaR1 protein interacts 
with the antibiotic, inducing a conformational change which activates a downstream 
signalling cascade, culminating in the induction of a zinc protease, relieving the 
action of the repressor and subsequent BlaZ activation. Interestingly, this system also 
causes the expression of mecA independently of a functional mecR, highlighting the 
importance of S. aureus response to β-lactams (591). This dual activation is 
extremely important as CA-MRSA strains possess a type IV SCCmec element, 








Figure 6.1: Sensing of β-lactam antibiotics in S. aureus. In the absence of β-lactam antibiotics 
(shown here as oxacillin) the repressor proteins, BlaI and MecI, are blocking the transcription of blaZ 
and mecA respectively.  Oxacillin enters the environment and interacts with the sensor domains in the 
MecR and BlaR proteins, causing a signal transduction event, leading to the activation of proteases 
and degradation of the repressors and expression of blaZ and mecA. 
 
 
It has been observed by us and others that HA-MRSA strains express higher levels of 
PBP2a than do CA-MRSA strains in the absence of β-lactam antibiotics (238, 592). 
This lab has also shown that high levels of PBP2a expression in HA-MRSA strains 
caused a significant downregulation in toxicity (238). CA-MRSA strains also express 
PBP2a, but this expression does not affect their toxicity, which was shown to be due 
to relatively lower basal levels of expression (238). As shown in figure 6.2, PBP2a 
expression can be induced by the presence of oxacillin (585, 586, 589, 591) and high 
PBP2a expression can attenuate toxicity by interrupting Agr signalling (238), we 
hypothesized that subinhibitory concentrations of oxacillin (determined to be 0.5 
μg/mL (593)) could stimulate PBP2a expression, thus reducing toxicity and therefore 
the severity of CA-MRSA infections.  However, a number of studies have 
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investigated the effects of subinhibitory oxacillin on toxin gene transcripts, where an 
increase, rather than a decrease in activity of α-haemolysin and PVL was observed 
(594-596). In this chapter, we sought to test our hypothesis by examining the lytic 
effect of bacterial supernatants after growth in medium containing subinhibitory 
concentrations of oxacillin (shown not to have any deleterious effect on growth 
(593)), on three important cell types. We also investigated the expression of an 
important cell surface protein, protein A, under these conditions, and whether any 
differences were observed in solid-phase binding assay and endothelial invasion 
assays. We found that the expression of PSMs can be repressed by inducing higher 
levels of PBP2a following subinhibitory oxacillin exposure. However, this treatment 
also induced an overall increase in exoprotein expression levels and specifically an 
increase in α-haemolysin and PVL expression. In our cytotoxicity assay, we found 
that where PSM and α-haemolysin are known to be important, oxacillin reduced cell 
lysis, but where PVL is important, it increased cell lysis. No difference was seen in 
cell invasion assays, but an increase in binding to fibrinogen during exponential 
phase binding with LAC was observed. Subinhibitory oxacillin also reduced the 
levels of protein A expression significantly, illustrating the pleiotropic effect of 




Figure 6.2: Oxacillin-induced expression of PBP2a in CA-MRSA strain LAC (USA300) and 
MW2 (USA400). Western blot of whole-cell lysates illustrating PBP2a expression in CA-MRSA 
strains. Lane 1, Molecular weight ladder; Lane 2, LAC after growth in antibiotic-free medium; Lane 
3, LAC after growth in medium containing 0.5 μg/mL oxacillin; Lane 4, MW2 after growth in 
antibiotic-free medium; Lane 5, MW2 after growth in medium containing 0.5 μg/mL oxacillin. Figure 






6.3 Results and Discussion 
__________________________________________________________________________________________ 
 
Previous results have shown that oxacillin-induced expression of PBP2a caused a 
decrease in toxicity in T cell survival experiments (593). The mechanism behind this 
reduced toxicity was shown to be dependent on Agr with quantitative real-time PCR 
experiments illustrating a decrease in RNAIII expression, the effector molecule of 
the Agr system, in LAC and MW2 grown in subinhibitory oxacillin (593). This 
chapter investigated the effects of subinhibitory oxacillin on secreted proteins, 
namely α-haemolysin and PVL toxin, and how this affects the outcome of cell lysis 
and on the S. aureus surface proteins, which are known to be important in adhering 
to matrix protein, evading the immune system and invading cells. The strains used in 
this study can be found in Table 3.2.  
 
6.3.1 T cells are susceptible to specific staphylococcal toxins 
 
As stated previously, a statistically significant decrease in lytic activity was observed 
after treatment with oxacillin in a subset of type IV CA-MRSA strains  (593). The 
immortalised T2 cell line was used in this study, so we therefore wanted to first 
analyse which staphylococcal toxins were important in T cell lysis using a variety of 
mutants and synthetic peptide toxins as shown in figure 6.3 a and b.  
 
The T cells were shown to be sensitive to α-, β-, γ-, and δ-haemolysin as well 
as highly susceptible to PSMα1, PSMα2 and PSMα3, but not susceptible to PVL, or 
the leukocidins, LukAB or LukED (Fig 6a). It has been shown recently that PVL 
requires the expression of human complement receptors C5aR and C5L2 for cell 
toxicity (308). Additionally, the LukAB and LukED cytotoxins require other specific 
host leucocytes surface receptors such as the CD11b subunit of the Mac-1 integrin 
for LukAB (443) and the CCR5 receptor for LukED (441) and it is possible that none 
of these receptors are expressed on T2 cell surface.  
 
Interestingly, the importance of specific toxins were shown to be strain 
specific; in the 8325-4 background, α-haemolysin was shown to be significant in T 
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cell lysis, as the hla mutant caused significantly lower lysis in all but the 0.125 
dilution factor. However, when hla was deleted in the Newman background, there 
was no significant difference in lysis potential across any of the dilutions used (Fig 
6.3a). To understand this discrepancy, western blot analysis on α-haemolysin was 
performed on both 8325-4 and Newman, and it was observed that strain 8325-4 
expresses 4.1 fold higher α-haemolysin than strain Newman under our growth 
conditions, possibly highlighting why α-haemolysin is important for strain 8325-4 
lysis (Fig 6.4c).  
 
Despite this, strain Newman has a higher lytic capacity than strain 8325-4, as 
shown by decrease in T cell viability resulting from differing supernatant 
concentrations (Fig 6.3a). To investigate whether other small peptides such as the 
PSMs are involved, hydrophobic peptide extractions were performed which 
demonstrated a 1.7 and 1.3 fold  higher concentration of δ-haemolysin/PSM peptides 
from strain Newman than from 8325-4 and LAC respectively (Fig 6.4d), which may 
in part explain the highly lytic potential of strain Newman, despite the lower levels of 
α-haemolysin secretion. PSM peptides have been shown previously to be highly lytic 
to a variety of cells and artificial membranes (312, 316, 546) and have been shown 
here to efficiently lyse T cells, in a lytic pattern consistent with other cell types with 
the PSMα1-3 and delta being lytic, while PSMα4 is lytic only at high concentrations, 


















Figure 6.3a-d: Specific toxins cause T cell lysis. A) Using isogenic mutants from three different 
genetic backgrounds allowed for the evaluation of staphylococcal toxin lytic capacity against the 
immortalised T2 cell line. We show that deletion of α-, β-, γ-, and δ-haemolysin results in a 
statistically significant decrease in T cell viability (all p values are lower than 0.05). B) Synthetic 
PSM peptides were used and illustrate the highly lytic capacity of the PSMα1-3 toxins and δ-
haemolysin to T cells C) Higher expression of α-toxin in 8325-4 than in Newman and D) Higher 
expression of δ-haemolysin and PSMs from Newman than 8325-4 and LAC, may explain the strain-
specific roles of some toxins in T cell lysis. T-cell experiments were done in duplicate three times 
with error bars representing the 95% confidence interval. * denotes a stastically significant difference 
using students t test P<0.05.  
 
 
6.3.2 Oxacillin alters the toxin expression profile of CA-MRSA 
 
The overall effect of treatment with subinhibitory oxacillin on the exoprotein 
expression profile of two clinically important CA-MRSA strains, LAC (USA300 
clone) and MW2 (USA400 clone), was determined. The supernatants of these strains 
grown with or without 0.5 μg/mL oxacillin were precipitated using trichloroacetic 
acid and further analysed. Despite the decrease in RNAIII expression (593) there was 
an overall increase in the expression levels of exoproteins by LAC and MW2 
following growth in subinhibitory oxacillin (Fig 6.4a). We next investigated the 
effects of oxacillin on specific toxins, known to be important in infection, namely the 
α-haemolysin and PVL toxin. Previous publications have reported increases in 
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transcript levels of important cytolytic toxins, specifically, α-haemolysin and PVL in 
response to subinhibitory oxacillin treatment (594-596). Western blots of these CA-
MRSA supernatant extracts demonstrated that although there was an increase in α-
haemolysin for both strains, this was not statistically significant (1.8- and 1.4- fold 
for LAC and MW2 respectively) as illustrated in figure 6.5b and table 6.1. However 
the level of PVL expression had increased significantly for both LAC and MW2 
(3.01- and 4.1- fold respectively) as shown in figure 6.5c and table 6.1. This 
complemented the results of previous qRT-PCR directed against lukS, where a 
significant increase in lukS transcript taken at 10 and 20 h growth correlated with 
oxacillin treatment (593).  
 
 PSMs are extremely important virulence factors, which are intimately 
associated with CA-MRSA strains (296, 301). Therefore we wanted to investigate 
the effect of subinhibitory oxacillin on PSM secretion qualitatively using a butanol- 
extraction process for hydrophobic peptides (546). These peptide toxin range in size 
from 2.3-4.5 kDa and therefore cannot be separated from each other and migrate as a 
signal band during sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS- 
PAGE); however a clear reduction in band intensity can be seen upon exposure of 
the bacterial cultures to subinhibitory oxacillin concentrations (Fig 6.5d). To fully 
examine and quantify these changes, supernatants were sent for HPLC/ mass 
spectrometry analysis (performed by Hwang-Soo Joo and Micheal Otto, NIAID, 
NIH, Bethesda, Maryland, USA), which showed a statistically significant reduction 
in the secretion of PSMα type peptide and δ-haemolysin in both LAC and MW2 (Fig 
6.4e), confirming the down-regulatory effect that subinhibitory oxacillin had on the 









Figure 6.4a-e: Oxacillin alters the toxin expression profile of CA-MRSA. Bacterial cultures were 
grown in the presence or absence of 0.5 μg/mL oxacillin as indicated. A) Exoprotein profile, Western 
blot using B) anti-LukS antibodies or C) anti-α-haemolysin antibodies. D) SDS-PAGE of butanol 
extracted PSM. E) Results of HPLC/MS signal intensities of each of the PSMs from LAC and MW2 
culture filtrates with and without oxacillin (error bars represent the 95% confidence). Western blot 




Isolate, locus Fold change ( +ox vs –ox) Significance (P) 
LAC, hla ↑ 1.8 0.19 
MW2, hla ↑ 1.4 0.29 
LAC, lukS ↑3.01 0.008* 
MW2, lukS ↑4.1 0.011* 
LAC, spa (Stationary phase) ↓2.6 0.024* 
MW2, spa (Stationary phase) ↓2.1 0.036* 
 
Table 6.1 Protein expression level changes in response to subinhibitory oxacillin 
treatment through western blot and band intensity analysis using Image J software. 
Arrows indicate the direction of the fold change in response to oxacillin (ox).             
* Indicates statistically significant values using student t test, P<0.05 
 
 
6.3.3 The effects of oxacillin on the cytolytic potential of bacterial 
supernatants are cell-specific  
 
S. aureus expresses a vast array of membrane-damaging toxins, a formidable arsenal 
which has been central to its success as a globally important pathogen. S aureus has 
evolved to employ an ‘insurance policy’ with regards toxins expression, where the 
activity of a subset of toxins is enough to lysis most human cells. Therefore, in order 
to understand the overall cytolytic effect, bacterial cultures, treated with and without 
oxacillin, were harvested and supernatants tested against a set of three cell types: the 
T cells, included here as a reference, human red blood corpuscles (RBCs), sensitive 
to α-haemolysin and PSMs and human polymorphonuclear leucocytes (PMNs) which 
are sensitive PVL and the PSMs.  
 
The effects of oxacillin on the lytic potential of both LAC and MW2 were 
compared across these cell types (Fig 6.5 a-f). PVL has been known to be 
overexpressed when grown in casein hydrolysate and yeast-extract containing 
medium (CCY) (458, 597) and here we show that growth in CYY causes differential 
exoprotein expression and higher PVL expression (Fig 6.5g-h). Therefore the effect 
of oxacillin treatment when LAC and MW2 were cultured in this medium was also 
compared in these assays. Subinhibitory oxacillin increased T cell survival in both 
LAC and MW2 and when grown in both culture media (Fig 6.5a-b). Despite an 
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increase in α-haemolysin expression, oxacillin decreased the lysis of RBC 
significantly in both TSB (LAC, P=0.0172 and MW2, P=0.0169 and CYY (LAC, 
P=0.0361 and MW2, P=0.0336). Therefore, with regards RBC lysis, the decrease in 
PSM secretion had more of a dominant effect than the increase in α-haemolysin. 
Contrarily, although human PMNs are sensitive to both PSMs and PVL, when LAC 
and MW2 were grown in CYY, the increase in the expression of PVL had more of a 
dominant effect, with PMN survival decreasing upon oxacillin exposure and 
statistically significant for LAC (P=0.0197) and MW2 (P=0.042) (Fig 6.5f). 
However, this was not the case when either strain was grown in TSB (Fig 6.5e), 
where an increase in survival was observed for both LAC (P=0.022) and MW2 
(0.01). These results illustrate that where PVL expression is important, oxacillin 
causes a decrease in PMN viability, but as shown here, specific conditions are 
required for maximum PVL expression, and how this relates to in vivo conditions 








Figure 6.5a-h. Oxacillin differentially alters the sensitivity of cells to lysis. Oxacillin decreased the 
ability of CA-MRSA to lyse immortalized T cells when strains were grown in A) TSB or B) CYY. 
Oxacillin decreased the ability of CA-MRSA to lyse fresh human RBCs when strains were grown in 
C) TSB or D) CYY. Oxacillin decreased the ability of CA-MRSA to lyse fresh human PMNs when 
grown in E) TSB, but increased the ability of CA-MRSA to lyse fresh human PMNs when grown in 
F) CYY. G) Comparison of exoprotein profile of LAC and MW2 grown in TSB or CYY. H) Higher 
PVL expression of LAC and MW2 grown in CYY rather than MW2. T-cell experiments were done in 
duplicate three times with error bars representing the 95% confidence interval. * denotes a stastically 




6.3.4 Oxacillin modulates surface protein expression 
 
A major part of S. aureus pathogenesis is the expression of surface proteins, 
collectively designated as microbial surface component recognising adhesive matrix 
molecules (MSCRAMMs). These proteins are intimately involved in initial host 
colonisation, attachment to extracellular matrix proteins and cell uptake/invasion.  
166 
 
Although the Agr system plays a major role in downregulating the expression of 
these factors in the transition from late exponential to early stationary phase of 
growth, further complex regulatory networks involving other two-component 
systems, DNA-binding proteins and non-coding regulatory RNAs are also important 
in regulation, many of which may be induced or repressed upon external stimuli, 
such as subinhibitory antibiotics.   
 
Here the effect of oxacillin treatment on the expression of a major surface 
protein protein A (SpA) was investigated. SpA is present in over 90% of S. aureus 
strains, (598) and is an important multifactorial virulence factor. SpA binds to a 
variety of ligands, including the Fc domain of IgG (599), von Willebrand factor 
(426) and tumour necrosis factor receptor-1 (TNFR-1) (600). This protein also 
allows the adherence to specific cells such as osteoblasts (601) and is an important 
component in disrupting opsonisation (423) (see section 1.3.5.1.3 for more details).  
 
Examining the overall surface protein profile of these two important CA-
MRSA strains reveals that LAC is affected quite substantially with many proteins 
being overexpressed when grown in subinhibitory oxacillin (Fig 6.6a). However, 
protein A expression was reduced significantly, as shown by the western blot in 
Figure 6.6b and Table 6.1. A 2.6- and 2.1- fold reduction was observed in LAC and 
MW2 respectively. Protein A expression is growth phase dependent and controlled 
by complex regulatory networks acting at the transcriptional, translational and post-
translational level (355, 370, 372, 389, 598, 602, 603). Previous studies have shown 
the reduction of spa mRNA after subinhibitory antibiotic treatment with clindamycin 
and linezolid (604, 605).  Both antibiotics inhibit protein synthesis, albeit through 
different mechanisms, which may result in the differential inhibition of one or more 







Figure 6.6a-b: Subinhibitory oxacillin reduces protein A expression in CA-MRSA strains. A) 
Oxacillin modulates surface protein expression in LAC and MW2 strain shown by SDS-PAGE of 
surface proteins isolated from raffinose mediated spheroplasts. B) Western blot of protein A showing 
decreased expression in both LAC and MW2 following growth in subinhibitory oxacillin. 
 
 
As subinhibitory oxacillin causes a reduction in RNAIII expression it was 
hypothesised that these strains would become hyper-adhesive after oxacillin 
exposure as RNA III expression is in part responsible for the down regulation of 
surface adhesins (329). To gain a greater understanding of this, a solid phase binding 
assay was performed using two important matrix proteins, fibrinogen (Fb) and 
fibronectin (Fn). The ability of S. aureus to bind to both of these molecules have 
been studied in depth, requiring primarily, clumping factor A (ClfA) for Fg (407, 
408)  and the fibronectin binding proteins (FnBPs) FnBPA and FnBPB which can 
interact with both Fb and Fn (405, 409). The results of the binding assay 
complemented the pattern of overexpression of surface proteins in LAC, as a 
statistically significant increase in binding to fibrinogen was observed with LAC 







Figure 6.7a-d: Effect of oxacillin on solid-phase binding of LAC and MW2 to fibrinogen (Fg) 
and fibronectin (Fn). A) Exponential phase binding to Fg and B) Fn showing a statistically 
significant increase in binding capacity of LAC grown with oxacillin. No difference in binding was 
observed for MW2 grown with or without oxacillin. Stationary phase binding to C) Fb and D) Fn 
illustrating no statistically significant difference in binding potential for LAC or MW2 with and 
without oxacillin. Solid-phase binding assays were done in duplicate three times with error bars 
representing the 95% confidence interval. * denotes a stastically significant difference using students t 




Interestingly, no difference was observed in the binding affinity to fibronectin by 
either of these strains, which suggests that the FnBPs are not overexpressed, but 
further experimentation is required to confirm this. These results are in contradiction 
to a previous study which observed a hyper-adhesive phenotype with subinhibitory 
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oxacillin (606), however these strains were not CA-MRSA and cultures were grown 
in different media and using a different sub-MIC. During stationary phase of growth, 
no difference was observed in the binding potential of LAC or MW2 grown with and 
without oxacillin (Fig 8 c-d), suggesting an induction of surface proteins seen in 
LAC is relieved during stationary phase of growth. 
 
S. aureus is well equipped to invade cells, relying heavily on the expression 
of FnBPs. Through their interaction with Fn they initiate integrin-mediated 
intracellular uptake/invasion by non-professional phagocytes such as keratinocytes, 
osteoblasts and endothelial cells (607-609). Due to the importance of invasion in         
S. aureus pathogenicity, the invasive capacity of LAC and MW2 with and without 
oxacillin over three time points (15, 30 and 60 min) was investigated (Fig 6.8a-c) 
using an endothelial cell invasions assay. Consistent with a previous publication 
which observed no difference in invasion of osetoblasts (606), no difference was 
observed over the three time points between untreated control and oxacillin treated 
culture. As a side observation, after 60 min incubation with endothelial cells, LAC 
grown with and without oxacillin displayed a statistically higher invasive capacity 
than MW2 under the same conditions (P=0.016), highlighting differences in 












Figure 6.8a-c: Effect of oxacillin on invasion of endothelial cells. LAC and MW2 were grown with 
and without oxacillin and their invasive capacity assessed using an endothelial cell line. No difference 
in invasion was observed over the three time points A) 15min, B) 30min and C) 60 min. Cell invasion 
experiments were done in duplicate three times with error bars representing the 95% confidence 











Previous work in this group demonstrated that increased PBP2a expression reduced 
disease severity in vivo by downregulating cytolytic toxin expression (238). We 
hypothesized that as this β-lactam antibiotic induced the expression of PBP2a, shown 
by RT-PCR (593) and western blotting (Fig 6.2), it could be used as an anti-virulence 
agent in conjunction with other antibiotics to attenuated virulence and therefore 
decrease disease severity in infected patients. The main findings show that although 
subinhibitory oxacillin interrupts and decreases Agr activity and PSM secretion in 
strains that represent two prominent CA-MRSA clones, it also up-regulates other 
cytolytic toxins.  
 
 One of the most widely studied and best characterised virulence factors of         
S. aureus is the heptameric β-barrel pore-forming α-haemolysin (314). At high 
concentrations it causes pore-formation depending on critical membrane domains 
and receptors (428), whereas at lower, sub-lytic concentrations, it has been shown to 
alter the cell signalling pathways that govern cell proliferation, inflammatory 
responses, cytokine secretion and cell-cell interactions (430). In this chapter, we 
show that in concordance with other studies, subinhibitory oxacillin increased the 
level of α-haemolysin expression; however this was not statistically significant when 
densitometry of the bands were analysed. Human red blood cells are the classical cell 
type used to study α-haemolysin, but previous studies have shown that the small, 
amphipathic alpha-helical PSM peptide toxins also lysis RBC (316). LAC/MW2 
supernatant-RBC lysis assays revealed that the overall effect on lysis of this type of 
cell decreased upon exposure to oxacillin, as the decrease in PSM secretion had a 
greater overall effect than the small increase in α-haemolysin. Like α-haemolysin, the 
PSMs have been shown to contribute to many infection types including skin and soft 
tissue infections (SSTI), bacteraemia, and osteomyelitis (610). PSMs are unique in 
that they do not require a proteinaceous receptor, but are only limited in their lytic 
ability based on the lipid membrane composition, permitting lysis on a broader range 
of cell types. The downregulating effect of oxacillin on PSMα1 and -β1 and δ-
haemolyin secretion by USA300 strain LAC was shown previously (611) and here 
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we show that it also affects the expression of PSMα2, -α3, and -α4 and PSMβ2 for 
LAC and MW2. 
 
 PVL is a member of the bi-component class of S. aureus leukocidins, 
consisting of two proteins synthesised and secreted separately which are inactive 
individually but act synergistically to efficiently damage white blood cells (612). 
This toxin has been the subject of debate concerning its role in CA-MRSA 
infections, but it is believed to contribute to necrotic and recurrent SSTIs, necrotizing 
pneumonia and bone and joint infections (296, 301). PMNs are one of the primary 
lines of defence against bacterial infections. The fact S. aureus employs both PVL 
and PSMs to lyse these cells is unsurprising given the importance for bacteria to 
survive this arm of host cell-mediated immunity. Oxacillin had opposite effects on 
the expression of these toxins, and as such, it was important to test which change had 
the more dominant effect on PMN killing. When bacterial cultures were grown in 
TSB, this lead to weak or no expression of PVL and therefore oxacillin caused a 
reduction of PMN death in both LAC and MW2. However, growth in CYY induces 
PVL expression (Fig 6.5h), and in this condition oxacillin stimulates higher 
expression of PVL and thus there was an increased killing of PMNs. However, the 
translation of these findings to infection models that are sensitive to α-haemolysin, 
PSMs, and PVL is critical to test the gross effect that oxacillin has on toxicity and 
virulence. 
 
 Full pathogenesis of S. aureus depends on the expression of a wide range of 
cell wall associated proteins which promote colonisation of host tissue and evasion 
of the immune system (98). Of these surface proteins, the FnBPs, ClfA and SpA are 
arguably the most important. FnBPs contain an A domain required for Fb binding 
and multiple non-identical repeat regions with differing affinities for Fn, which is 
required for host invasion and sepsis in a murine model (410). The ClfA protein 
binds to Fb, and mediates bacterial attachment to platelets and plasma clots, which is 
believed to be an important mechanism for initiating endocardial infection (613, 
614). SpA, like FnBPs and ClfA, is a cell wall LPXTG anchored protein, and has 
multiple domains, important in binding IgG and adhering to susceptible cells. We 
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investigated the effects of oxacillin of the surface protein expression profile, and 
specifically on SpA. In both LAC and MW2, oxacillin caused a statistically 
significant reduction of SpA (Fig 6.6b). This was the first time that a reduction in 
SpA was observed after subinhibitory oxacillin treatment and as SpA is anti-
phagocytic, it would be interesting to assess the effects of subinhibitory oxacillin in a 
phagocytosis assay, which may reveal an important anti-virulence effect. The ability 
of LAC and MW2 to bind Fb and Fn was assessed and observed that, during 
exponential phase, LAC bound to Fb a statistically higher capacity when grown in 
oxacillin then without (Fig 6.7 a). No difference was recorded for MW2 under the 
same conditions. In contrast to previous publications, no difference in binding to Fn 
was observed (606). To further investigate the effects of oxacillin on surface 
expression, an endothelial cell invasion assay was performed, however growth in 
subinhibitory oxacillin confirmed no benefit or loss in the invasion capacity of LAC 
or MW2 (Fig 6.8a-c). 
 
 S. aureus virulence gene expression is regulated by specific elements 
clustered into complex networks driving specific interactions. Important within this 
regulatory network are the two-component regulatory systems, composed of a sensor 
domain and response regulator, which are sensitive to environmental signals, such as 
the agr (335), autolysis-related locus arlRS (353), S. aureus exoprotein expression 
saeRS (343)  and staphylococcal respiratory response srrAB (348) systems (see 
section 1.3.4 for more details).  DNA-binding proteins, such as SarA (615) and its 
homologues SarR (369), Rot (616), SarS (372), SarT (617) and SarU (375) also 
regulate virulence factor expression. Subinhibitory oxacillin reduces toxicity directly 
by down regulating RNAIII and δ-haemolysin expression by an as yet unidentified 
mechanism, but it is proposed to affect the cell wall peptidoglycan and interfere with 
auto-inducing peptide signalling (238). The PSMs and δ-haemolysin are regulated 
directly by the Agr system in an RNA-dependent and independent fashion (215). 
Although Agr is important for regulating toxicity and adhesins, many of the other 




Previous studies analysing the effects of subinhibitory antibiotics observed an 
increase in alpha and PVL toxins (594-596). Others have shown that the induction of 
the saeRS system after subinhibitory β-lactam exposure caused an increase in α-
haemolysin at the transcript level using hla::blaZ promoter fusions (618).  saeRS 
differentially regulates many virulence genes but also modulates an additional 22 
genes including sarA and sarT, resulting in reduced transcript levels. Accordingly 
using this model, saeRS induction after subinhibitory oxacillin exposure could 
account for the increase in α-haemolysin and PVL toxin expression, even in the 
context of RNAIII reduction. The effect of reducing sarT transcript levels may also 
increase α-haemolysin expression, as sarT is a repressor of this haemolysin (617). 
The potential decrease in SarA/T may also explain the reduced SpA levels, as SarT 
induces the expression of another SarA homologue, SarS, which directly binds to the 
spa promoter stimulating SpA expression  (372). Work by Dumitrescu et al, 
observed an induction of SarA and a reduction in Rot mRNA levels which conferred 
an increase in PVL expression when grown with imipenem and oxacillin (596). In 
terms of regulatory elements effecting PVL expression, they observed no relevant 
contribution of the saeRS system as opposed to Kuorda et al (618). However 
different strains, β-lactams antibiotics and MIC were used which may trigger 
different signalling pathways affecting different regulatory elements. To understand 
the exact mechanisms causing this oxacillin-mediated pleiotropic effect, specific 
regulatory elements must be assessed in this context under these conditions. These 
experiments using subinhibitory antibiotics highlighted how bacteria differentially 
regulated important virulence genes in response to their environment. These changes 
may help us understand how the complex regulatory network which governs S. 
aureus virulence interacts upon external stimuli.  
 
Exposure of bacteria to sub-lethal levels of β-lactam antibiotics can also lead 
to the activation of several stress responses, most notably the SOS-response (619). 
The SOS system is a global response to DNA damage and is classically governed by 
two major genes: lexA and recA (620). The LexA protein acts as a repressor binding 
to specific operator sites of SOS-regulating genes, inhibiting their expression. In 
response to DNA damage, the RecA protein becomes activated and acts a protease, 
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enabling full cleavage of the LexA protein and this inducing the expression of some 
SOS-regulated genes. The affinity of LexA to each SOS-regualted gene promoter is 
different leading to a temporal expression of genes, where some genes are expressed, 
partially expressed or only expressed under conditions of high or persistent DNA 
damage (621). Once DNA damage has been repaired, RecA and LexA restore 
repression to the system. Previous work has highlighted that induction of the SOS-
response by sub-inhibitory antibiotics can result in the expression of virulence genes 
for example the adhesins, FnBPB (622), or can trigger the induction of 
staphylococcal prophage carrying virulence determinants such as TSST-1 (623). 
Recently it has been shown that sub-inhibitory levels of oxacillin (and other 
antibiotics which target PBP-1) triggers the SOS-response in a lexA/recA dependent 
fashion which lead to an increased mutation rate and selection of homogenous high 
level resistance (624). Therefore it would be interesting to investigate the effects of 
sub-inhibitory oxacilin in a recA mutant to determine whether this SOS-response 
plays a role in modulating toxicity in S. aureus.  
 
Future work to evaluate the potential of other cell-wall-active antibiotics that 
can mediate PBP2a-dependent agr repression will be of interest in the context of 
virulence attenuation, but ultimately, the potential of beta-lactams and related 
antimicrobials as anti-virulence drugs may depend on the site of infection, the          









Identifying virulence associated SNPs in the Genome of 






Staphylococcus aureus employs hundreds of genes which are dedicated to the 
regulation and expression of virulence factors. Virulence is a complex and often 
multifactorial process. This chapter attempts to investigate genetic polymorphisms 
which are associated with a specific virulent phenotype. Toxicity, the ability to 
destroy host cell membranes, and adhesion, the ability to adhere to human tissues, 
are the major virulence factors of many bacterial pathogens, including S. aureus. 
Here, we assayed the toxicity and adhesiveness of 90 closely related MRSA 
(methicillin resistant S. aureus) ST239 isolates derived from four hospitals in 
Turkey. We found that while there was remarkably little variation in adhesion, 
toxicity varied by over an order of magnitude between these isolates, suggesting that 
different evolutionary selection pressures acts on these two traits and that significant 
variation exists within specific S. aureus lineages. To understand the genetic factors 
responsible for this observed variation a genome wide association study was 
performed on the genomes of these 90 clinical isolates. 124 single nucleotide 
polymorphism (SNPs) and insertion/deletions (InDels) were identified to be 
associated with toxicity. By using a transposon mutagenesis library we highlight four 
novel genetic loci associated with a decrease in toxicity, underlying the applicability 









taphylococcus aureus is a major human pathogen, the treatment of which has 
been complicated by the worldwide emergence of multiple lineages that 
have acquired resistance to methicillin (275, 276, 296). Its virulence is 
conferred by the activity of many effector molecules (reviewed in section 1.3.5) 
which can be broadly grouped into being either toxins – factors that cause specific 
tissue damage in the host, or adhesins – factors that facilitate adherence to and 
invasion of host tissues. A complex network of regulatory proteins controls the 
expression of many individual toxins (reviewed in section 1.3.4) such that various 
sites on the S. aureus chromosome contribute to the overall toxicity of an individual 
isolate. The ability of S. aureus cells to bind human glycoproteins, such as fibrinogen 
and fibronectin, is another critical determinant in disease outcome. It facilitates 
attachment to and damage of host tissues, host cell invasion, and systemic 
dissemination (404). Several genes encode fibronectin- and fibrinogen-binding 
proteins (e.g., fnbA, fnbB, clfA, clfB, eap, isdA, emp, ebh, see table 1.1.), whose 
expression is again controlled by a complex regulatory network (96). Similar to 
toxicity, many sites on the chromosome can therefore contribute to the overall 
adhesiveness of S. aureus, with many regulators common to both adhesion and 
toxicity (96).  
 
A key factor affecting the severity and outcome of any infection is the 
virulence potential of the infecting organism. Since the first whole genome sequence 
of a free-living organism, Haemophilus influenzae, was published (625) sequencing 
technology has advanced to a stage where a bacterial genome can be sequenced in a 
matter of hours (479, 626). This has led to an explosion of genomic data that has 
revolutionised molecular epidemiology allowing the close monitoring of outbreaks in 
hospitals (224, 225, 627), tracking strains transitioning from carrier to invasive status 
(627), and performing detailed epidemiological studies to understand aspects of 
pathogen biology (180, 241, 628, 629). This huge advancement in sequencing 
technology and what can be done with the ensuing enormity of genomic data 





 If the virulence phenotype could be determined directly from its genome 
sequence, next generation sequencing technology would provide for the first time an 
opportunity to make predictions of virulence at an early stage of infection. While 
there has been some success in predicting the antimicrobial resistance from the 
genome (241, 630) complex phenotypes such as virulence, involving the contribution 
of several genes, as discussed above, has not yet been possible. The success of 
epidemic MRSA clones such as USA300 and ST239 may be attributed to the 
variation in the expression of their toxin or adhesion genes, presumably through 
modification of the main virulence regulatory genes. The ability to identify virulence 
associate genetic polymorphisms may help firstly in unravelling the complex genetic 
regulatory network, highlighting which regulators and specifically which residues are 
important in cross regulation, but could also be implemented in a predictive model, 
which may infer virulence directly from the genome sequence.  
 
 Here we addressed this by first adopting a direct approach analysing the 
sequence variation in virulence regulators from a diverse collection of sequence 
types (STs) in an attempt to explain why strains from different STs are more virulent 
than others. We investigated the impact of SNPs on the SarS virulence regulator, 
known to be important in the regulation of protein A. The second approach used a 
more general approach, measuring the lytic and adhesive potential of a collection of 
90 closely related ST239 MRSA clinical isolates derived from four hospitals in 
Turkey. ST239 contains a type III SCCmec element and is a highly transmissible, 
highly antibiotic resistant MRSA clone, which is associated with a strong biofilm 
phenotype and enhanced ability to adhere and invade airway epithelial cells (631). 
Epidemiological studies suggest that at least 90% of the cases of HA-MRSA within a 
geographical region encompassing >60% of the world’s population can be attributed 
to this single clonal subgroup (234, 632, 633). ST239 has evolved through a large 
scale recombination event, involving the construction of a mosaic chromosome 
composed of a majority CC8 genetic background while approximately 20% of the 
genome is derived from a CC30 lineage (634). To investigate genetic polymorphisms 
associated with virulence we adopted a genome-wide association study (GWAS) 
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which highlighted novel loci which were associated with either an increase or 
decrease in toxicity. Using this information we were able to functionally verify four 
novel loci which when inactivated resulted in a decrease in toxicity. 
 
 
7.3 Results and Discussion 
__________________________________________________________________________________________ 
 
7.3.1 Investigating the effect of SNPs in the virulence regulatory 
activity of SarS 
 
A bioinformatics approach addressing the sequence variability within the virulence 
regulatory genes across ten S. aureus strains that represented a diverse collection of 
sequence types highlighted two strains (MRSA252 and TW20) which contained two 
SNPs in the virulence regulator SarS (96). These SNPs conferred an asparagine-to-
aspartic acid substitution at positions 221 and 243. Additionally, mapping of the 
SNPs onto the crystal structure of the SarS protein confirmed that these SNPs were 
localised within a region predicted to interact with RNA polymerase (96). Given the 
change in local charge associated with the above N221D and N243D mutations, an 
investigation into the effect of these polymorphisms on SarS regulatory activity was 
examined. As described in section 1.3.4.3, SarS is a DNA binding regulatory protein 
which induces the expression of protein A by directly binding and activating the spa 
promoter (372). Therefore, we investigated the regulatory potential of WT SarS and 
SarS containing the above SNPs using protein A expression as an indication of SarS 
activity (Fig 7.1). Both genes were cloned into the inducible plasmid, pRMC2, and 
electroporated into a sarS knockout strain, ALC1927, creating ALCML1 (WT SarS) 
and ALCML2 (N221D & N243D SarS) (Table 7.1). Probing for protein A 
expression as an end-stage measure of SarS activity illustrated no detectable 
difference via western blot analysis (Fig 7.1). A series of concentrations of the 
inducible chemical (10-100 nM; anhydrous tetracycline) was used to investigate any 
minor changes which may have been masked due to high expression of SarS from 
the plasmid resulting in high protein A expression, but again no differences were 
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observed, suggesting that these two SNP changes did not affect the ability of SarS to 
induce protein A expression.  
 
 
Figure 7.1: Investigating the effect of SNPs in the virulence regulatory activity of SarS by 
analysing protein A expression via western blotting. WT SarS and SarS containing the N221D & 
N243D SNPs were cloned into the pRMC2 plasmid and transformed into the sarS knockout 
ALC1927, generating ALCML1 and ALCML2 respectively. Analysis of protein A expression using a 
series of concentrations of the inducible chemical revealed no difference in the protein A expression. 
ALCML1 is designated * and ALCML2 is designated ‡. 
 
 
7.3.2 Analysis of toxicity and adhesiveness between closely related 
ST239 strains  
 
As the direct approach in identifying SNPs important in virulence did not yield 
positive results we opted to look more broadly for the effect of SNPs on virulence 
across the whole genome. In order to investigate this, we chose to look within a 
single clone as there would have been too much variation across many different 
clones. The strain collection chosen was previously described by Castillo-Ramiriez et 
al and comprises of 90 clinically derived ST239 strains, isolated from one of four 
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hospitals in Turkey. These strain have been previously sequenced using an Illumina 
Genome Analyser with 75 base paired-end reads and mapped onto the chromosome 
of S. aureus TW20 (180).  
 
To investigate SNP association with virulence, we first assayed the ability of 
90 closely related clinically derived ST239 strains to bind two important matrix 
proteins, fibrinogen (Fb) and fibronectin (Fn) during both the exponential and 
stationary phase of growth (Fig 7.2 a-d). As expected the adhesiveness was higher in 
the exponential phase of growth. However, across the 90 isolates only two were 
significant from the others (DEU16 and HU2) with strain HU2 retaining the adhesive 
phenotype during stationary phase. The limited variability of this virulence 
phenotype suggests it may be under strong stabilizing selection and would provide 
limited information on which to base a prediction of disease severity. Comparing the 
core genomes of DEU16 and HU2 with the reference strain, TW20, highlighted no 
mutation in any of the known virulence regulators, adhesin genes or proteases which 
may account for the highly adhesive phenotype. Results of gene association studies 
were inconclusive in providing statistically significant SNPs associated with high or 






Figure 7.2: Adhesive activity of clinical ST239 isolates. (a) adherence of 90 ST239 isolates to 
fibrinogen in exponential phase of growth. (b) adherence of 90 ST239 isolates to fibronectin in 
exponential phase of growth. (c) adherence of 90 ST239 isolates to fibrinogen in stationary phase of 
growth. (d) adherence of 90 ST239 isolates to fibronectin in stationary phase of growth. 
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Secondly, the gross lytic activity of the 90 ST239 isolates was measured using the T 
cell assay and vesicle lysis test (VLT) described previously. As illustrated in the 
previous chapters, the T cell assay is sensitive to α- β-, γ-, δ-haemolysins and 
PSMα1-3 peptides whereas the vesicles are sensitive to the δ-haemolysin and 
PSMα1-3 toxins. No differences were observed between the two assays, illustrated in 
figure 7.3a, where the data from each assay from a representative sample of seven 
high and seven low toxic isolates is presented. This suggests the effect is either 
largely PSM driven for the ST239 clone, or that the toxins assayed here are co-
regulated. Due to the important role α-haemolysin plays in in vivo pathogenesis we 
also investigated the expression of this toxin from this set of clinical strains; however 
no α-haemolysin was detected, illustrated here by a western blot negative phenotype 
in a subset of strains both of high and low toxic background (Fig 7.3b).  
 
 
Figure 7.3: ST239 supernatants lyse T cell and vesicles equivalently and do not express α-
haemolysin. A) The ST239 MRSA isolates used in this study lysed T cells and lipid vesicles 
equivalently. A subset of 14 isolates is shown for illustrative purposes. Their ability to lyse T cells is 
represented in blue and on the left hand Y axis, and their ability to lyse the lipid vesicles is represented 
in red and on the right hand Y axis. B) The ST239 isolates used in this study do not express detectable 
amounts of α-haemolysin. Western blots using anti-α-haemolysin antibodies were performed on TCA 
precipitated 18h bacterial supernatants of all 90 isolates. A subset of seven isolates is shown for 
illustrative purposes. As a positive control the laboratory strains 8325-4 was included as it produces 
detectable amount of α-haemolysin. 
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The full set of toxicity data from the vesicle assay is presented in figure 7.4a. Despite 
the lack of α-haemolysin expression, many isolates were highly lytic and the 
combined activity of the other toxins varied widely between the 90 isolates, with an 
18-fold difference between the most and least toxic isolates. Interestingly, both the 
highly adhesive isolates identified above expressed low level toxicity. (NB: This 
clone does not contain the Panton-Valentine leukocidin [PVL] containing phage 
(180)).  
 
To understand how differences in toxicity are distributed across the genetic 
variability that exists within this collection of isolates we divided the data into three 
classes, scoring isolates as expressing either high (red: levels of >63,000 units), 
medium (amber: levels of 30,000:63,000 units) or low (green: levels of <30,000 
units) toxicity. These three data ranges were selected so that a mid-toxicity range was 
included to account for possible cumulative effects of genetic polymorphisms. This 
was mapped onto a maximum likelihood tree based on the genome sequences of 
these isolates, showing a broad distribution of toxicity phenotypes across the 
genotypes as well as some clustering (Fig 7.4b; this figure was constructed by Dr. 








Figure 7.4: Toxic activity of clinical ST239 isolates. (A) The toxic activity of 90 ST239 isolates was 
assayed by incubating their supernatants with lipid vesicles containing a fluorescent dye. Dye release 
due to toxin-mediated vesicle lysis is determined using a fluorometer. (B) A maximum likelihood tree 
based on whole-genome sequences of the 90 isolates illustrating the distribution of the toxic activities 
of each isolate. Toxicity has been colour-coded (red for highly lytic, yellow/amber for moderately 
lytic and green for low level lysis). Clusters 1–4 are indicated for use in the stringent GWAS analysis. 
 
 
7.3.3 Toxicity correlates with disease severity in vivo 
 
To verify that toxicity correlated with disease severity, two isolates shown to have 
the highest and the lowest levels of toxicity in vitro (HU13 and MU9, respectively) 
were selected and their in vivo pathogenicity compared in a model of invasive 
infection (635). Mice were injected intravenously with two different inoculum sizes; 
and murine survival, the development of septic arthritis, and weight loss were 
monitored over two weeks as a measure of disease severity (Animal experiments 
were carried out by Dr. E. Josefsson, University of Gothenburg, Sweden). 
Uninfected control mice did not die, did not develop septic arthritis, and did not lose 
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weight over the duration of this experiment. In each aspect of disease measured here, 
the highly toxic HU13 isolate caused the most severe disease symptoms (Fig 7.5a-f). 
It led to more deaths at both doses, although this was not statistically significant, 
caused significantly more severe arthritis at both doses at day 4, and resulted in 
significantly greater weight loss at both doses across many time points.  
 
The isolates tested here are from the same sequence type but are not isogenic, 
and so other virulence-related traits may have played a role in the disease outcome. 
However, as toxicity is well established to affect disease severity, its variability even 
within this closely related group of isolates suggests that the ability to predict toxicity 






















Figure 7.5: Predicted toxicity correlates with disease severity in vivo. Using high and low doses 
(7.8–8.0 and 3.7–4.1 x 107 CFU, respectively), mice were inoculated intravenously with the high and 
low toxic isolates (HU13 and MU9, respectively), and survival of the mice, the development of septic 
arthritis, and weight loss were recorded as indications of disease severity. In each case the highly toxic 
HU13 isolate caused the most severe disease symptoms. (A) n = 10–15. (B) n = 8–10. (C) n = 10–20. 






7.3.4 Identifying virulence associated loci 
 
To identify the genetic polymorphisms that may be associated with the toxic 
phenotype, a genome-wide association study (GWAS) was adopted on the genomes 
of the 90 S. aureus isolates using the genome association tool Plink (467). Out of a 
total of 3060 SNPs, we identified 102 that associated significantly with toxicity (with 
P <0.05 after Bonferroni correction) as shown in figure 7.6 and listed in table 7.1 
(polymorphisms associated with an increase in toxicity) and table 7.2 
(polymorphisms associated with a decrease in toxicity), using a frequency cut off for 
the occurrence of a polymorphism across the population of >90% and a minor allele 
frequency of >5%.  We further identified 22 toxicity associated InDels, using the 
same cut offs for quality control. These SNPs and InDels were distributed across the 
genome amongst mobile genetic elements, genes involved in metabolism and 
regulation, in hypothetical genes, and in intergenic regions (Table 7.1 and 7.2). Two 
genes previously shown to affect the expression of toxins contained significantly 
associated SNPs: mecA (238) and agrC (636, 637) which provided some proof of 
principle for the validity of our approach. Mobile genetic elements, such as the S. 
aureus pathogenicity Island I (SaPI1) (196) and the β-haemolytic converting phage 
(638) also contained several associated genetic changes, implying that variability in 
many diverse regions of the genome contributes to the toxicity of a given isolate. 
Some of the polymorphisms appeared to be in linkage disequilibrium which will 
increase the rate of false positive associations, but many were uniquely occurring 
(i.e., unique patterns of polymorphisms across isolates).  
  
 This GWAS approach only requires an excess association between a SNP and 
the phenotype in question, and as such is likely to produce false positives with 
linkage disequilibrium and phylogenetic structure affecting the outcome. We 
therefore performed a second, more stringent approach, similar to those described in 
other recent work (630, 639) which instead requires repeatable independent evolution 
of a marker to be associated with the phenotype (toxicity). Although this approach 
should have a lower false positive rate, it is likely to produce a higher false negative 
rate. We focused on four clusters of isolates (indicated on Fig 7.4b): cluster 1 
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(isolates IU20–IU2), cluster 2 (isolates HU16–HU13), cluster 3 (isolates MU2–IU7), 
and cluster 4 (isolates DEU3– DEU19). Clusters 1 and 2 contained the majority of 
the highly toxic isolates in this study, whereas clusters 3 and 4 represent the closest 
related clusters of low toxicity isolates to clusters 1 and 2. When toxicity-associated 
polymorphisms are found in both clusters 1 and 2 but are absent from clusters 3 and 
4 suggest that they have arisen independently. As such they are likely to be causative 
as they are independent of phylogeny. Of the 124 polymorphic sites that associated 
significantly with toxicity, only four were found in both high toxicity clusters (1 and 
2) but not in their sister, low-toxicity clusters (3 and 4). All four of these 
polymorphisms (SNPs 78396, 2128192 and InDels 2111134 and 2147199, see 
Tables 7.2 and 7.3) reside on mobile genetic elements, suggesting they may have 
been acquired horizontally. Of these four polymorphic loci, the mecA gene (in which 
SNP78396 resides) confers methicillin resistance and has previously been shown to 




Figure 7.6: Identification of SNPs significantly associated with toxicity. GWAS was used to 
identify toxicity associated SNPs; shown here on the X axis which represents the S. aureus genome 
with 0 representing the origin of replication and the Y axis representing the statistical significance of 
each SNP associating with increased or decreased toxicity. Using a cut-off of –log (p) of 5 (illustrated 
by red dots representing a p<0.05 after Bonferroni correction) left 104 SNPs and 20 InDels 






Table 7.2 Polymorphisms associated with an increase in toxicity  
 
 
Table 7.3 Polymorphisms associated with a decrease in toxicity 
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7.3.5 Functional verification of effect of polymorphisms on toxicity  
 
Two SNPs (78119 and 78396) which were hypothesised to affect toxicity were 
present in the mecA gene, which codes for the alternative penicillin binding protein 
2a. Recently, the deletion of the SCCmec element from a HA-MRSA background 
drastically affected toxicity leading to a statistically significant increase in toxicity 
measured by the T cell assay (238). Complementation of this strain with the mecA 
gene expressed from an inducible plasmid restored the non-toxic phenotype 
illustrating that mecA negatively affected toxicity. The exact mechanism for this 
repression is unknown but does involve agr interference possibly through 
peptidoglycan modifications imposed by PBP2a (238). Therefore, we sought to 
investigate the contribution of these SNPs to toxicity. As described in section 2.5.3, 
four mecA genes were amplified, cloned into the inducible plasmid pRMC2and 
electroporated into the SCCmec deletion mutant BHICCΔSCCmec. Four mecA 
constructs were required due to SNP78119 and SNP78396 only occurring in mecA 
genes which already had two SNPs present which differed from the WT, which were 
SNP78097 and SNP78222. These SNPs were not highlighted as modulating toxicity 
from the GWAS studies. Nonetheless we constructed pRMC2 containing TW20 WT 
mecA (pmecA1; ML122), TW20 mecA containing SNPs 78097 & 78222 (pmecA2; 
ML123), mecA containing the SNPs of pmecA2 and SNP78396 (pmecA3; ML124) 
and mecA containing the SNPs of pmecA3 and SNP78119 (pmecA4l ML125). All 
strains containing the mecA plasmid constructs when induced conferred resistance to 
oxacillin up to128 μg/mL when induced with anhydrous tetracycline and therefore 
were considered to be expressing the PBP2a, whereas those induced with the empty 
plasmid (pRMC2; ML121) did not (data not shown). However, toxicity did not differ 
significantly from strains expressing the 4 different mecA alleles suggesting that 
these two SNPs were not involved in increasing toxicity (Fig 7.7). Interestingly, 
unlike previous work in the laboratory where the BH1CC mecA gene was used to 
restore methicillin resistance, none of these mecA genes when used to complement 
the SCCmec mutant restored the non toxic phenotype. The sequence of mecA from 
TW20 differs from mecA derived from BH1cc (CC8) in three positions (K146N, 
K204N and E246G, whereby the first amino acid is found in TW20 at the indicated 
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position and the second amino acid is present in BH1cc). This suggests that mecA 
from different SCCmec backgrounds may differentially regulate toxicity.      
 
 
Figure 7.7: Effect of mecA SNPs on toxicity. pmecA constructs were electroporated into a 
BH1ccΔSCCmec background to assess the affect of mecA SNPs on toxicity using the T cell assay.  
Deletion of SCCmec leads to a decrease in T cell survival (an increase in toxicity). Complementing 
this strain with 4 different mecA alleles did not restore a non-toxic phenotype nor illustrate a 
difference between the mecA alleles. 
 
  
With the initial GWAS approach likely to produce a high number of false positive 
associations, we sought to obtain an estimate of this by determining the functional 
effect of a subset of these polymorphisms. We focused on 14 of the intergenic 
polymorphisms that could either affect the transcription of neighbouring genes, or 
encode novel regulatory RNA molecules. We obtained transposons insertions in 
these intergenic polymorphic loci, ranging from 10 to 304 bp distal to the 
polymorphic site from the Nebraska Transposon Mutant library (640), and 
determined the effect of this insertion on the toxicity of the mutant. The transposon 
(Tn) library was constructed in the USA300 LAC background cured of plasmids 
(JE2 strain) using a mini-mariner bursa aurealis plasmid containing a transposon 
region, generating random mutations in S. aureus. This delivery vector contains and 
erythromycin resistance gene (ermB) for selection and AciI sites used for cleavage of 
DNA isolated form Tn clones. Cleavage of AciI sites closest to the insertion sites 
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occurs and DNA is circularized and amplified by inverse PCR using primers 
complementary to regions on the Tn insertion site. Sequencing of the genomic 
regions identifies site of disruption (640).   
 
Five of the 14 insertions affected toxicity (Fig 7.8a) verifying that these loci 
contain toxicity-regulating activity. The SNP at position 301,089 (represented by the 
transposon insertion in strain 95E07 in Fig 7.8) is in between the tarK and tarF genes 
that are involved in the synthesis of wall teichoic acids (641). The SNP at position 
1,121,452 (represented by the transposon insertion in strain 207A03 in Fig 7.8) is 
between a hypothetical gene and fmt, which is involved in methicillin resistance and 
autolysis (642) both activities known to contribute to staphylococcal virulence. The 
SNP at position 1,503,110 (represented by the transposon insertion in strain 90D01 
in Fig 7.8) is in a locus annotated as a pseudogene in TW20, but as intergenic 
between genes encoding a TelA-like protein and a putative branched-chain amino 
acid transporter protein in FPR3757. The SNP at position 2,532,617 (represented by 
the transposon insertion in strain 108B09 and 184F11 in Fig 7.8) is annotated in 
FPR3757 as intergenic between a hypothetical and an AcrB/AcrD/AcrF family 
protein-encoding gene; however, in TW20 it has been annotated as a hypothetical 
gene. To determine more specifically the effect these transposons have on specific 
expression of toxins we examined their protein expression profiles. As shown in 
figure 7.8 b-d, the protein profiles, α-haemolysin and PSM expression are 
significantly affected in two strains with more subtle differences in the others. The 
two with significant effect were108B09 and 184F11 are in the same locus and further 
molecular characterization is underway to determine the activity of these loci, but 
this work demonstrates that although this approach produces false positive 








Figure 7.8: Functional verification using transposon mutagenesis. A) Mutated S. aureus isolates 
with transposon insertions in 15 of the 124 toxicity associated loci were isolated (all in intergenic 
loci). Four of the 15 transposon insertions affected the toxicity of the isolate. The bars represent the 
mean % T cell survival following incubation with bacterial supernatant, and the error bars the 95% 
confident intervals. Wild type represents the unmutated parent isolate, ΔagrB is a negative control, 
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and the following are the transposon insertion mutants and their associated polymorphism: 95E07: 
301089; 93B09: 761112; 82B04: 787629; 180A03: 799276; 207A03: 1121452; 90D01: 1503110; 
137C12: 1931155; 45D06: 2027204; 179E03: 211134; 108B09: 2532617; 113D01: 2571739; 86C03: 
2640325; 168E05: 2657438; 72A04: 2753734; 64A09: 2810368. B), C) and D) represent the 
exoprotein profile, α-haemolysin and PSM expression respectively of the wild type and toxicity 
deficient strains highlighted from the T cell assay. * highlights that these strains contain a Tn insertion 
in close proximity to each other.  
 
 
As the more stringent approach described above yielded a shortlist of only four 
toxicity-affecting polymorphisms, we also sought to determine whether this 
approach, while reducing the false positive rate, would inadvertently dismiss 
potentially important loci. For example, a SNP in the agrC gene was identified by 
the initial approach as significantly associated with toxicity, but dismissed by the 
secondary more stringent approach. This protein forms part of a critical toxin 
regulatory system (reviewed in section 1.3.4.1), and the SNP results in an A343T 
change to the amino acid sequence of the protein. The particular nucleotide change 
described here had not been identified previously, although other polymorphisms in 
the agrC gene have been shown to delay activation of the Agr system and as a 
consequence reduced the toxicity (475). Using a reporter system the impact of 
SNP2174068 on the function of AgrC was evaluated with respect to activation by 
exogenous AIP 315 (643) (This agr reporter system experiment was constructed by 
Dr. Tim Sloan at the University of Nottingham, United Kingdom). The response of 
AgrC from the ST239 isolate TW20 was compared with the AgrC encoded by the 
SNP2174068 containing agrC variant, by determining the half maximal effective 
concentration (EC50) of exogenous synthetic AIP-1 for both (Fig 7.9). The EC50 for 
the TW20 allele was 17.4 ±3.5 nM, but almost twice as much AIP (29.5 ±3.1 nM) 
was needed for the SNP2174068 containing AgrC variant, which suggests that, like 
previously identified polymorphisms in agrC, SNP2174068 delays the activation of 
the Agr system and as a consequence reduces toxicity. This work functionally 
verified the contribution of this particular polymorphism to the toxic phenotype, 






Figure 7.9: SNP2174068 has a major impact on the response of AgrC to AIP and hence toxicity. 
Dose-response curves for the activation of the lux based agrP3 reporter via AIP-1 by the TW20 agrC 






Antibiotic-resistant bacteria are a major global threat to human health. The rate at 
which these organisms acquire resistance to new drugs is such that it is clear that 
novel methods to control disease are required. A greater understanding of bacterial 
virulence is needed to develop such novel control strategies. While new 
antimicrobial compounds are being developed, the introduction of novel drugs into 
the hospital population will undoubtedly select for resistance, highlighting the need 
for clinicians to be able to tailor treatment to the specific requirements of the 
infection. Currently, there is progress in the development of identifying antibiotic 
resistance genes from the microbial genome; however there are no methods in place 
to understand the virulence potential of an infecting strain.  
 
 The production of toxins and the ability to adhere to host proteins are major 
contributors to microbial virulence. Initially, in an effort to understand how genetic 
polymorphisms affect virulence and how this information could be used in 
developing new ways to understand and control disease, experiments were designed 
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to assess the role of SNPs in known virulence regulators. Here we investigated the 
effect of mutations in SarS, an important transcription factor involved in regulating 
protein A. In these experiments we found no difference in the ability of wild type 
SarS and SarS containing the SNPs of interest to activate protein A expression. In a 
separate, more general approach we sought to determine the toxicity and adhesive 
activity in a set of 90 clinical ST239 strains. Although little variation in adhesiveness 
was observed, toxicity varied substantially and to our knowledge this was the first 
time such variation was observed within a single clone of S. aureus, thus, 
understanding the genetic basis of this variation became the main focus of this 
chapter.  
 
 GWAS has been used extensively to identify disease loci associated with the 
five most common cancer types (644). Although phylogenetic structure may affect 
the application of this to a prokaryotic system, GWAS is still a useful tool to identify 
candidate virulence affecting loci. Bacteria possess a single chromosome and have 
high mutation rates enabling the phenotypic effects of these mutations to be detected 
immediately. Furthermore, bacteria readily undergo horizontal gene transfer which is 
independent of phylogeny. Taking these considerations into account we used GWAS 
to investigate the association of genetic polymorphisms with toxicity resulting in 124 
polymorphisms (102 SNPS and 22 InDels) significantly associated. Initially we 
anticipated that the majority of the polymorphisms associated with a change in 
toxicity would be present in the known virulence regulators. However, only one SNP 
(2174068) associated and verified with a decrease in toxicity was found in the agrC 
gene, a histidine kinase known to be a central component in toxin regulation (329). 
Surprisingly, SNPs associated with toxicity variation were found in diverse regions 
on the chromosome, with many of them never been associated with toxicity or 
virulence before. A more stringent analysis was also used and reduced the number of 
SNPs to a more manageable number, highlighting only four candidate loci. While 
this is an easier number to functionally verify, at least one functional locus (agrC 
SNP) was lost by this method. Although one method produced a high rate of false 
positives and the other dismissed potentially important loci, both have proven to be 
informative. When we attempted to functionally verify a subset of loci (n = 13) from 
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the long list of 121 by testing transposon insertion mutants in these regions, four 
proved to have toxicity regulating activity. This provided an indication of the false 
positive rate associated with the GWAS approach, and demonstrated that it is an 
effective means of prioritizing candidate genes for further functional 
characterization.  
 
 The results of this chapter have shown that virulence regulation, particularly 
in toxin expression, is highly complex. In addition to the already intricate virulence 
regulatory system discussed in section 1.3.4 the results of this chapter suggest that 
there is an added layer of virulence regulation yet to be defined. Transposon insertion 
within the intergenic regions outlined in section 7.3.5 caused a statistically 
significant reduction in toxicity. Based on the location of this region and preliminary 
analysis of the sequence of this site illustrating a high level of secondary structure in 
the single stranded form, we hypothesise that the Tn insertions lead to inactivation of 
small noncoding RNA molecules (sRNAs) which are playing a role in modulating 
global toxicity. Generally sRNAs regulate gene expression by either base-pairing 
with target mRNAs in an anti-sense mechanism preventing translation and assisting 
degradation of the target RNA or interact with proteins and modify their activities 
(394). This represents a rapid method of gene regulation and future work into 
unravelling these structures is underway.  
 
 The identification of SNPs and InDels associated with variation in toxicity 
has been used in the development of predictive models designed to assess the toxic 
phenotype of clinical isolates solely from the genomic sequence (645). Here a 
machine learning algorithm has been used to run a series of decision trees based on 
the presence of significant polymorphisms associated with toxicity to generate a 
predication on the likely phenotypic outcome. The results are promising with the 
majority of isolates predicted correctly. This approach of toxicity prediction is an 
attractive control strategy, as knowledge of the virulence potential of an infecting 
organism allows for the patient to be isolated, administered with virulence-
modulating antibiotics and monitored more stringently for potential complications. In 
summary, the identification of SNPs associated with phenotypic variability can be 
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used in identifying new virulence regulatory circuits and developing new control 
strategies, with future work in fully characterising these genetic polymorphisms and 


































Burn injury represents one of the most frequent causes of hospitalisation. Globally in 
2004, approximately 11 million people required medical attention due to burn trauma 
(646). Infection complications following burn injury account for 75% of burn-related 
deaths (3, 4). Two major factors contribute to the predisposition of burn victims to 
infection: firstly the skin and gastrointestinal epithelium barrier fails, which can lead 
to bacterial translocation and subsequent burn wound infection derived from the 
patients’ endogenous flora. Secondly, the immune system becomes dysfunctional, 
expressing anti-inflammatory mediators which can interfere with immune cell 
(PMNs and macrophages) microbial killing potential. Therefore, the natural barriers 
to infection in the burn victim are distorted resulting in colonisation by opportunistic 
microorganisms.  
 
 S. aureus and P. aeruginosa are regarded as the most frequent burn wound 
colonisers. Currently, there is no burn wound dressings which can report on the 
microbiological content of the burn. The Bacteriosafe project was established to 
address this medical requirement. The objective of the Bacteriosafe project was to 
develop a smart wound dressing that would signal infection in a burn wound through 
the development and immobilisation of novel nanocapsules onto specific wound 
dressings.  
 
In this thesis the use of phospholipid vesicles (vesicles) as the core 
nanocapsule central in the smart dressing, is described. Vesicles are produced 
naturally in the body, consisting of a lipid bilayer membrane trapping a specific 
solution, generally used for transport within the cells (transport vesicles) or for 
housing enzymes important in cellular or microbial digestion (lysosomes). Vesicles 
used in this project are synthesised through sonication and extrusion of a cocktail of 
synthetic phospholipids, cholesterol and polydiacetylene molecules. These vesicles 
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are formed in a solution of self-quenchable fluorescent dye which remains non-
fluorescent in intact vesicles.  
 
A major contributor to the pathogenic success of S. aureus and P. aeruginosa 
is the ability to secrete membrane damaging factors.  The active secretion of bacterial 
cytolytic exofactors is also fundamental in the application of this microbial signalling 
system. Here, the vesicle represents a mimic of the eukaryotic membrane, susceptible 
to bacterial mediated lysis culminating in the release and switch on of the fluorescent 
cargo, which can be observed and measured. The identification of the bacterial 
factors which resulted in vesicle lysis is critical to the development of a smart 
dressing. Both S. aureus and P. aeruginosa secrete a number of factors which could 
have been important in lysing the vesicle membrane. In this thesis we highlight the 
role of molecules with surfactant-like properties; the phenol-soluble modulin (PSM) 
peptides α1-3 and δ-haemolysin secreted from S. aureus and the glycolipid molecule, 
rhamnolipid (RL), from P. aeruginosa as the sole agents in rupturing vesicles.  
 
δ-haemolysin is the translatable product of rnaIII, the effector molecule of 
the accessory gene regulator (agr) system, which is involved in the up-regulation of 
toxins/enzymes in S. aureus. The importance of Agr in disease progression in animal 
models is well documented. Therefore, this toxin is a prime candidate in which to act 
as a trigger for a microbial sensing system (i.e. the smart wound dressing) as 
expression of rnaIII appears to be a conserved feature required for S. aureus 
pathogenesis. This conserved expression of δ-haemolysin is represented by the high 
percentage of clinical isolates (96.6%) that caused vesicle lysis (Fig 3.4). This toxin 
is also involved in measuring the activity of agr using the CAMP assay. In chapter 3 
we highlight the use of the Vesicle Lysis Test (VLT) in measuring agr activity. Our 
results suggest that the CAMP assay is not sensitive enough to fully discriminate 
between agr positive and negative strains and therefore over- represents agr-negative 
strains and thus agr dysfunction.  These results may have important clinical 
implications as it has been reported that agr dysfunction is associated with increased 
vancomycin resistance and persistent bacteraemia (474, 476, 477). Many of these 
studies used the CAMP assay as the sole measure of agr activity. For this reason it 
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would be interesting to see whether the same associations are confirmed using the 
more sensitive VLT.  
 
Using vesicles to investigate the lytic potential of toxins is well documented. 
In the second part of chapter 3 we demonstrate that the PSMα and β class of PSMs 
have different lytic activities. The pattern of lysis observed using vesicles outlined in 
this thesis is similar to that observed using immortalised T cell line (Figure 6.4b). To 
investigate why such differences in lysis were observed in such related peptide 
toxins, we analysed some of the structural parameters of the PSMs and highlighted 
the alpha helicity of the peptide through circular dichroism measurements as the 
single most important factor involved in vesicle, and by extension, cell lysis. 
Recently, we have shown that the percentage of cholesterol in the membrane plays a 
major role in the ability of PSMs to lyse vesicles (647). We hypothesise that 
cholesterol shifts the membrane form a liquid disordered to a liquid ordered state, 
making the lipid membrane more stable and less susceptible to PSM integration and 
permeablization. The results of these experiments may help to explain why PSMs 
lyse certain cells more efficiently than others, considering that no proteinaceous 
receptor is known to be involved.  
 
RL were identified as the only P. aeruginosa factor lysing vesicles. Like δ-
haemolysin and PSMs, this molecule has a surfactant-like property enabling the rapid 
solubilisation of membranes. In chapter 4 we highlight the development of a novel 
assay designed to measure RL directly from the supernatant. As with δ-haemolysin, 
we wanted to examine the percentage of P. aeruginosa clinical strains that expressed 
RL that was detected by our vesicles system. Interestingly, we show a significant 
difference in RL expression from strains derived from acute infections (wound and 
bloodstream) and chronic infections (cystic fibrosis patients) (Fig 4.5). This assay 
may be useful in quantifying RL expression from strains isolated from different 





As described previously, two parameters are essential for a working vesicle 
signalling system: sensitivity and stability. The results reported in this thesis show 
that the vesicles are more sensitive to bacterial factors than eukaryotic cells. This 
suggests that in a wound environment if toxins are actively secreted and can diffuse 
to the signalling system then vesicles would lyse first and would signal infection 
before the onset of cellular and tissue destruction. These factors (δ-haemolysin/PSMs 
and RL) are also very important in biofilm formation and maintenance. Current 
unpublished work form our group has shown that our vesicles also respond to 
microbial biofilm growth, important as biofilms have been recently implicated in 
burn infection (102-104). In chapter 5 we demonstrate that the proposed repressive 
role of toxic shock syndrome toxin-1 (TSST-1) on global exoprotein expression not 
only has no impact on vesicle lysis but does not appear to down-regulated toxin 
production. Considering that TSST-1 has been implicated in rapid mortality in young 
burn victims, our in vitro experiments show that TSST-1 expression occurs at the 
same time or after the expression of toxins suggesting that if this is reflected in a 
burn wound, vesicles will lyse and respond before or at the same time as TSST-1 is 
expressed. As a group we have investigated the impact of different environmental 
conditions on the stability of vesicles. Various temperature, pH and stability in 
human serum and in the presence of growing skin cells (HaCATs) has been 
examined extensively with high levels of stability shown (165, 456).  
 
However, they are also limitations associated with this vesicle signalling 
system which require attention. Although toxicity contributes to pathogenesis, the 
results shown in chapter 7 highlight that strains within certain S. aureus lineages 
have low or no toxin production. Here we show that 70% of a set of related clinical 
ST239 strains were shown by the vesicle lysis assay as non-toxic and would not 
signal infection in a burn wound in which a vesicle-based smart dressing was 
applied. Future work requires analysing the toxicity associated with burn wounds 
isolates. It would be interesting to further determine the epidemiology of burn wound 
isolates, whether a specific S. aureus lineage is dominant in burn wounds, to 
compare the toxicity of strains isolated from burn wounds and other diseases 
(abscess/bacteraemia/SSTI) and to what extent strains isolated from burn wounds are 
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MSSA, MSSA, HA- or CA-MRSA. Other burn wound colonisers such as Klebsiella 
pneumoniae and Acinetobacter baumannii do not express vesicle lysing agents (data 
not shown) and therefore would not signal infection in a burn wound using this smart 
wound dressing, highlighting another limitation. However, in spite of this, vesicle 
signalling infection of the most common burn wound colonisers is still an advantage 
over current systems in use. Presently we do not know the diffusion constant of these 
toxins through a hydrogel; an important consideration as these vesicles will be 
immobilised within a hydrogel for improved stability and shelf-life. Preliminary in 
vitro experiments show switch on of vesicles within this hydrogel triggered using 
bacterial supernatant however how this will act within a wound is currently 
unknown.  
 
Although vesicles are stabile in human serum, their stability in a sterile burn 
wound environment is unknown. Phospholipases A2 (PLA2) molecules are central in 
inducing inflammation as they lead to the degradation of phospholipids important in 
stimulating the formation of eicosanoid and related bioactive lipid mediators (648). 
(PLA2) attacks the sn-2 position of phospholipids, including those present in our 
vesicles. The concentration of (PLA2) required to lyse vesicles used in this study and 
that present in a burn wound needs to be measured to investigate whether in a non-
infected wound, vesicles will remain stable. In summary, the primary objective of 
identifying the vesicle lysing agents of S. aureus and P. aeruginosa has been 
achieved. An extension of this work saw the development of two novel, highly 
sensitive assays for measuring agr and RL activity (chapters 3 and 4). We also 
question the validity of the proposed TSST-1 mediated global exoprotein repression 
as discussed by Vojtov et al (457). However there is still much work required to 
evaluate the role smart wound dressing may play in the future of burn wound 
management. 
 
In chapter 6 we investigated the use of sub-inhibitory concentrations of 
oxacillin as a means of anti-virulence treatment in CA-MRSA strains. Previous work 
in the Massey lab demonstrated that over-expression of the mecA gene, encoding the 
alternative penicillin binding protein PBP2a, decreased toxicity in HA-MRSA 
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strains. CA-MRSA strains are considered highly toxic but have considerably lower 
PBP2a expression. Therefore, treatment of CA-MRSA stains with sub-inhibitory 
oxacillin was hypothesised to induce higher levels of PBP2a expression with the 
added effect of decreasing toxicity. In this chapter we demonstrate that oxacillin 
treatment does in fact interfere with agr signalling resulting in altered toxin 
expression in CA-MRSA strains. As S. aureus expresses many different cytolytic 
toxins we assessed the impact of oxacillin treatment on three cell types.  Our results 
demonstrate that oxacillin treatment leads to a decrease in PSM expression but also 
an increase in PVL expression. Therefore, where PSMs are important in cell lysis, 
such as with T cells and erythrocytes overall cell lysis is reduced, however where 
PVL is important such as lysing PMNs, overall cell lysis is increased with respect to 
oxacillin treatment. The impact on protein A and bacterial adherence to extracellular 
matrix proteins and invasion of endothelial cells following oxacillin treatment was 
also assessed. We show that oxacillin treatment results in a decrease in protein A 
expression but causes increased binding of the USA300 strain LAC to Fb in response 
to sub-inhibitory oxacillin treatment. No difference in the invasiveness of CA-MRSA 
strain was observed.  
 
The results presented demonstrate that sub-inhibitory oxacillin modulates 
global virulence regulation, down regulating Agr and associated agr-dependent 
virulence factors but up-regulating other cytolytic toxins such as PVL. RNAseq 
analysis should help unravel how the complex regulatory network involved in S. 
aureus toxicity responds to sub-inhibitory antibiotics. Future work in analysing the 
impact of other cell wall antibiotics which may mediate PBP2a-dependent agr 
repression is ongoing and may facilitate our initial application of using sub-inhibitory 
antibiotics for virulence attenuation. The mechanism of how overexpression of 
PBP2a leads to reduced agr-specific toxins such as δ-haemolysin and PSMs is 
unknown. Previous work highlighted that removal of the cell wall by-passed this 
repression (238). This suggests that PBP2a expression leads to changes in the 
architecture of the cell wall which inhibits agr signalling and/or response. It has been 
shown before that the methicillin resistance strains produce abnormal peptidogylcan 
when grown in the presence of β-lactam antibiotics (649). It is possible that subtle 
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changes in the cell wall as a result of PBP2a expression may lead to a charge 
difference preventing the AIP from diffusing through the cell wall to reach AgrC. 
The identification of novel chemically distinct peptide cross-bridges present in 
MRSA cell walls and the role of the other PBPs may highlight the mechanism of 
PBP2a mediated agr repression.    
 
Keeping with the theme of S. aureus toxicity, in chapter 7 we investigate the 
potential of using the genomes of 90 closely related ST239 strains to identify genetic 
polymorphisms associated with variation in toxicity, as measured by the VLT and T 
cell assay. Here we evaluate two methods to identify specific single nucleotide 
polymorphisms (SNPs) and insertion/deletions (InDels) present in the core genomes 
that are associated with either an increase or decrease in toxicity. The genome wide 
association study (GWAS) is a robust method, requiring only an association between 
polymorphism and phenotype and therefore is likely to result in false positives. The 
second approach is much more stringent and requires the repeated independent 
evolution of the polymorphism to be associated toxicity variation. Although the 
GWAS approach results in false positives the stringent approach failed to identify a 
SNP known to affect toxicity (SNP identified in AgrC, verified to reduce agr 
activity) and thus produce a higher false negative rate.    
 
Using the GWAS approach we sought to functional verify some of the 
genetic polymorphisms associated with a decrease in toxicity. Interestingly, we 
identified and verified four novel genetic loci, which, when mutated through 
transposons insertion, resulted in a drastic and significant decrease in toxicity. This 
suggested that there is an added layer of virulence regulation yet to be defined. 
However, inactivation of the gene does not tell us if the SNP in question caused the 
predicted decrease in toxicity. Future work is in place to complement mutant strains 
with wild type and SNP containing gene to fully understand the role of individual 
SNPs in toxicity variation. The elucidation of the impact the specific SNP plays in 
modulating toxicity is important in investigating or predicting the virulence potential 
of a strain directly from its genome sequence. This prediction approach has been 
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employed by our group and has been shown to be an effective model with the 
toxicity of the majority of isolates predicted correctly.   
 
In this chapter we show that the GWAS approach is a good method in 
identifying SNPs responsible for variation in toxicity. In addition to using the 
Turkish collection of ST239 strains, we have also investigated the toxicity of other 
ST239 strains from other geographical regions. Preliminary experiments illustrate a 
large difference in the toxicities of strains derived from the Turkish collection and 
global collection of ST239 clinical isolates (Figure 8.1). The box plot in figure 8.1 
shows that the majority of isolates from the global collection are highly lytic, 
whereas the opposite is true for the Turkish collection. The line within the box 
represents the median value, again highlighting the vast difference in toxicity 
between these related groups within this S. aureus lineage. 
  
 
Figure 8.1: Differences in vesicle lysis from strains derived from the Turkish and global 
collection of ST239 strains. The box plot represents the differences in the lytic activity defined by 
fluorescence release from vesicles. 
 
 
Both groups of ST239 strains have been isolated from the hospital environment. The 
degree of antibiotic resistance, particularly to beta-lactam antibiotics, between the 
two ST239 groups may determine the observed toxicity as resistance to beta-lactams 
conferred by the mecA gene has been shown to influence toxicity in HA-MRSA 
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containing the type II SCCmec element (238). Differences in resistance to 
antimicrobial peptides, which has been linked to thicker cell walls (650), may also 
interfere with agr signalling and affect overall toxin output. Another possibility 
which may explain the large deviation in toxicity profiles from the two ST239 groups 
may lie within the sequencing technology used. One of the limitations of the 
genomic data used in these studies is that DNA not found in the reference genome 
(TW20) is ignored. Therefore, ST239 strains form the Global collection may possess 
mobile genetic elements which express novel genes conferring the observed highly 
toxic phenotype. The improvement of sequencing technology and de novo assembly 
of genome sequences will report on the entire sequence of the strains highlighting all 
genetic differences between strains. 
 
This thesis represents an interdisciplinary approach to investigating bacterial 
virulence in areas of detection, identification and prevention. Work in this thesis has 
assisted collaborative work in developing an active wound dressing for burn wound 
management. In areas of prevention we address the use of sub-inhibitory oxacillin to 
reduced overall toxicity, highlighting mixed results. Finally, we develop a novel 
method to identify genetic polymorphism associated with, and verify four novel loci 
affecting, toxicity. These results have future implications in areas of elucidating 
novel virulence regulatory circuits and in developing predictive models for assessing 













Appendix A: Strain Collection 
 
Chapters 3 and 6: 
Strain/peptide/primer Description Reference 
RN6390B                                                        NCTC8325 cured of three prophages  (331) 
RN6911                 RN6390B Δagr::tetM        (335) 
8325-4                                          Lab strain NCTC8325 cured of three prophages  (651) 
DU1090                                                                           
 
8325-4 Δhla::Emr (652) 
DU5719                                      β- haemolysin - ve Phage 42E lysogen of 8325-4  (652) 
LAC (USA300)      Community acquired MRSA strain      (305) 
LAC Δhld            LAC hld deletion mutant; hld start codon 
changed from ATG to ATT 
(317) 
MW2 (USA400)   Community acquired MRSA strain        (305) 
MW2 Δpvl                                                                            MW2 ΔlukF/S-PV::spcm (305) 
MSSA 476           Community-acquired invasive MSSA strain       (427) 
RN4220                                 Restriction negative derivative of 8325-4          (462) 
Newman                                                                    MSSA lab strain (437) 
NewmanΔlukAB     Constructed using pKOR-1 plasmid  (437) 
NewmanΔlukDE      Constructed using pKOR-1 plasmid (437) 
NewmanΔhlg           NewmanΔhlg::tetM  (653) 
   
Purified toxins    
Δ-haemolysin               fMAQDIISTIGDLVKWIIDTVNKFTKK  
PSMα1                      fMGIIAGIIKVIKSLIEQFTGK  
PSMα2                                                   fMGIIAGIIKFIKGLIEKFTGK  
PSMα3                      fMEFVAKLFKFFKDLLGKFLGNN   
PSMα4                      fMAIVGTIIKIIKAIIDIFAK   
PSMβ1                      fMEGLFNAIKDTVTAAINNDGAKLGTSIVSI
VENGVGLLGKLFGF 
 
PSMβ2                      fMTGLAEAIANTVQAAQQHDSVKLGTSIV
DIVANGVGLLGKLFGF 
 
   
Primers   
gyrB Forward                CCAGGTAAATTAGCCGATTGC  
gyrB Reverse                 AAATCGCCTGCGTTCTAGAG  
RNA III Forward            GAAGGAGTGATTTCAATGGCACAAG  
RNA III Reverse     
 









Strain Description Reference 
PAO1 Nottingham collection wild type P. aeruginosa strain (654) 
PAOlΔrhlR rlhlR mutant of PAO1 (655) 















PAOlΔplcH plcH mutant of PAO1 (658) 
PAOlΔpqsA pqsA mutant of PAO1 (659) 
PAO1ΔpqsE pqsE mutant of PAO1 (79) 
PAO1ΔpqsH pqsH mutant of PAO1 (79) 
PAO1ΔrhlA rhlA mutant of PAO1 (660) 
   
Chronic isolates n=48 isolated from patients with cystic fibrosis Gift from 
M.C. Enright 






Strain Description Reference 
RN6390B NCTC8325 cured of three phages (331) 
RN6911 RN6390BΔagr::tetM (335) 
RN4282 Wild type TSST-1 producing strain (462) 
RN6938 RN4282Δtst::tetM (661) 
MSSA 101 Invasive CA-MRSA strain tst+
 
(427) 
MSSA 253 Invasive CA-MRSA strain tst+ (427) 








Strain/primer/plasmid Description Reference 
Strain   
RN4220 Restriction negative derivative of 8325-4          (462) 
RN6390B                                                        NCTC8325 cured of three prophages  (331) 
ALC1927  RN6390ΔsarS::ermC  (372) 
ALCML1 ALC1927 with pRMC2ML1 This work 
ALCML2 ALC1927 with pRMC2ML2 This work 
BH1CC Clinical isolate, type II MRSA CC8 (414) 
BH1CCΔSccmec SCCmec excised using plasmid pSR2  (581) 
ML121 BH1ccΔSccmec complemented with pRMC2 This work 
ML122 BH1ccΔSccmec complemented with pmecA1 This work 
ML123 BH1ccΔSccmec complemented with pmecA2 This work 
ML124 BH1ccΔSccmec complemented with pmecA3 This work 
ML125 BH1ccΔSccmec complemented with pmecA4 This work 
FPR3757 Wild type USA300 isolate (640) 
AgrB- FPR3757 Tn::agrB (640) 
95A07 FPR3757 Tn::298351 (640) 
93B09 FPR3757 Tn::690868 (640) 
82B04 FPR3757 Tn::717257 (640) 
180A03 FPR3757 Tn::728946 (640) 
207A03 FPR3757 Tn::1050930 (640) 
90D01 FPR3757 Tn::1429479 (640) 
137C12 FPR3757 Tn::1907464 (640) 
45D06 FPR3757 Tn::2003286 (640) 
179A03 FPR3757 Tn::2087951 (640) 
108B09 FPR3757 Tn::2380097 (640) 
184F11 FPR3757 Tn::2379899 (640) 
86C03 FPR3757 Tn::2487759 (640) 
168A05 FPR3757 Tn::2504661 (640) 
72A04 FPR3757 Tn::2601159 (640) 
Plasmid   
pRMC2 Plasmid containing a tetracycline-inducible 
promoter  
(461) 
pRMC2ML1 pRMC2 containing sarS amplified from strain  
N315 
This work 
pRMC2ML2 pRMC2 containing sarS amplified from strain 
252 
This work 
pmecA1 pRMC2 containing mecA amplified from  
strain TW20 
This work 
pmecA2 pRMC2 containing mecA1 harbouring SNPs 
78097 and 78222  
This work 





pmecA4 pRMC2 containing mecA3 harbouring 
SNP78119 
This work 
Primer   
sarS Fw GGCGGTACCGGAGATAGAACAATG This work 




mecA Rv AAAGAGCTCCGTTATCGCTGAAATTAC (238) 
ST239 Strains    
Isolate Hospital Infectious source Reference 
DEU1 Dokuz Eylul University, Turkey. Abscess (180) 
DEU2 Dokuz Eylul University, Turkey. Aspiration (180) 
DEU3 Dokuz Eylul University, Turkey. Blood (180) 
DEU4 Dokuz Eylul University, Turkey. Blood (180) 
DEU5 Dokuz Eylul University, Turkey. Wound (180) 
DEU6 Dokuz Eylul University, Turkey. Wound (180) 
DEU7 Dokuz Eylul University, Turkey. Blood (180) 
DEU8 Dokuz Eylul University, Turkey. Wound (180) 
DEU9 Dokuz Eylul University, Turkey. Aspiration (180) 
DEU10 Dokuz Eylul University, Turkey. Catheter (180) 
DEU11 Dokuz Eylul University, Turkey. Blood (180) 
DEU12 Dokuz Eylul University, Turkey. Sputum (180) 
DEU14 Dokuz Eylul University, Turkey. Bronchoalveoler 
lavage 
(180) 
DEU15 Dokuz Eylul University, Turkey. Aspiration (180) 
DEU16 Dokuz Eylul University, Turkey. Blood (180) 
DEU17 Dokuz Eylul University, Turkey. Blood (180) 
DEU19 Dokuz Eylul University, Turkey. Peritoneum fluid (180) 
DEU20 Dokuz Eylul University, Turkey. Blood (180) 
DEU22 Dokuz Eylul University, Turkey. Wound (180) 
DEU23 Dokuz Eylul University, Turkey. Urine (180) 
DEU25 Dokuz Eylul University, Turkey. Blood (180) 
DEU27 Dokuz Eylul University, Turkey. Catheter (180) 
DEU28 Dokuz Eylul University, Turkey. Blood (180) 
DEU29 Dokuz Eylul University, Turkey. Blood (180) 
DEU30 Dokuz Eylul University, Turkey. Wound (180) 
DEU35 Dokuz Eylul University, Turkey. Tracheal secretion (180) 
DEU36 Dokuz Eylul University, Turkey. Plevral fluid (180) 
DEU37 Dokuz Eylul University, Turkey. Blood (180) 
DEU38 Dokuz Eylul University, Turkey. Aspiration (180) 
DEU39 Dokuz Eylul University, Turkey. Catheter (180) 
DEU40 Dokuz Eylul University, Turkey. Wound (180) 
DEU41 Dokuz Eylul University, Turkey. Blood (180) 
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DEU42 Dokuz Eylul University, Turkey. Blood (180) 
DEU43 Dokuz Eylul University, Turkey. Blood (180) 
DEU46 Dokuz Eylul University, Turkey. Blood (180) 
DEU47 Dokuz Eylul University, Turkey. Wound (180) 
DEU49 Dokuz Eylul University, Turkey. Blood (180) 
DEU50 Dokuz Eylul University, Turkey. Tracheal secretion (180) 
HU2 Hacettepe University, Turkey. Blood (180) 
HU4 Hacettepe University, Turkey. Tracheal secretion (180) 
HU5 Hacettepe University, Turkey. Catheter (180) 
HU6 Hacettepe University, Turkey. Sputum (180) 
HU7 Hacettepe University, Turkey. Abscess (180) 
HU8 Hacettepe University, Turkey. Abscess (180) 
HU9 Hacettepe University, Turkey. Liver cyst (180) 
HU10 Hacettepe University, Turkey. Catheter (180) 
HU11 Hacettepe University, Turkey. Blood (180) 
HU12 Hacettepe University, Turkey. Catheter (180) 
HU13 Hacettepe University, Turkey. Brain abscess (180) 
HU14 Hacettepe University, Turkey. Catheter (180) 
HU15 Hacettepe University, Turkey. Catheter (180) 
HU16 Hacettepe University, Turkey. Spinal fluid (180) 
HU17 Hacettepe University, Turkey. Brain abscess (180) 
HU18 Hacettepe University, Turkey. Catheter (180) 
HU19 Hacettepe University, Turkey. Tracheal secretion (180) 
HU21 Hacettepe University, Turkey. Spinal fluid (180) 
HU23 Hacettepe University, Turkey. Spinal fluid (180) 
HU24 Hacettepe University, Turkey. Blood (180) 
HU25 Hacettepe University, Turkey. Abscess (180) 
HU26 Hacettepe University, Turkey. Blood (180) 
IU1 Istanbul University, Turkey. Blood (180) 
IU2 Istanbul University, Turkey. Blood (180) 
IU3 Istanbul University, Turkey. Blood (180) 
IU4 Istanbul University, Turkey. Sputum (180) 
IU6 Istanbul University, Turkey. Blood (180) 
IU7 Istanbul University, Turkey. Catheter (180) 
IU8 Istanbul University, Turkey. Blood (180) 
IU9 Istanbul University, Turkey. Nasal swab (180) 
IU10 Istanbul University, Turkey. Blood (180) 
IU11 Istanbul University, Turkey. Blood (180) 
IU12 Istanbul University, Turkey. Abscess (180) 
IU13 Istanbul University, Turkey. Abscess (180) 
IU14 Istanbul University, Turkey. Sputum (180) 
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IU15 Istanbul University, Turkey. Transtracheal asp. 
fluid 
(180) 
IU16 Istanbul University, Turkey. No info. (180) 
IU17 Istanbul University, Turkey. No info. (180) 
IU18 Istanbul University, Turkey. No info. (180) 
IU19 Istanbul University, Turkey. No info. (180) 
IU20 Istanbul University, Turkey. No info. (180) 
MU1 Marmara University, Turkey. Blood (180) 
MU2 Marmara University, Turkey. Blood (180) 
MU3   Marmara University, Turkey. Wound (180) 
MU4  Marmara University, Turkey. Abscess (180) 
MU5  Marmara University, Turkey. Wound (180) 
MU6  Marmara University, Turkey. Blood (180) 
MU7  Marmara University, Turkey. Blood (180) 
MU9  Marmara University, Turkey. Wound (180) 
MU11  Marmara University, Turkey. Blood (180) 
MU19 Marmara University, Turkey. Blood (180) 
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